EurekaMag PDF full texts Chapter 8,982

Santana, V.M.; Abromowitch, M.; Sandlund, J.T.; Behm, F.G.; Ayers, G.D.; Roberson, P.K.; Pui, C.H. 1993: MACOP-B treatment in children and adolescents with advanced diffuse large-cell non-Hodgkin's lymphoma. Leukemia 7(2): 187-191

Sertoli, M.R.; Santini, G.; Chisesi, T.; Congiu, A.M.; Rubagotti, A.; Contu, A.; Salvagno, L.; Coser, P.; Porcellini, A.; Vespignani, M. 1994: MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 12(7): 1366-1374

Lima, C.D.; D'amico, K.L.; Naday, I.; Rosenbaum, G.; Westbrook, E.M.; Hendrickson, W.A. 1997: MAD analysis of FHIT, A putative human tumor suppressor from the HIT protein family. Structure 5(6): 763-774

Terwilliger, T.C. 1994: MAD phasing: Bayesian estimates of F(A). Acta Crystallographica. Section D Biological Crystallography 50(Part 1): 11-16

Terwilliger, T.C. 1994: MAD phasing: treatment of dispersive differences as isomorphous replacement information. Acta Crystallographica. Section D Biological Crystallography 50(Part 1): 17-23

Maesawa, C.; Tamura, G.; Nishizuka, S.; Iwaya, T.; Ogasawara, S.; Ishida, K.; Sakata, K.; Sato, N.; Ikeda, K.; Kimura, Y.; Saito, K.; Satodate, R. 1997: MAD-related genes on 18q21.1, Smad2 and Smad4, are altered infrequently in esophageal squamous cell carcinoma. Japanese Journal of Cancer Research: Gann 88(4): 340-343

Li, Y.; Gorbea, C.; Mahaffey, D.; Rechsteiner, M.; Benezra, R. 1997: MAD2 associates with the cyclosome/anaphase-promoting complex and inhibits its activity. Proceedings of the National Academy of Sciences of the United States of America 94(23): 12431-12436

Schievella, A.R.; Chen, J.H.; Graham, J.R.; Lin, L.L. 1997: MADD, a novel death domain protein that interacts with the type 1 tumor necrosis factor receptor and activates mitogen-activated protein kinase. Journal of Biological Chemistry 272(18): 12069-12075

Hoodless, P.A.; Haerry, T.; Abdollah, S.; Stapleton, M.; O'connor, M.B.; Attisano, L.; Wrana, J.L. 1996: MADR1, a MAD-related protein that functions in BMP2 signaling pathways. Cell 85(4): 489-500

Macías-Silva, M.; Abdollah, S.; Hoodless, P.A.; Pirone, R.; Attisano, L.; Wrana, J.L. 1996: MADR2 is a substrate of the TGFbeta receptor and its phosphorylation is required for nuclear accumulation and signaling. Cell 87(7): 1215-1224

Eppert, K.; Scherer, S.W.; Ozcelik, H.; Pirone, R.; Hoodless, P.; Kim, H.; Tsui, L.C.; Bapat, B.; Gallinger, S.; Andrulis, I.L.; Thomsen, G.H.; Wrana, J.L.; Attisano, L. 1996: MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 86(4): 543-552

Turnley, A.M.; Bartlett, P.F. 1998: MAG and MOG enhance neurite outgrowth of embryonic mouse spinal cord neurons. Neuroreport 9(9): 1987-1990

Jonsson, H.; Frykberg, L.; Rantamäki, L.; Guss, B. 1994: MAG, a novel plasma protein receptor from Streptococcus dysgalactiae. Gene 143(1): 85-89

Neubauer, N.; Johnson, L.; Lemmers, M.; Petri, B.; Stevens, J.S. 1996: MAG3 renal transplant tomography SPECT with a non-SPECT agent. Clinical Nuclear Medicine 21(1): 11-14

Bajén, M.T.; Puchal, R.; González, A.; Grinyó, J.M.; Castelao, A.; Mora, J.; Martin-Comin, J. 1997: MAG3 renogram deconvolution in kidney transplantation: utility of the measurement of initial tracer uptake. Journal of Nuclear Medicine: Official Publication Society of Nuclear Medicine 38(8): 1295-1299

McCurdy, D.K.; Tai, L.Q.; Nguyen, J.; Wang, Z.; Yang, H.M.; Udar, N.; Naiem, F.; Concannon, P.; Gatti, R.A. 1998: MAGE Xp-2: a member of the MAGE gene family isolated from an expression library using systemic lupus erythematosus sera. Molecular Genetics and Metabolism 63(1): 3-13

Gao, Q.; Yang, X.; Yun, R.; Li, C. 1996: MAGE, a dynamic model of alkaline grassland ecosystems with variable soil characteristics. Ecological Modelling 93(1-3): 2

Ishida, H.; Matsumura, T.; Salgaller, M.L.; Ohmizono, Y.; Kadono, Y.; Sawada, T. 1996: MAGE-1 and MAGE-3 or -6 expression in neuroblastoma-related pediatric solid tumors. International Journal of Cancer 69(5): 375-380

Schultz-Thater, E.; Juretic, A.; Dellabona, P.; Lüscher, U.; Siegrist, W.; Harder, F.; Heberer, M.; Zuber, M.; Spagnoli, G.C. 1994: MAGE-1 gene product is a cytoplasmic protein. International Journal of Cancer 59(3): 435-439

Toso, J.F.; Oei, C.; Oshidari, F.; Tartaglia, J.; Paoletti, E.; Lyerly, H.K.; Talib, S.; Weinhold, K.J. 1996: MAGE-1-specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen-specific activation. Cancer Research 56(1): 16-20

Jurk, M.; Kremmer, E.; Schwarz, U.; Förster, R.; Winnacker, E.L. 1998: MAGE-11 protein is highly conserved in higher organisms and located predominantly in the nucleus. International Journal of Cancer 75(5): 762-766

Hofbauer, G.F.; Schaefer, C.; Noppen, C.; Böni, R.; Kamarashev, J.; Nestle, F.O.; Spagnoli, G.C.; Dummer, R. 1997: MAGE-3 immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution. American Journal of Pathology 151(6): 1549-1553

Retamar, R.A.; Magnin, P.H. 1996: MAGIC syndrome. Revista Argentina de Dermatologia 77(1): 17-21

Birren, S.J. 1995: MAH cells and the development of rat sympathetic neurons. Methods (orlando). 7(3): 268-276

Mahan, S.; Jolles, P.R. 1995: MAI osteomyelitis. 18-year scintigraphic follow-up. Clinical Nuclear Medicine 20(7): 594-598

Yamashita, N.; Goto, K.; Nakamura, N.; Nishiya, T.; Tamura, G. 1994: MAL sequence on chromosome IV of shochu yeast. Seibutsu-Kogaku Kaishi. 72(2): 87-94

Burgess, K.; Russell, D., H.; Shitangkoon, A.; Zhang, A., J. 1996: MALDI and FAB mass spectrometry of nucleoside triphosphates: A comparative study. Nucleosides and Nucleotides 15(11-12): 1719-1723

Wang, Y.J.; Yurttas, L.; Dale, B.E.; Russell, D.H.; Kinsel, G.; Preston-Schaffter, L.M.; Johnson, V.; Hayes, T.K. 1997: MALDI-MS as a monitor of the purification and folding of synthetic eclosion hormone. Peptides 18(3): 337-346

Yu, Z.; Yu, X.C.; Chu, Y.H. 1998: MALDI-MS determination of cyclic peptidomimetic sequences on single beads directed toward the generation of libraries. Tetrahedron Letters 39(1-2): 1-4,. 1

Thiede, B.; Wittmann-Liebold, B.; Bienert, M.; Krause, E. 1995: MALDI-MS for C-terminal sequence determination of peptides and proteins degraded by carboxypeptidase Y and P. FEBS Letters 357(1): 65-69

Fei, Z.; Ono, T.; Smith, L.M. 1998: MALDI-TOF mass spectrometric typing of single nucleotide polymorphisms with mass-tagged ddNTPs. Nucleic Acids Research 26(11): 2827-2828

Berchter, M.; Meister, J.; Hammes, C. 1997: MALDI-TOF-MS: A new analytical technique for characterizing products on the base of renewable resources. Fett 99(11): 384-391

Berrebi, D.; Lescoeur, B.; Faye, A.; Faure, C.; Vilmer, E.; Peuchmaur, M. 1998: MALT lymphoma of labial minor salivary gland in an immunocompetent child with a gastric Helicobacter pylori infection. Journal of Pediatrics 133(2): 290-292

Kim, K.-Ho; Lee, M.-Soo; Kim, C.-Woo 1996: MALT lymphoma of the eyelid and nostril: A case report. Annals of Dermatology 8(4): 295-299

Maehara, C.; Nakano, H.; Oka, Y.; Hirabayashi, N.; Morise, K. 1994: MALT lymphoma of the remnant stomach, report of a case. Stomach and Intestine 29(6): 593-598

Yokota, Kin-Ichi 1993: MALT lymphoma of the stomach diagnosed by gene detection, after being followed up for four years and eight months as a pseudolymphoma: Report of a case. Stomach and Intestine 28(10): 1101-1108

Eck, M.; Schmausser, B.; Haas, R.; Greiner, A.; Czub, S.; Müller-Hermelink, H.K. 1997: MALT-type lymphoma of the stomach is associated with Helicobacter pylori strains expressing the CagA protein. Gastroenterology 112(5): 1482-1486

O'Gorman, P.; Bennett, D.; Kavanagh, E.; Twohig, L.B.; O'Sullivan, G.C.; O'Regan, P.; Shanahan, F. 1996: MALTectomy (appendectomy/tonsillectomy) does not influence the occurrence or mode of presentation of adult celiac disease. American Journal of Gastroenterology 91(4): 723-725

Enno, A.; O'Rourke, J.L.; Howlett, C.R.; Jack, A.; Dixon, M.F.; Lee, A. 1995: MALToma-like lesions in the murine gastric mucosa after long-term infection with Helicobacter felis. A mouse model of Helicobacter pylori-induced gastric lymphoma. American Journal of Pathology 147(1): 217-222

Kuhn de Chizelle, A.N.; DiStefano, J.J. 1994: MAMCAT: an expert system for distinguishing between mammillary and catenary compartmental models. Computers in Biology and Medicine 24(3): 189-204

Lemesle-Varloot, L.; Gaboriaud, C.; Morgat, A.; Pantel, G.; Mornon, J.P.; Lavaitte, S.; Lestang, F.; Henrissat, B. 1993: MANSEK and SUNHCA. Two interactive programs for the hydrophobic cluster analysis of protein sequences. Computer Applications in the Biosciences: Cabios 9(1): 37-44

van Vliet, I.M.; Westenberg, H.G.; Den Boer, J.A. 1993: MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine. A double blind placebo controlled study. Psychopharmacology 112(4): 483-489

Suzuki, T.; Akaike, N.; Ueno, K.; Tanaka, Y.; Himori, N. 1995: MAO inhibitors, clorgyline and lazabemide, prevent hydroxyl radical generation caused by brain ischemia/reperfusion in mice. Pharmacology 50(6): 357-362

Mészáros, Z.; Borcsiczky, D.; Máté, M.; Tarcali, J.; Tekes, K.; Magyar, K. 1998: MAO inhibitory side effects of neuroleptics and platelet serotonin content in schizophrenic patients. Journal of Neural Transmission. Supplementum 52: 79-85

Barthalmus, G.T.; Hardin, L.K.; Thompson, D. 1993: MAO-A and -B inhibitors selectively alter Xenopus mucus-induced behaviors of snakes. Pharmacology Biochemistry and Behavior 44(2): 321-327

Bergström, M.; Westerberg, G.; Németh, G.; Traut, M.; Gross, G.; Greger, G.; Müller-Peltzer, H.; Safer, A.; Eckernäs, S.A.; Grahnér, A.; Långström, B. 1997: MAO-A inhibition in brain after dosing with esuprone, moclobemide and placebo in healthy volunteers: In vivo studies with positron emission tomography. European Journal of Clinical Pharmacology 52(2): 121-128

Thase, M.E.; Trivedi, M.H.; Rush, A.J. 1995: MAOIs in the contemporary treatment of depression. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 12(3): 185-219

Modig, C.; Rutberg, M.; Detrich, H.W.; Billger, M.; Strömberg, E.; Wallin, M. 1997: MAP 0, a 400-kDa microtubule-associated protein unique to teleost fish. Cell Motility and the Cytoskeleton 38(3): 258-269

Eckberg, W.R. 1997: MAP and cdc2 kinase activities at germinal vesicle breakdown in Chaetopterus. Developmental Biology 191(2): 182-190

Dimon-Gadal, S.; Raynaud, F.; Evain-Brion, D.; Keryer, G. 1998: MAP kinase abnormalities in hyperproliferative cultured fibroblasts from psoriatic skin. Journal of Investigative Dermatology 110(6): 872-879

Paslaru, L.; Trigon, S.; Kuhlmann, M.; Morange, M. 1997: MAP kinase activation by cyclosporine a. Biochemical and Biophysical Research Communications 236(3): 599-603

Dubois, M.F.; Bensaude, O. 1993: MAP kinase activation during heat shock in quiescent and exponentially growing mammalian cells. Febs Letters 324(2): 191-195

Hansson, A. 1994: Map kinase activation in Swiss 3T3 cells stimulated with gastrin-releasing peptide is associated with increased phosphorylation of a 78,000 M(r) protein immunoprecipitated by anti-raf kinase anti-serum. Cellular Signalling 6(4): 423-431

Okazaki, K.; Sagata, N. 1995: MAP kinase activation is essential for oncogenic transformation of NIH3T3 cells by Mos. Oncogene 10(6): 1149-1157

Philipova, R.; Whitaker, M. 1998: MAP kinase activity increases during mitosis in early sea urchin embryos. Journal of Cell Science 111: 2497-2505

Xu, J.R.; Hamer, J.E. 1996: MAP kinase and cAMP signaling regulate infection structure formation and pathogenic growth in the rice blast fungus Magnaporthe grisea. Genes and Development 10(21): 2696-2706

Verlhac, M.H.; de Pennart, H.; Maro, B.; Cobb, M.H.; Clarke, H.J. 1993: MAP kinase becomes stably activated at metaphase and is associated with microtubule-organizing centers during meiotic maturation of mouse oocytes. Developmental Biology 158(2): 330-340

Haraguchi, S.; Naito, K.; Sato, E. 1998: MAP kinase cascade, but not ERKs, activated during early cleavage of mouse embryos. Molecular Reproduction and Development 51(2): 148-155

Abrieu, A.; Lorca, T.; Labbé, J.C.; Morin, N.; Keyse, S.; Dorée, M. 1996: MAP kinase does not inactivate, but rather prevents the cyclin degradation pathway from being turned on in Xenopus egg extracts. Journal of Cell Science 109: 239-246

Wang, Y.; Liu, J.; Segall, J.E. 1998: MAP kinase function in amoeboid chemotaxis. Journal of Cell Science 111: 373-383

Gabay, L.; Seger, R.; Shilo, B.Z. 1997: MAP kinase in situ activation atlas during Drosophila embryogenesis. Development 124(18): 3535-3541

Hartley, R.S.; Lewellyn, A.L.; Maller, J.L. 1994: MAP kinase is activated during mesoderm induction in Xenopus laevis. Developmental Biology 163(2): 521-524

Takenaka, K.; Gotoh, Y.; Nishida, E. 1997: MAP kinase is required for the spindle assembly checkpoint but is dispensable for the normal M phase entry and exit in Xenopus egg cell cycle extracts. Journal of Cell Biology 136(5): 1091-1097

Tachibana, K.; Machida, T.; Nomura, Y.; Kishimoto, T. 1997: MAP kinase links the fertilization signal transduction pathway to the G1/S-phase transition in starfish eggs. EMBO Journal 16(14): 4333-4339

Braconi Quintaje, S.; Rebsamen, M.; Church, D.J.; Vallotton, M.B.; Lang, U. 1998: MAP kinase mediates epidermal growth factor- and phorbol ester-induced prostacyclin formation in cardiomyocytes. Journal of Molecular and Cellular Cardiology 30(5): 933-945

Brunet, A.; Brondello, J.M.; L'Allemain, G.; Lenormand, P.; McKenzie, F.; Pagès, G.; Pouysségur, J. 1995: MAP kinase module: role in the control of cell proliferation. Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales 189(1): 43-57

Niiro, H.; Otsuka, T.; Ogami, E.; Yamaoka, K.; Nagano, S.; Akahoshi, M.; Nakashima, H.; Arinobu, Y.; Izuhara, K.; Niho, Y. 1998: MAP kinase pathways as a route for regulatory mechanisms of IL-10 and IL-4 which inhibit COX-2 expression in human monocytes. Biochemical and Biophysical Research Communications 250(2): 200-205

Winter, C.; Schenkel, J.; Zimmermann, M.; Herdegen, T. 1998: MAP kinase phosphatase 1 is expressed and enhanced by FK506 in surviving mamillary, but not degenerating nigral neurons following axotomy. Brain Research 801(1-2): 198-205

Peinado-Ramón, P.; Wallén, A.; Hallböök, F. 1998: MAP kinase phosphatase-1 mRNA is expressed in embryonic sympathetic neurons and is upregulated after NGF stimulation. Brain Research. Molecular Brain Research 56(1-2): 256-267

Rozakis-Adcock, M.; van der Geer, P.; Mbamalu, G.; Pawson, T. 1995: MAP kinase phosphorylation of mSos1 promotes dissociation of mSos1-Shc and mSos1-EGF receptor complexes. Oncogene 11(7): 1417-1426

Tan, P.B.; Lackner, M.R.; Kim, S.K. 1998: MAP kinase signaling specificity mediated by the LIN-1 Ets/LIN-31 WH transcription factor complex during C. elegans vulval induction. Cell 93(4): 569-580

Martin, K.C.; Michael, D.; Rose, J.C.; Barad, M.; Casadio, A.; Zhu, H.; Kandel, E.R. 1997: MAP kinase translocates into the nucleus of the presynaptic cell and is required for long-term facilitation in Aplysia. Neuron 18(6): 899-912

Thorburn, J.; Xu, S.; Thorburn, A. 1997: MAP kinase- and Rho-dependent signals interact to regulate gene expression but not actin morphology in cardiac muscle cells. EMBO Journal 16(8): 1888-1900

Janknecht, R.; Nordheim, A. 1996: MAP kinase-dependent transcriptional coactivation by Elk-1 and its cofactor CBP. Biochemical and Biophysical Research Communications 228(3): 831-837

Yang, H.; Raizada, M.K. 1998: MAP kinase-independent signaling in angiotensin II regulation of neuromodulation in SHR neurons. Hypertension 32(3): 473-481

Errede, B.; Gartner, A.; Zhou, Z.; Nasmyth, K.; Ammerer, G. 1993: MAP kinase-related FUS3 from Saccharomyces cerevisiae is activated by STE7 in vitro. Nature (London) 362(6417): 261-264

Childs, T.J.; Mak, A.S. 1993: MAP kinases from bovine brain: Purification and characterization. Biochemistry and Cell Biology 71(11-12): 544-555

Jonak, C.; Heberle-Bors, E.; Hirt, H. 1994: MAP kinases: Universal multi-purpose signaling tools. Plant Molecular Biology 24(3): 407-416

DiTella, M.C.; Feiguin, F.; Carri, N.; Kosik, K.S.; Cáceres, A. 1996: MAP-1B/TAU functional redundancy during laminin-enhanced axonal growth. Journal of Cell Science 109: 467-477

Triarhou, L.C.; Solà, C.; Palacios, J.M.; Mengod, G. 1998: MAP2 and GAP-43 expression in normal and weaver mouse cerebellum: correlative immunohistochemical and in situ hybridization studies. Archives of Histology and Cytology 61(3): 233-242

Giovanini, M.A.; Reier, P.J.; Eskin, T.A.; Anderson, D.K. 1997: MAP2 expression in the developing human fetal spinal cord and following xenotransplantation. Cell Transplantation 6(3): 339-346

Riederer, B.M..; Innocenti, G.M.. 1992: MAP2 isoforms in developing cat cerebral cortex and corpus callosum. European Journal of Neuroscience 4(12): 1376-1386

Díez-Guerra, F.J.; Avila, J. 1993: MAP2 phosphorylation parallels dendrite arborization in hippocampal neurones in culture. Neuroreport 4(4): 419-422

Martinez, G.; Di Giacomo, C.; Carnazza, M.L.; Sorrenti, V.; Castana, R.; Barcellona, M.L.; Perez-Polo, J.R.; Vanella, A. 1997: MAP2, synaptophysin immunostaining in rat brain and behavioral modifications after cerebral postischemic reperfusion. Developmental Neuroscience 19(6): 457-464

Chung, W.J.; Kindler, S.; Seidenbecher, C.; Garner, C.C. 1996: MAP2a, an alternatively spliced variant of microtubule-associated protein 2. Journal of Neurochemistry 66(3): 1273-1281

Ferhat, L.; Represa, A.; Bernard, A.; Ben-Ari, Y.; Khrestchatisky, M. 1996: MAP2d promotes bundling and stabilization of both microtubules and microfilaments. Journal of Cell Science 109: 1095-1103

Peterson, B.E.; Merzenich, M.M. 1995: MAP: A Macintosh program for generating categorical maps applied to cortical mapping. Journal of Neuroscience Methods 57(2): 133-144

Aguilar, R.C.; Retegui, L.A.; Roguin, L.P. 1994: MAPAG: A computer program to construct 2- and 3-dimensional antigenic maps. International Journal of Bio-Medical Computing 37(3): 225-235

Attar, B.M.; Atten, M.J.; Holian, O. 1996: MAPK activity is down-regulated in human colon adenocarcinoma: correlation with PKC activity. Anticancer Research 16(1): 395-399

Abrieu, A.; Fisher, D.; Simon, M.N.; Dorée, M.; Picard, A. 1997: MAPK inactivation is required for the G2 to M-phase transition of the first mitotic cell cycle. EMBO Journal 16(21): 6407-6413

Engel, K.; Ahlers, A.; Brach, M.A.; Herrmann, F.; Gaestel, M. 1995: MAPKAP kinase 2 is activated by heat shock and TNF-alpha: in vivo phosphorylation of small heat shock protein results from stimulation of the MAP kinase cascade. Journal of Cellular Biochemistry 57(2): 321-330

Stokoe, D.; Campbell, D.G.; Nakielny, S.; Hidaka, H.; Leevers, S.J.; Marshall, C.; Cohen, P. 1992: MAPKAP kinase-2; a novel protein kinase activated by mitogen-activated protein kinase. EMBO Journal 11(11): 3985-3994

Ni, H.; Wang, X.S.; Diener, K.; Yao, Z. 1998: MAPKAPK5, a novel mitogen-activated protein kinase (MAPK)-activated protein kinase, is a substrate of the extracellular-regulated kinase (ERK) and p38 kinase. Biochemical and Biophysical Research Communications 243(2): 492-496

Machida, Y.; Nakashima, M.; Morikiyo, K.; Banno, H.; Ishikawa, M.; Soyano, T.; Nishihama, R. 1998: MAPKKK-related protein kinase NPK1: Regulation of the M phase of plant cell cycle. Journal of Plant Research 111(1102): 243-246

Ukai, Y.; Osawa, R.; Saito, A.; Hayashi, T. 1995: MAPL: A package of computer programs for construction of DNA polymorphism linkage maps and analysis of QTL. Breeding Science 45(1): 139-142

Deehan, M.R.; Klaus, G.G.; Holman, M.J.; Harnett, W.; Harnett, M.M. 1998: MAPkinase: a second site of G-protein regulation of B-cell activation via the antigen receptors. Immunology 95(2): 169-177

Meberg, P.J.; McCabe, B.J.; Routtenberg, A. 1996: MARCKS and protein F1/GAP-43 mRNA in chick brain: effects of imprinting. Brain Research. Molecular Brain Research 35(1-2): 149-156

Stumpo, D.J.; Bock, C.B.; Tuttle, J.S.; Blackshear, P.J. 1995: MARCKS deficiency in mice leads to abnormal brain development and perinatal death. Proceedings of the National Academy of Sciences of the United States of America 92(4): 944-948

Brooks, G.; Brooks, S.F.; Goss, M.W. 1996: MARCKS functions as a novel growth suppressor in cells of melanocyte origin. Carcinogenesis 17(4): 683-689

Myat, M.M.; Anderson, S.; Allen, L.A.; Aderem, A. 1997: MARCKS regulates membrane ruffling and cell spreading. Current Biology: Cb 7(8): 611-614

Probst, T.; Dabrowski, H.; Liebler, G.; Wist, E.R. 1993: MARDER--multi-axes rotation device for experimental research. A new concept for investigations of the vestibular, oculomotor, and visual systems of humans in three-dimensional space. Journal of Neuroscience Methods 49(1-2): 49-61

Uso-Domenech, J.L.; Villacampa-Esteve, Y.; Stubing-Martinez, G.; Karjalainen, T.; Ramo, M.P. 1995: MARIOLA: A model for calculating the response of mediterranean bush ecosystem to climatic variations. Ecological Modelling 80(2-3): 113-129

Marshall, G.; Guo, W.; Jones, R.H. 1995: MARKOV: A computer program for multi-state Markov models with covariables. Computer Methods and Programs in Biomedicine 47(2): 147-156

Walter, W.R.; Singh, G.B.; Krawetz, S.A. 1998: MARs mission update. Biochemical and Biophysical Research Communications 242(2): 419-422

Anderson, D.J. 1993: MASH genes and the logic of neural crest cell lineage diversification. Comptes Rendus de l'Academie des Sciences. Serie Iii Sciences de la Vie 316(9): 1082-1096

Lo, L.; Tiveron, M.C.; Anderson, D.J. 1998: MASH1 activates expression of the paired homeodomain transcription factor Phox2a, and couples pan-neuronal and subtype-specific components of autonomic neuronal identity. Development 125(4): 609-620

Lo, L.; Sommer, L.; Anderson, D.J. 1997: MASH1 maintains competence for BMP2-induced neuronal differentiation in post-migratory neural crest cells. Current Biology: Cb 7(6): 440-450

Perper, M.M.; Breitkopf, L.J.; Breitstein, R.; Cody, R.P.; Manowitz, P. 1993: MAST scores, alcohol consumption, and gynecological symptoms in endometriosis patients. Alcoholism Clinical and Experimental Research 17(2): 272-278

Takimoto, H.; Suzuki, S.; Masui, S.; Shibata, K.; Tomita, Y.; Shibahara, S.; Nakano, H. 1995: MAT-1, a monoclonal antibody that specifically recognizes human tyrosinase. Journal of Investigative Dermatology 105(6): 764-768

Adamczewski, J.P.; Rossignol, M.; Tassan, J.P.; Nigg, E.A.; Moncollin, V.; Egly, J.M. 1996: MAT1, cdk7 and cyclin H form a kinase complex which is UV light-sensitive upon association with TFIIH. EMBO Journal 15(8): 1877-1884

Depiereux, E.; Feytmans, E. 1992: MATCH-BOX: a fundamentally new algorithm for the simultaneous alignment of several protein sequences. Computer Applications in the Biosciences: Cabios 8(5): 501-509

Shimizu, C.; Akazawa, C.; Nakanishi, S.; Kageyama, R. 1995: MATH-2, a mammalian helix-loop-helix factor structurally related to the product of Drosophila proneural gene atonal, is specifically expressed in the nervous system. European Journal of Biochemistry 229(1): 239-248

Chen, H.; Pulido, J.C.; Duyk, G.M. 1995: MATS: A rapid and efficient method for the development of microsatellite markers from YACs. Genomics 25(1): 1-8

Wu, X.; Haber, J.E. 1995: MATa donor preference in yeast mating-type switching: activation of a large chromosomal region for recombination. Genes and Development 9(15): 1922-1932

Bergeron, A.; Champetier, S.; LaRue, H.; Fradet, Y. 1996: MAUB is a new mucin antigen associated with bladder cancer. Journal of Biological Chemistry 271(12): 6933-6940

Kohut, C., K.; Abley, M.; Dudas, M.J. 1993: MAX: An interactive computer program for teaching identification of clay minerals by X-ray diffraction. Journal of Natural Resources and Life Sciences Education 22(2): 169-172

Ashfield, R.; Patel, A.J.; Bossone, S.A.; Brown, H.; Campbell, R.D.; Marcu, K.B.; Proudfoot, N.J. 1994: MAZ-dependent termination between closely spaced human complement genes. EMBO Journal 13(23): 5656-5667

Schrijvers, A.H.; Quak, J.J.; Uyterlinde, A.M.; van Walsum, M.; Meijer, C.J.; Snow, G.B.; van Dongen, G.A. 1993: MAb U36, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck. Cancer Research 53(18): 4383-4390

Matsui, H.; Hashimoto, H.; Fukushima, A.; Kanayama, H.; Mitani, S.; Toki, Y.; Okumura, K.; Ito, T. 1996: MB fraction of cumulative creatine kinase correlates with insulin secretion in patients with acute myocardial infarction: Insulin as a possible determinant of myocardial MB creatine kinase. American Heart Journal 131(1): 24-31

Korotkov, E.V. 1992: MB1 family repeats in genomes of some mammals. Izvestiya Rossiiskoi Akademii Nauk Seriya Biologicheskaya 1992(4): 546-557

Rep, M.; Grivell, L.A. 1996: MBA1 encodes a mitochondrial membrane-associated protein required for biogenesis of the respiratory chain. Febs Letters 388(2-3): 185-188

Sellebjerg, F.; Christiansen, M.; Garred, P. 1998: MBP, anti-MBP and anti-PLP antibodies, and intrathecal complement activation in multiple sclerosis. Multiple Sclerosis 4(3): 127-131

Daignan-Fornier, B.; Nguyen, C.C.; Reisdorf, P.; Lemeignan, B.; Bolotin-Fukuhara, M. 1994: MBR1 and MBR3, two related yeast genes that can suppress the growth defect of hap2, hap3 and hap4 mutants. Molecular and general genetics: MGG 243(5): 575-583

Claro, F.; Perez Izquierdo, M.A.; Del Abril, A.; Segovia, S.; Guillamon, A.; Del Cerro, M.C. 1994: MBR: A computer program to record and analyze parental behavior in rodents. Physiology and Behavior 56(5): 1069-1073

Dardel, F. 1994: MC-Fit: using Monte-Carlo methods to get accurate confidence limits on enzyme parameters. Computer Applications in the Biosciences: Cabios 10(3): 273-275

Bonucci, E.; Silvestrini, G.; Mocetti, P. 1997: MC22-33F monoclonal antibody shows unmasked polar head groups of choline-containing phospholipids in cartilage and bone. European Journal of Histochemistry: Ejh 41(3): 177-190

Shakhtarin, V.V.; Izotova, I.A.; Parshkov, E.M.; Chekin, S.Y.; Simakov, G.M. 1992: MCA and CA-125 tumor markers in diagnosis and follow-up of breast cancer. Voprosy Onkologii (St Petersburg) 38(4-6): 433-439

Brint, S.U.; Al-Khalidi, H.R.; Vatel, B.; Hier, D.B. 1996: MCA flow asymmetry is a marker for cerebrovascular disease. Neurological Research 18(2): 163-167

Hatzimanikatis, V.; Bailey, J.E. 1996: MCA has more to say. Journal of Theoretical Biology 182(3): 233-242

Donadeo, A.; Micelli, G.; Quaranta, M.; Atlante, A.; Schittulli, F. 1995: MCA performance in preoperative breast cancer patients. Anticancer Research 15(2): 527-529

Engel, A.M.; Svane, I.M.; Rygaard, J.; Werdelin, O. 1997: MCA sarcomas induced in scid mice are more immunogenic than MCA sarcomas induced in congenic, immunocompetent mice. Scandinavian Journal of Immunology 45(5): 463-470

Dominguez-Gadea, L.; Martin-Curto, L.M.; Crespo, A.; Avila, C. 1993: MCA serum determination in breast carcinoma patients for the diagnosis of bone metastases. International Journal of Biological Markers 8(4): 203-207

Matsumine, A.; Senda, T.; Baeg, G.H.; Roy, B.C.; Nakamura, Y.; Noda, M.; Toyoshima, K.; Akiyama, T. 1996: MCC, a cytoplasmic protein that blocks cell cycle progression from the G0/G1 to S phase. Journal of Biological Chemistry 271(17): 10341-10346

Davy, S.L.; Breton, J.; Osborne, M.J.; Thomson, A.J.; Thurgood, A.P.; Lian, L.Y.; Pétillot, Y.; Hatchikian, C.; Moore, G.R. 1994: MCD and 1H-NMR spectroscopic studies of Desulfovibrio africanus ferredoxin I: Revised amino-acid sequence and identification of secondary structure. Biochimica et Biophysica Acta 1209(1): 33-39

Cox, M.C.; Le Brun, N.; Thomson, A.J.; Smith, A.; Morgan, W.T.; Moore, G.R. 1995: MCD, EPR and NMR spectroscopic studies of rabbit hemopexin and its heme binding domain. Biochimica Et Biophysica Acta 1253(2): 215-223

Calaora, V.; Chazal, G.; Nielsen, P.J.; Rougon, G.; Moreau, H. 1996: MCD24 expression in the developing mouse brain and in zones of secondary neurogenesis in the adult. Neuroscience 73(2): 581-594

Shewan, D.; Calaora, V.; Nielsen, P.; Cohen, J.; Rougon, G.; Moreau, H. 1996: mCD24, a glycoprotein transiently expressed by neurons, is an inhibitor of neurite outgrowth. Journal of Neuroscience: the Official Journal of the Society for Neuroscience 16(8): 2624-2634

Costa, M.; Danesi, R.; Agen, C.; Di Paolo, A.; Basolo, F.; Del Bianchi, S.; Del Tacca, M. 1994: MCF-10A cells infected with the int-2 oncogene induce angiogenesis in the chick chorioallantoic membrane and in the rat mesentery. Cancer Research 54(1): 9-11

Ways, D.K.; Kukoly, C.A.; deVente, J.; Hooker, J.L.; Bryant, W.O.; Posekany, K.J.; Fletcher, D.J.; Cook, P.P.; Parker, P.J. 1995: MCF-7 breast cancer cells transfected with protein kinase C-alpha exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. Journal of Clinical Investigation 95(4): 1906-1915

Kilgore, M.W.; Tate, P.L.; Rai, S.; Sengoku, E.; Price, T.M. 1997: MCF-7 and T47D human breast cancer cells contain a functional peroxisomal response. Molecular and Cellular Endocrinology 129(2): 229-235

Liu, Y.; el-Ashry, D.; Chen, D.; Ding, I.Y.; Kern, F.G. 1995: MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Research and Treatment 34(2): 97-117

Zhang, L.; Kharbanda, S.; Chen, D.; Bullocks, J.; Ding, D.L.V.M.lleran Y.F.; Hanfelt, J.; Mcleskey, S.W.; Kern, F.G. 1997: MCF-7 breast carcinoma cells overexpression FGF-1 form vascularized, metastatic tumors in ovariectomized or tamoxifen-treated nude mice. Oncogene 15(17): 2093-2108

Es-Saady, D.; Simon, A.; Jayat-Vignoles, C.; Chulia, A.J.; Delage, C. 1996: MCF-7 cell cycle arrested at G1 through ursolic acid, and increased reduction of tetrazolium salts. Anticancer Research 16(1): 481-486

Wilson, J.W.; Wakeling, A.E.; Morris, I.D.; Hickman, J.A.; Dive, C. 1995: MCF-7 human mammary adenocarcinoma cell death in vitro in response to hormone-withdrawal and DNA damage. International Journal of Cancer 61(4): 502-508

Dawson, P.J.; Wolman, S.R.; Tait, L.; Heppner, G.H.; Miller, F.R. 1996: MCF10AT: a model for the evolution of cancer from proliferative breast disease. American Journal of Pathology 148(1): 313-319

Brünner, N.; Frandsen, T.L.; Holst-Hansen, C.; Bei, M.; Thompson, E.W.; Wakeling, A.E.; Lippman, M.E.; Clarke, R. 1993: MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Research 53(14): 3229-3232

Brünner, N.; Boysen, B.; Jirus, S.; Skaar, T.C.; Holst-Hansen, C.; Lippman, J.; Frandsen, T.; Spang-Thomsen, M.; Fuqua, S.A.; Clarke, R. 1997: MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICi 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Cancer Research 57(16): 3486-3493

Saikia, B.; Agarwal, A.K. 1991: MCH services in ICDS and non-ICDS area: A study of mothers, knowledge and practices in resettlement colonies of Delhi. Health and Population Perspectives and Issues 14(3-4): 136-141

Miyoshi, H.; Nakaya, Y.; Saito, K.; Kishi, F.; Takakura, M.; Nomura, M. 1995: MCI-154 activates the Ca(2+)-activated K+ channel of vascular smooth muscle cells. Life Sciences 56(15): Pl291-Pl298

Sata, M.; Sugiura, S.; Yamashita, H.; Fujita, H.; Momomura, S.; Serizawa, T. 1995: MCI-154 increases Ca2+ sensitivity of reconstituted thin filament. A study using a novel in vitro motility assay technique. Circulation Research 76(4): 626-633

Onishi, K.; Sekioka, K.; Ishisu, R.; Abe, Y.; Tanaka, H.; Nakamura, M.; Ueda, Y.; Nakano, T. 1997: MCI-154, a Ca2+ sensitizer, decreases the oxygen cost of contractility in isolated canine hearts. American Journal of Physiology 273(4): H1688-H1695

Kitada, Y. 1997: MCI-154, a cardiac Ca2+ sensitizer, reverses the depression in maximal Ca2+-activated force by inorganic phosphate and acidic pH in skinned fiber of guinea pig heart. Cardiovascular Drugs and Therapy 11(5): 611-618,.

Kitada, Y. 1996: MCI-154-induced relaxation in vascular smooth muscles of guinea pig. Journal of Cardiovascular Pharmacology 27(4): 519-526

Eguchi, J.; Saitoh, Y.; Egawa, M.; Saito, K.; Kawamura, H. 1997: MCI-225, a novel thienopyrimidine analog, enhances attentional eye tracking in midpontine pretrigeminal preparation. Pharmacology Biochemistry and Behavior 56(2): 229-234

Watanabe-Kohno, S.; Yamamura, H.; Nabe, T.; Horiba, M.; Ohata, K. 1992: MCI-826 is a potent and selective antagonist of peptide leukotrienes (p-LTs) and has characteristics distinctive from those of FPL 55712. Japanese Journal of Pharmacology 60(1): 1-8

Yang, T.; Buchan, H.L.; Townsend, K.J.; Craig, R.W. 1996: MCL-1, a member of the BLC-2 family, is induced rapidly in response to signals for cell differentiation or death, but not to signals for cell proliferation. Journal of Cellular Physiology 166(3): 523-536

Kozopas, K.M.; Yang, T.; Buchan, H.L.; Zhou, P.; Craig, R.W. 1993: MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proceedings of the National Academy of Sciences of the United States of America 90(8): 3516-3520

Errede, B. 1993: MCM1 binds to a transcriptional control element in Ty1. Molecular and Cellular Biology 13(1): 57-62

Ladenburger, E.M.; Fackelymayer, F.O.; Hameister, H.; Knippers, R. 1997: MCM4 and PRKDC, human genes encoding proteins MCM4 and DNA-PKcs, are close neighbours located on chromosome 8q12 fwdarw q13. Cytogenetics and Cell Genetics 77(3-4): 268-270

Lawson, A.B. 1995: MCMC methods for putative pollution source problems in environmental epidemiology. Statistics in Medicine 14(21-22): 2473-2485

Heath, S.C.; Snow, G.L.; Thompson, E.A.; Tseng, C.; Wijsman, E.M. 1997: MCMC segregation and linkage analysis. Genetic Epidemiology 14(6): 1011-1016

Wang, L.; Jacques, S.L.; Zheng, L. 1995: MCML--Monte Carlo modeling of light transport in multi-layered tissues. Computer Methods and Programs in Biomedicine 47(2): 131-146

Murakami, H.; Tamura, J.; Sawamura, M. 1993: MCNU in the treatment of essential thrombocythemia--a pilot study. Annals of Hematology 66(5): 247-249

Sozzani, S.; Introna, M.; Bernasconi, S.; Polentarutti, N.; Cinque, P.; Poli, G.; Sica, A.; Mantovani, A. 1997: MCP-1 and CCR2 in HIV infection: regulation of agonist and receptor expression. Journal of Leukocyte Biology 62(1): 30-33

Paine, R.; Rolfe, M.W.; Standiford, T.J.; Burdick, M.D.; Rollins, B.J.; Strieter, R.M. 1993: MCP-1 expression by rat type II alveolar epithelial cells in primary culture. Journal of Immunology 150(10): 4561-4570

Gillitzer, R.; Wolff, K.; Tong, D.; Müller, C.; Yoshimura, T.; Hartmann, A.A.; Stingl, G.; Berger, R. 1993: MCP-1 mRNA expression in basal keratinocytes of psoriatic lesions. Journal of Investigative Dermatology 101(2): 127-131

Zisman, D.A.; Kunkel, S.L.; Strieter, R.M.; Tsai, W.C.; Bucknell, K.; Wilkowski, J.; Standiford, T.J. 1997: MCP-1 protects mice in lethal endotoxemia. Journal of Clinical Investigation 99(12): 2832-2836

Boitelle, A.; Gosset, P.; Copin, M.C.; Vanhee, D.; Marquette, C.H.; Wallaert, B.; Gosselin, B.; Tonnel, A.B. 1997: MCP-1 secretion in lung from nonsmoking patients with coal worker's pneumoconiosis. European Respiratory Journal 10(3): 557-562

Cashman, J.D.; Eaves, C.J.; Sarris, A.H.; Eaves, A.C. 1998: MCP-1, not MIP-1alpha, is the endogenous chemokine that cooperates with TGF-beta to inhibit the cycling of primitive normal but not leukemic (CML) progenitors in long-term human marrow cultures. Blood 92(7): 2338-2344

Yen, H.; Zhang, Y.; Penfold, S.; Rollins, B.J. 1997: MCP-1-mediated chemotaxis requires activation of non-overlapping signal transduction pathways. Journal of Leukocyte Biology 61(4): 529-532

Zhang, Y.jun; Ernst, Catherine, A.; Rollins, Barrett, J. 1996: MCP-1: Structure/activity analysis. Methods (Orlando) 10(1): 93-103

Garlaschelli, L.; Vidari, G.; Zanoni, G. 1992: MCPBA oxidation of bicyclo(3.3.0)octane-3,7-dione: An easy entry to a new functionalized cyclopentanoid building block. Tetrahedron 48(43): 9495-9502

Manzoni, O.J.; Weisskopf, M.G.; Nicoll, R.A. 1994: MCPG antagonizes metabotropic glutamate receptors but not long-term potentiation in the hippocampus. European Journal of Neuroscience 6(6): 1050-1054

Chattopadhyaya, J.; Doemling, A.; Lorenz, K.; Ugi, W.-Vv-Richterar; Werner, B. 1997: MCR III. Multicomponent reactions and their libraries, a new type of organic chemistry of the isocyanides and phosphorus derivatives. Nucleosides and Nucleotides 16(5-6): 843-848

Bock, K.W.; Birbaumer, N. 1997: MCS (Multiple Chemical Sensitivity): cooperation between toxicology and psychology may facilitate solutions of the problems: commentary. Human and Experimental Toxicology 16(9): 481-484

Timmermans, J.W.; De Wit, D.; Tournois, H.; Leeflang, B.R.; Vliegenthart, J.F.G. 1993: MD calculations on nystose combined with NMR spectroscopy on inulin relate oligosaccharides. Journal of Carbohydrate Chemistry 12(7): 969-979

Heiner, A.P.; Berendsen, H.J.; van Gunsteren, W.F. 1992: MD simulation of subtilisin BPN' in a crystal environment. Proteins 14(4): 451-464

Garmer, D.R. 1997: MD simulations of a 5-HT2A receptor model in DOPC membranes. Journal of Biomolecular Structure and Dynamics 14(5): 525-546

Gordon, D. 1996: MDs' failure to use plain language can lead to the courtroom. Cmaj: Canadian Medical Association Journal 155(8): 1152-1154

Gormezano, I. 1994: MDA effects on classical appetitive conditioning of the rabbit jaw movement response. Brain Research Bulletin 35(2): 183-187

Dalene, M.; Jakobsson, K.; Rannug, A.; Skarping, G.; Hagmar, L. 1996: MDA in plasma as a biomarker of exposure to pyrolysed MDI-based polyurethane: correlations with estimated cumulative dose and genotype for N-acetylation. International Archives of Occupational and Environmental Health 68(3): 165-169

Lazzarino, G.; Vagnozzi, R.; Tavazzi, B.; Pastore, F.S.; Di Pierro, D.; Siragusa, P.; Belli, A.; Giuffré, R.; Giardina, B. 1992: MDA, oxypurines, and nucleosides relate to reperfusion in short-term incomplete cerebral ischemia in the rat. Free Radical Biology and Medicine 13(5): 489-498

McLeskey, S.W.; Ding, I.Y.; Lippman, M.E.; Kern, F.G. 1994: MDA-MB-134 breast carcinoma cells overexpress fibroblast growth factor (FGF) receptors and are growth-inhibited by FGF ligands. Cancer Research 54(2): 523-530

Hall, R.E.; Birrell, S.N.; Tilley, W.D.; Sutherland, R.L. 1994: MDA-MB-453, an androgen-responsive human breast carcinoma cell line with high level androgen receptor expression. European Journal of Cancer 30a(4): 484-490

Xie, W.; Su, K.; Wang, D.; Paterson, A.J.; Kudlow, J.E. 1997: MDA468 growth inhibition by EGF is associated with the induction of the cyclin-dependent kinase inhibitor p21WAF1. Anticancer Research 17(4a): 2627-2633

Urabe, M.; Tanaka, T.; Tobita, K. 1993: MDBK cells which survived infection with a mutant of influenza virus A/WSN and subsequently received many passages contained viral M and NS genes in full length in the absence of virus production. Archives of Virology 130(3-4): 457-462

Weskamp, G.; Krätzschmar, J.; Reid, M.S.; Blobel, C.P. 1996: MDC9, a widely expressed cellular disintegrin containing cytoplasmic SH3 ligand domains. Journal of Cell Biology 132(4): 717-726

Rothen-Rutishauser, B.; Krämer, S.D.; Braun, A.; Günthert, M.; Wunderli-Allenspach, H. 1998: MDCK cell cultures as an epithelial in vitro model: Cytoskeleton and tight junctions as indicators for the definition of age-related stages by confocal microscopy. Pharmaceutical Research 15(7): 964-971

Yamaoka, M.; Homma, M.; Hotta, H. 1995: MDCK cell cultures supplemented with high concentrations of trypsin exhibit remarkable susceptibility to influenza C virus. Archives of Virology 140(5): 937-944

Tsatsakis, A.M.; Michalodimitrakis, M.N.; Patsalis, A.N. 1997: MDEA related death in Crete: a case report and literature review. Veterinary and Human Toxicology 39(4): 241-244

Ruschmeyer, D.; Thude, H.; Mühlradt, P.F. 1993: MDHM, a macrophage-activating product of Mycoplasma fermentans, stimulates murine macrophages to synthesize nitric oxide and become tumoricidal. Fems Immunology and Medical Microbiology 7(3): 223-229

Kehne, J.H.; Baron, B.M.; Harrison, B.L.; McCloskey, T.C.; Palfreyman, M.G.; Poirot, M.; Salituro, F.G.; Siegel, B.W.; Slone, A.L.; Van Giersbergen, P.L. 1995: MDL 100,458 and MDL 102,288: two potent and selective glycine receptor antagonists with different functional profiles. European Journal of Pharmacology 284(1-2): 109-118

Johnson, M.P.; Mccarty, D.R.; Velayo, N.L.; Markgraf, C.G.; Chmielewski, P.A.; Ficorilli, J.V.; Cheng, H.C.; Thomas, C.E. 1998: MDL 101,002, a free radical spin trap, is efficacious in permanent and transient focal ischemia models. Life Sciences 63(4): 241-253

Ferretti, M.E.; Sonetti, D.; Pareschi, M.C.; Buzzi, M.; Colamussi, M.L.; Biondi, C. 1996: MDL 12330A inhibits the non-neuronal adenylyl cyclase from the freshwater snail Planorbarius corneus, but the neuronal enzyme is activated by this compound. Neuroscience Letters 207(3): 191-194

Kehne, J.H.; Ketteler, H.J.; Kane, J.M.; Mccloskey, T.C.; Senyah, Y.; Palfreyman, M.G. 1992: MDL 27,531 reduces spontaneous hindlimb contractions in rats with chronic transections of the spinal cord. Neuroscience Letters 147(1): 101-105

Johnson, M.B.; Heineke, E.W.; Rhinehart, B.L.; Sheetz, M.J.; Barnhart, R.L.; Robinson, K.M. 1993: MDL 29311. Antioxidant with marked lipid- and glucose-lowering activity in diabetic rats and mice. Diabetes 42(8): 1179-1186

Lacosta, S.; Roberts, D.C. 1993: MDL 72222, ketanserin, and methysergide pretreatments fail to alter breaking points on a progressive ratio schedule reinforced by intravenous cocaine. Pharmacology Biochemistry and Behavior 44(1): 161-165

Cowley, D.J.; Lukovic, L.; Petty, M.A. 1996: MDL 74,180 reduces cerebral infarction and free radical concentrations in rats subjected to ischaemia and reperfusion. European Journal of Pharmacology 298(3): 227-233

Bridges, C.G.; Taylor, D.L.; Ahmed, P.S.; Brennan, T.M.; Hornsperger, J.M.; Navé, J.F.; Casara, P.; Tyms, A.S. 1996: MDL 74,968, a new acyclonucleotide analog: activity against human immunodeficiency virus in vitro and in the hu-PBL-SCID.beige mouse model of infection. Antimicrobial Agents and Chemotherapy 40(5): 1072-1077

Manzanares, J.; Edwards, J.V.; Lookingland, K.J.; Moore, K.E. 1994: MDL-101,562 blocks the stimulatory effects of bombesin and gastrin-releasing peptide on hypothalamic dopaminergic neurons. European Journal of Pharmacology 257(1-2): 199-202

Pruneri, G.; Pignataro, L.; Carboni, N.; Luminari, S.; Capaccio, P.; Neri, A.; Buffa, R. 1997: MDM-2 oncoprotein overexpression in laryngeal squamous cell carcinoma: association with wild-type p53 accumulation. Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology Inc 10(8): 785-792

Kanavaros, P.; Kouvidou, C.; Dai, Y.; Tzardi, M.; Datseris, G.; Darivianaki, K.; Rontogianni, D.; Delides, G. 1995: MDM-2 protein expression in nasopharyngeal carcinomas. Comparative study with p53 protein expression. Clinical Molecular Pathology 48(6): M322-M325

Meddeb, M.; Valent, A.; Danglot, G.; Nguyen, V.C.; Duverger, A.; Fouquet, F.; Terrier-Lacombe, M.J.; Oberlin, O.; Bernheim, A. 1996: MDM2 amplification in a primary alveolar rhabdomyosarcoma displaying a t(2;13)(q35;q14). Cytogenetics and Cell Genetics 73(4): 325-330

Ladanyi, M.; Lewis, R.; Jhanwar, S.C.; Gerald, W.; Huvos, A.G.; Healey, J.H. 1995: MDM2 and CDK4 gene amplification in Ewing's sarcoma. Journal of Pathology 175(2): 211-217

Sánchez-Beato, M.; Piris, M.A.; Martínez-Montero, J.C.; García, J.F.; Villuendas, R.; García, F.J.; Orradre, J.L.; Martínez, P. 1996: MDM2 and p21WAF1/CIP1, wild-type p53-induced proteins, are regularly expressed by Sternberg-Reed cells in Hodgkin's disease. Journal of Pathology 180(1): 58-64

Ambros, R.A.; Sheehan, C.E.; Kallakury, B.V.; Ross, J.S.; Malfetano, J.; Paunovich, E.; Figge, J. 1996: MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma. Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology Inc 9(12): 1165-1169

Léveillard, T.; Gorry, P.; Niederreither, K.; Wasylyk, B. 1998: MDM2 expression during mouse embryogenesis and the requirement of p53. Mechanisms of Development 74(1-2): 189-193

Martinez, J.C.; Mateo, M.; Sánchez-Beato, M.; Villuendas, R.; Orradre, J.L.; Algara, P.; Sánchez-Verde, L.; García, P.; López, C.; Martínez, P. 1995: MDM2 expression in lymphoid cells and reactive and neoplastic lymphoid tissue. Comparative study with p53 expression. Journal of Pathology 177(1): 27-34

Flørenes, V.A.; Maelandsmo, G.M.; Forus, A.; Andreassen, A.; Myklebost, O.; Fodstad, O. 1994: MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. Journal of the National Cancer Institute 86(17): 1297-1302

Nilbert, M.; Rydholm, A.; Willén, H.; Mitelman, F.; Mandahl, N. 1994: MDM2 gene amplification correlates with ring chromosome in soft tissue tumors. Genes Chromosomes and Cancer 9(4): 261-265

Nakayama, T.; Toguchida, J.; Wadayama, B.; Kanoe, H.; Kotoura, Y.; Sasaki, M.S. 1995: MDM2 gene amplification in bone and soft-tissue tumors: Association with tumor progression in differentiated adipose-tissue tumors. International Journal of Cancer 64(5): 342-346

Quesnel, B.; Preudhomme, C.; Fournier, J.; Fenaux, P.; Peyrat, J.P. 1994: MDM2 gene amplification in human breast cancer. European Journal of Cancer 30a(7): 982-984

Ladanyi, M.; Cha, C.; Lewis, R.; Jhanwar, S.C.; Huvos, A.G.; Healey, J.H. 1993: MDM2 gene amplification in metastatic osteosarcoma. Cancer Research 53(1): 16-18

Henning, W.; Rohaly, G.; Kolzau, T.; Knippschild, U.; Maacke, H.; Deppert, W. 1997: MDM2 is a target of simian virus 40 in cellular transformation and during lytic infection. Journal of Virology 71(10): 7609-7618

Maestro, R.; Gloghini, A.; Doglioni, C.; Gasparotto, D.; Vukosavljevic, T.; De Re, V.; Laurino, L.; Carbone, A.; Boiocchi, M. 1995: MDM2 overexpression does not account for stabilization of wild-type p53 protein in non-Hodgkin's lymphomas. Blood 85(11): 3239-3246

Kondo, S.; Barnett, G.H.; Hara, H.; Morimura, T.; Takeuchi, J. 1995: MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis. Oncogene 10(10): 2001-2006

Urashima, M.; Teoh, G.; Chauhan, D.; Ogata, A.; Shirahama, S.; Kaihara, C.; Matsuzaki, M.; Matsushima, H.; Akiyama, M.; Yuza, Y.; Maekawa, K.; Anderson, K.C. 1998: MDM2 protein overexpression inhibits apoptosis of TF-1 granulocyte-macrophage colony-stimulating factor-dependent acute myeloblastic leukemia cells. Blood 92(3): 959-967

Teoh, G.; Urashima, M.; Ogata, A.; Chauhan, D.; DeCaprio, J.A.; Treon, S.P.; Schlossman, R.L.; Anderson, K.C. 1997: MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells. Blood 90(5): 1982-1992

Dubs-Poterszman, M.C.; Tocque, B.; Wasylyk, B. 1995: MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest. Oncogene 11(11): 2445-2449

Aguirre, N.; Ballaz, S.; Lasheras, B.; Del Río, J. 1998: MDMA ('Ecstasy') enhances 5-HT1A receptor density and 8-OH-DPAT-induced hypothermia: Blockade by drugs preventing 5-hydroxytryptamine depletion. European Journal of Pharmacology 346(2-3): 181-188

Schifano, F.; Di Furia, L.; Forza, G.; Minicuci, N.; Bricolo, R. 1998: MDMA ('ecstasy') consumption in the context of polydrug abuse: A report on 150 patients. Drug and Alcohol Dependence 52(1): 85-90

Meehan, S.M.; Gordon, T.L.; Schechter, M.D. 1995: MDMA (Ecstasy) substitutes for the ethanol discriminative cue in HAD but not LAD rats. Alcohol 12(6): 569-572

Schwartz, R.H.; Miller, N.S. 1997: MDMA (ecstasy) and the rave: a review. Pediatrics 100(4): 705-708

Sanchez-Hervas, E.; Gradoli, V.T.mas 1998: MDMA (ecstasy): Potential of abuse. Psiquis 19(4): 57-62

Lesage, M.; Poling, A. 1997: MDMA and d-amphetamine produce comparable effects in pigeons performing under a multiple fixed-ratio interresponse-time-greater-than-t schedule of food delivery. Pharmacology Biochemistry and Behavior 57(1-2): 173-177

Lesage, M.; Clark, R.; Poling, A. 1993: MDMA and memory: The acute and chronic effects of MDMA in pigeons performing under a delayed-matching-to-sample procedure. Psychopharmacology 110(3): 327-332

Kalivas, P.W.; Duffy, P.; White, S.R. 1998: MDMA elicits behavioral and neurochemical sensitization in rats. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 18(6): 469-479

Romano, A.G.; Harvey, J.A. 1994: MDMA enhances associative and nonassociative learning in the rabbit. Pharmacology Biochemistry and Behavior 47(2): 289-293

Koch, S.; Galloway, M.P. 1997: MDMA induced dopamine release in vivo: Role of endogenous serotonin. Journal of Neural Transmission 104(2-3): 135-146

Glennon, R.A. 1993: MDMA-like stimulus effects of alpha-ethyltryptamine and the alpha-ethyl homolog of DOM. Pharmacology Biochemistry and Behavior 46(2): 459-462

Schechter, M.D. 1998: MDMA-like stimulus effects of hallucinogens in male fawn-hooded rats. Pharmacology Biochemistry and Behavior 59(2): 265-270

Shvarts, A.; Steegenga, W.T.; Riteco, N.; van Laar, T.; Dekker, P.; Bazuine, M.; van Ham, R.C.; van der Houven van Oordt, W.; Hateboer, G.; van der Eb, A.J.; Jochemsen, A.G. 1996: MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO Journal 15(19): 5349-5357

Zunic, M.; Bahr, G.M.; Mudde, G.C.; Meingassner, J.G.; Lam, C. 1998: MDP(Lysyl)GDP, a nontoxic muramyl dipeptide derivative, inhibits cytokine production by activated macrophages and protects mice from phorbol ester- and oxazolone-induced inflammation. Journal of Investigative Dermatology 111(1): 77-82

Zoladek, T.; Tobiasz, A.; Vaduva, G.; Boguta, M.; Martin, N.C.; Hopper, A.K. 1997: MDP1, a Saccharomyces cerevisiae gene involved in mitochondrial/cytoplasmic protein distribution, is identical to the ubiquitin-protein ligase gene RSP5. Genetics 145(3): 595-603

van den Heuvel-Eibrink, M.M.; van der Holt, B.; te Boekhorst, P.A.; Pieters, R.; Schoester, M.; Löwenberg, B.; Sonneveld, P. 1997: MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia. British Journal of Haematology 99(1): 76-83

Richardson, C.; Ward, M.; Bank, A. 1995: MDR gene transfer into live mice. Journal of Molecular Medicine 73(4): 189-195

Cornelissen, J.J.; Sonneveld, P.; Schoester, M.; Raaijmakers, H.G.; Nieuwenhuis, H.K.; Dekker, A.W.; Lokhorst, H.M. 1994: MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 12(1): 115-119

Kim, H.M.; Oh, G.T.; Hong, D.H.; Kim, M.S.; Kang, J.S.; Park, S.M.; Han, S.B. 1997: MDR-1 gene expression is a minor factor in determining the multidrug resistance phenotype of MCF7/ADR and KB-V1 cells. Febs Letters 412(1): 201-206

Ramachandran, C.; Sauerteig, A.; Sridhar, K.S.; Thurer, R.J.; Krishan, A. 1993: MDR-1 gene expression, anthracycline retention and cytotoxicity in human lung-tumor cells from refractory patients. Cancer Chemotherapy and Pharmacology 31(6): 431-441

Russo, D.; Michelutti, A.; Melli, C.; Damiani, D.; Michieli, M.G.; Candoni, A.; Zhou, D.C.; Marie, J.P.; Zittoun, R.; Baccarani, M. 1995: MDR-related P170-glycoprotein modulates cytotoxic activity of homoharringtonine. Leukemia 9(3): 513-516

Ferrand, V.L.; Chauvet, M.M.; Dell'Amico, M.H.; Tsuruo, T.; Hirn, M.H.; Bourdeaux, M.J. 1996: MDR-related properties of K 562 cells grown in two different culture media. Anticancer Research 16(6b): 3653-3658

Miyachi, H.; Takemura, Y.; Yonekura, S.; Komatsuda, M.; Nagao, T.; Arimori, S.; Ando, Y. 1993: MDR1 (multidrug resistance) gene expression in adult acute leukemia: correlations with blast phenotype. International Journal of Hematology 57(1): 31-37

Chenivesse, X.; Franco, D.; Bréchot, C. 1993: MDR1 (multidrug resistance) gene expression in human primary liver cancer and cirrhosis. Journal of Hepatology 18(2): 168-172

Stein, U.; Shoemaker, R.H.; Schlag, P.M. 1996: MDR1 gene expression: evaluation of its use as a molecular marker for prognosis and chemotherapy of bone and soft tissue sarcomas. European Journal of Cancer 32A(1): 86-92

Van Helvoort, A.; Smith, A.J.; Sprong, H.; Fritzsche, I.; Schinkel, A.H.; Borst, P.; Van Meer, G. 1996: MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 87(3): 507-517

Tóth, K.; Vaughan, M.M.; Peress, N.S.; Slocum, H.K.; Rustum, Y.M. 1996: MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors. American Journal of Pathology 149(3): 853-858

Zöchbauer, S.; Wallner, J.; Haider, K.; Depisch, D.; Huber, H.; Pirker, R. 1997: MDR1 RNA transcripts do not indicate long-term prognosis in colorectal carcinomas. European Journal of Cancer 33(9): 1516-1518

Webb, M.; Brun, M.; McNiven, M.; Le Couteur, D.; Craft, P. 1998: MDR1 and MRP expression in chronic B-cell lymphoproliferative disorders. British Journal of Haematology 102(3): 710-717

Kavallaris, M.; Leary, J.A.; Barrett, J.A.; Friedlander, M.L. 1996: MDR1 and multidrug resistance-associated protein (MRP) gene expression in epithelial ovarian tumors. Cancer Letters 102(1-2): 7-16

de Kant, E.; Heide, I.; Thiede, C.; Herrmann, R.; Rochlitz, C.F. 1996: MDR1 expression correlates with mutant p53 expression in colorectal cancer metastases. Journal of Cancer Research and Clinical Oncology 122(11): 671-675

Metge, K.; Steube, K.; Uphoff, C.C.; Gignac, S.M.; Drexler, H.G. 1993: MDR1 expression in human leukemia-lymphoma cell lines. Leukemia 7(6): 896-897

Dunne, B.M.; McNamara, M.; Clynes, M.; Shering, S.G.; Larkin, A.M.; Moran, E.; Barnes, C.; Kennedy, S.M. 1998: MDR1 expression is associated with adverse survival in melanoma of the uveal tract. Human Pathology 29(6): 594-598

Nørgaard, J.M.; Bukh, A.; Langkjer, S.T.; Clausen, N.; Palshof, T.; Hokland, P. 1998: MDR1 gene expression and drug resistance of AML cells. British Journal of Haematology 100(3): 534-540

Wallner, J.; Depisch, D.; Gsur, A.; Götzl, M.; Haider, K.; Pirker, R. 1993: MDR1 gene expression and its clinical relevance in primary gastric carcinomas. Cancer 71(3): 667-671

Tabata, M.; Ohnoshi, T.; Ueoka, H.; Kiura, K.; Kimura, I. 1993: MDR1 gene expression and treatment outcome in small cell lung cancer: MDR1 gene expression as an independent prognostic factor. Acta Medica Okayama 47(4): 243-248

Tishler, D.M.; Weinberg, K.I.; Hinton, D.R.; Barbaro, N.; Annett, G.M.; Raffel, C. 1995: MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 36(1): 1-6

Götzl, M.; Wallner, J.; Gsur, A.; Zöchbauer, S.; Kovarik, J.; Balcke, P.; Pirker, R. 1995: MDR1 gene expression in lymphocytes of patients with renal transplants. Nephron 69(3): 277-280

Park, J.G.; Lee, S.K.; Hong, I.G.; Kim, H.S.; Lim, K.H.; Choe, K.J.; Kim, W.H.; Kim, Y.I.; Tsuruo, T.; Gottesman, M.M. 1994: MDR1 gene expression: its effect on drug resistance to doxorubicin in human hepatocellular carcinoma cell lines. Journal of the National Cancer Institute 86(9): 700-705

Rao, V.V.; Anthony, D.C.; Piwnica-Worms, D. 1994: MDR1 gene-specific monoclonal antibody C494 cross-reacts with pyruvate carboxylase. Cancer Research 54(6): 1536-1541

Jakob, I.; Hauser, I.A.; Thévenod, F.; Lindemann, B. 1998: MDR1 in taste buds of rat vallate papilla: functional, immunohistochemical, and biochemical evidence. American Journal of Physiology 274(1): C182-C191

Hegewisch-Becker, S. 1996: MDR1 reversal: criteria for clinical trials designed to overcome the multidrug resistance phenotype. Leukemia 10(Suppl): S32-S38

Liu, Y.; Huang, L.; Hoffman, T.; Gosland, M.; Vore, M. 1996: MDR1 substrates/modulators protect against beta-estradiol-17beta-D-glucuronide cholestasis in rat liver. Cancer Research 56(21): 4992-4997

Beck, J.; Niethammer, D.; Gekeler, V. 1996: MDR1, MRP, topoisomerase IIalpha/beta, and cyclin A gene expression in acute and chronic leukemias. Leukemia 10(Suppl): S39-S45

Lechapt-Zalcman, E.; Hurbain, I.; Lacave, R.; Commo, F.; Urban, T.; Antoine, M.; Milleron, B.; Bernaudin, J.F. 1997: MDR1-Pgp 170 expression in human bronchus. European Respiratory Journal 10(8): 1837-1843

Linn, S.C.; Giaccone, G. 1995: MDR1/P-glycoprotein expression in colorectal cancer. European Journal of Cancer 31a(7-8): 1291-1294

Weaver, J.L.; McKinney, L.; Schoenlein, P.V.; Goldenberg, S.; Gottesman, M.M.; Aszalos, A. 1996: MDR1/P-glycoprotein function. I. Effect of hypotonicity and inhibitors on rhodamine 123 exclusion. American Journal of Physiology 270(5 Pt 1): C1447-C1452

Weaver, J.L.; Aszalos, A.; McKinney, L. 1996: MDR1/P-glycoprotein function. II. Effect of hypotonicity and inhibitors on Cl- efflux and volume regulation. American Journal of Physiology 270(5 Pt 1): C1453-C1460

Zöchbauer, S.; Gsur, A.; Götzl, M.; Wallner, J.; Lechner, K.; Pirker, R. 1994: MDR1 gene expression in myelodysplastic syndrome and in acute myeloid leukemia evolving from myelodysplastic syndrome. Anticancer Research 14(3B): 1293-1295

Ohmori, S.; Ohmori, M.; Yamagishi, M.; Okuma, M. 1993: MDS-macrophage derived inhibitory activity on myelopoiesis of MDS abnormal clones. British Journal of Haematology 83(3): 388-391

Puziss, J.W.; Hardy, T.A.; Johnson, R.B.; Roach, P.J.; Hieter, P. 1994: MDS1, a dosage suppressor of an mck1 mutant, encodes a putative yeast homolog of glycogen synthase kinase 3. Molecular and Cellular Biology 14(1): 831-839

Fredriksson, A.; Archer, T. 1994: MPTP-induced behavioural and biochemical deficits: a parametric analysis. Journal of Neural Transmission. Parkinson's Disease and Dementia Section 7(2): 123-132

Berlin, E.A.; Jara, V.M. 1993: ME' winik: Discovery of the biomedical equivalence for a Maya ethnomedical syndrome. Social Science and Medicine 37(5): 671-678

Urushidani, T.; Muto, Y.; Nagao, T.; Yao, X.; Forte, J.G. 1997: ME-3407, a new antiulcer agent, inhibits acid secretion by interfering with redistribution of H(+)-K(+)-ATPase. American Journal of Physiology 272(5 Part 1): G1122-G1134

Neuman, T.; Keen, A.; Knapik, E.; Shain, D.; Ross, M.; Nornes, H.O.; Zuber, M.X. 1993: ME1 and GE1: basic helix-loop-helix transcription factors expressed at high levels in the developing nervous system and in morphogenetically active regions. European Journal of Neuroscience 5(4): 311-318

Kapasi, K.; Inman, R.D. 1994: ME1 epitope of HLA-B27 confers class I-mediated modulation of gram-negative bacterial invasion. Journal of Immunology 153(2): 833-840

Nagura, J.; Hui, C.; Yamamoto, M.; Yasuda, S.; Abe, M.; Hachisu, M.; Konno, F. 1996: ME3221, a surmountable angiotensin AT1-receptor antagonist, prevents hypertensive complications in aged stroke-prone spontaneously hypertensive rats. Japanese Journal of Pharmacology 71(1): 39-49

Taveggia, C.; Pizzagalli, A.; Feltri, M.L.; Grinspan, J.B.; Kamholz, J.; Wrabetz, L. 1998: MEBA derepresses the proximal myelin basic protein promoter in oligodendrocytes. Journal of Biological Chemistry 273(42): 27741-27748

Emili, A. 1998: MEC1-dependent phosphorylation of Rad9p in response to DNA damage. Molecular Cell 2(2): 183-189

Martin, J.; Sarai, K.; Schindler, M.; van de Loo, A.; Yoshitake, M.; Beyersdorf, F. 1997: MEDOS HIA-VAD biventricular assist device for bridge to recovery in fulminant myocarditis. Annals of Thoracic Surgery 63(4): 1145-1146

Miyazaki, Y.; Sun, X.; Uchida, H.; Zhang, J.; Nimer, S. 1996: MEF, a novel transcription factor with an Elf-1 like DNA binding domain but distinct transcriptional activating properties. Oncogene 13(8): 1721-1729

Lakich, M.M.; Diagana, T.T.; North, D.L.; Whalen, R.G. 1998: MEF-2 and Oct-1 bind to two homologous promoter sequence elements and participate in the expression of a skeletal muscle-specific gene. Journal of Biological Chemistry 273(24): 15217-15226

Ornatsky, O.I.; McDermott, J.C. 1996: MEF2 protein expression, DNA binding specificity and complex composition, and transcriptional activity in muscle and non-muscle cells. Journal of Biological Chemistry 271(40): 24927-24933

Dodou, E.; Sparrow, D.B.; Mohun, T.; Treisman, R. 1995: MEF2 proteins, including MEF2A, are expressed in both muscle and non-muscle cells. Nucleic Acids Research 23(21): 4267-4274

Katoh, Y.; Molkentin, J.D.; Dave, V.; Olson, E.N.; Periasamy, M. 1998: MEF2B is a component of a smooth muscle-specific complex that binds an A/T-rich element important for smooth muscle myosin heavy chain gene expression. Journal of Biological Chemistry 273(3): 1511-1518

Molkentin, J.D.; Firulli, A.B.; Black, B.L.; Martin, J.F.; Hustad, C.M.; Copeland, N.; Jenkins, N.; Lyons, G.; Olson, E.N. 1996: MEF2B is a potent transactivator expressed in early myogenic lineages. Molecular and Cellular Biology 16(7): 3814-3824

Leifer, D.; Krainc, D.; Yu, Y.T.; McDermott, J.; Breitbart, R.E.; Heng, J.; Neve, R.L.; Kosofsky, B.; Nadal-Ginard, B.; Lipton, S.A. 1993: MEF2C, a MADS/MEF2-family transcription factor expressed in a laminar distribution in cerebral cortex. Proceedings of the National Academy of Sciences of the United States of America 90(4): 1546-1550

Gharib, S.; Sutherling, W.W.; Nakasato, N.; Barth, D.S.; Baumgartner, C.; Alexopoulos, N.; Taylor, S.; Rogers, R.L. 1995: MEG and ECoG localization accuracy test. Electroencephalography and Clinical Neurophysiology 94(2): 109-114

Guy, C.N.; Walker, S.; Alarcon, G.; Binnie, C.D.; Chesterman, P.; Fenwick, P.; Smith, S. 1993: MEG and EEG in epilepsy: is there a difference?. Physiological Measurement 14(Suppl): A99-A102

Iramina, K.; Ueno, S.; Matsuoka, S. 1996: MEG and EEG topography of frontal midline theta rhythm and source localization. Brain Topography 8(3): 329-331

Reite, M.; Sheeder, J.; Teale, P.; Richardson, D.; Adams, M.; Simon, J. 1995: MEG based brain laterality: Sex differences in normal adults. Neuropsychologia 33(12): 1607-1616

Jäntti, V.; Baer, G.; Yli-Hankala, A.; Hämäläinen, M.; Hari, R. 1995: MEG burst suppression in an anaesthetized dog. Acta Anaesthesiologica Scandinavica 39(1): 126-128

Simos, P.G.; Breier, J.I.; Zouridakis, G.; Papanicolaou, A.C. 1998: MEG correlates of categorical-like temporal cue perception in humans. Neuroreport 9(11): 2475-2479

Hellstrand, E.; Abraham-Fuchs, K.; Jernberg, B.; Kihlström, L.; Knutsson, E.; Lindquist, C.; Schneider, S.; Wirth, A. 1993: MEG localization of interictal epileptic focal activity and concomitant stereotactic radiosurgery. A non-invasive approach for patients with focal epilepsy. Physiological Measurement 14(2): 131-136

Kellar, K.L.; Hooper, W.C.; Benson, J.M. 1995: MEG-01s cells have receptors for and respond to IL-3, IL-6, and SCF. Experimental Hematology 23(6): 557-564

Virtanen, J.; Rinne, T.; Ilmoniemi, R.J.; Näätänen, R. 1996: MEG-compatible multichannel EEG electrode array. Electroencephalography and Clinical Neurophysiology 99(6): 568-570

Kumar, S.; Tamura, K.; Nei, M. 1994: MEGA: Molecular Evolutionary Genetics Analysis software for microcomputers. Computer Applications in the Biosciences: Cabios 10(2): 189-191

Reddy, B.V.; Ramesh, P.; Tiwari, S. 1998: MEICPS: substitution mutations to engineer intracellular protein stability. Bioinformatics 14(2): 225-226

Weiss, R.H.; Maga, E.A.; Ramirez, A. 1998: MEK inhibition augments Raf activity, but has variable effects on mitogenesis, in vascular smooth muscle cells. American Journal of Physiology 274(6): C1521-C1529

Widmann, C.; Gerwins, P.; Johnson, N.L.; Jarpe, M.B.; Johnson, G.L. 1998: MEK kinase 1, a substrate for DEVD-directed caspases, is involved in genotoxin-induced apoptosis. Molecular and Cellular Biology 18(4): 2416-2429

Hirano, M.; Osada, S.; Aoki, T.; Hirai, S.; Hosaka, M.; Inoue, J.; Ohno, S. 1996: MEK kinase is involved in tumor necrosis factor alpha-induced NF-kappaB activation and degradation of IkappaB-alpha. Journal of Biological Chemistry 271(22): 13234-13238

Fanger, G.R.; Johnson, N.L.; Johnson, G.L. 1997: MEK kinases are regulated by EGF and selectively interact with Rac/Cdc42. EMBO Journal 16(16): 4961-4972

Gardner, A.M.; Vaillancourt, R.R.; Lange-Carter, C.A.; Johnson, G.L. 1994: MEK-1 phosphorylation by MEK kinase, Raf, and mitogen-activated protein kinase: analysis of phosphopeptides and regulation of activity. Molecular Biology of the Cell 5(2): 193-201

Whitehurst, C.E.; Geppert, T.D. 1996: MEK1 and the extracellular signal-regulated kinases are required for the stimulation of IL-2 gene transcription in T cells. Journal of Immunology 156(3): 1020-1029

Karpova, A.Y.; Abe, M.K.; Li, J.; Liu, P.T.; Rhee, J.M.; Kuo, W.L.; Hershenson, M.B. 1997: MEK1 is required for PDGF-induced ERK activation and DNA synthesis in tracheal myocytes. American Journal of Physiology 272(3 Part 1): L558-L565

Zimmermann, S.; Rommel, C.; Ziogas, A.; Lovric, J.; Moelling, K.; Radziwill, G. 1997: MEK1 mediates as positive feedback on Raf-1 activity independently of Ras and Src. Oncogene 15(13): 1503-1511

Brott, B.K.; Alessandrini, A.; Largaespada, D.A.; Copeland, N.G.; Jenkins, N.A.; Crews, C.M.; Erikson, R.L. 1993: MEK2 is a kinase related to MEK1 and is differentially expressed in murine tissues. Cell Growth and Differentiation: the Molecular Biology Journal of the American Association for Cancer Research 4(11): 921-929

Lee, F.S.; Peters, R.T.; Dang, L.C.; Maniatis, T. 1998: MEKK1 activates both IkappaB kinase alpha and IkappaB kinase beta. Proceedings of the National Academy of Sciences of the United States of America 95(16): 9319-9324

Xu, S.; Robbins, D.; Frost, J.; Dang, A.; Lange-Carter, C.; Cobb, M.H. 1995: MEKK1 phosphorylates MEK1 and MEK2 but does not cause activation of mitogen-activated protein kinase. Proceedings of the National Academy of Sciences of the United States of America 92(15): 6808-6812

Fuchs, S.Y.; Adler, V.; Pincus, M.R.; Ronai, Z. 1998: MEKK1/JNK signaling stabilizes and activates p53. Proceedings of the National Academy of Sciences of the United States of America 95(18): 10541-10546

Turakainen, H.; Aho, S.; Korhola, M. 1993: MEL gene polymorphism in the genus Saccharomyces. Applied and Environmental Microbiology 59(8): 2622-2630

Ciotti, P.; Imro, A.; Scudeletti, M.; Rainero, M.L.; Defferrari, R.; Ghiorzo, P.; Indiveri, F.; Bianchi-Scarrà, G. 1996: MEL-P, a GM-CSF-producing human melanoma cell line. Melanoma Research 6(3): 203-213

Taylor, R.W.; Chinnery, P.F.; Haldane, F.; Morris, A.A.; Bindoff, L.A.; Wilson, J.; Turnbull, D.M. 1996: MELAS associated with a mutation in the valine transfer RNA gene of mitochondrial DNA. Annals of Neurology 40(3): 459-462

Li, J.Y.; Kong, K.W.; Chang, M.H.; Cheung, S.C.; Lee, H.C.; Pang, C.Y.; Wei, Y.H. 1996: MELAS syndrome associated with a tandem duplication in the D-loop of mitochondrial DNA. Acta Neurologica Scandinavica 93(6): 450-455

Yang, C.Y.; Lam, H.C.; Lee, H.C.; Wei, Y.H.; Lu, C.C.; Han, T.M.; Tsai, J.L.; Chuang, Y.H.; Lee, J.K. 1995: MELAS syndrome associated with diabetes mellitus and hyperthyroidism: A case report from Taiwan. Clinical Endocrinology 43(2): 235-239

Johns, D.R.; Stein, A.G.; Wityk, R. 1993: MELAS syndrome masquerading as herpes simplex encephalitis. Neurology 43(12): 2471-2473

Huang, C.C.; Chen, R.S.; Chen, C.M.; Wang, H.S.; Lee, C.C.; Pang, C.Y.; Hsu, H.S.; Lee, H.C.; Wei, Y.H. 1994: MELAS syndrome with mitochondrial tRNA(Leu(UUR)) gene mutation in a Chinese family. Journal of Neurology Neurosurgery and Psychiatry 57(5): 586-589

Drouet, A.; Mousson, B.; Carrier, H.; Baverel, G.; Ribot, C. 1997: MELAS syndrome with only stroke-like episodes?. Revue Neurologique (Paris) 153(10): 591-594

Liou, C.W.; Huang, C.C.; Chee, E.C.; Jong, Y.J.; Tsai, J.L.; Pang, C.Y.; Lee, H.C.; Wei, Y.H. 1994: MELAS syndrome: Correlation between clinical features and molecular genetic analysis. Acta Neurologica Scandinavica 90(5): 354-359

Castillo, M.; Kwock, L.; Green, C. 1995: MELAS syndrome: imaging and proton MR spectroscopic findings. Ajnr. American Journal of Neuroradiology 16(2): 233-239

Ujike, H.; Wakagi, T.; Kohira, I.; Kuroda, S.; Otsuki, S.; Sato, T. 1993: MELAS without ragged red fibers or lactic acidosis diagnosed by mitochondrial DNA testing. Japanese Journal of Psychiatry and Neurology 47(3): 637-641

Hanna, M.G.; Nelson, I.P.; Morgan-Hughes, J.A.; Wood, N.W. 1998: MELAS: a new disease associated mitochondrial DNA mutation and evidence for further genetic heterogeneity. Journal of Neurology Neurosurgery and Psychiatry 65(4): 512-517

Miyahara, S.; Akita, M. 1994: MEM analysis of EEG evoked by colored lights. Neurosciences 20(Suppl ): P109-P112

Alvarado, M.; Klassen, C.; Cerny, J.; Horejsí, V.; Schmidt, R.E. 1995: MEM-59 monoclonal antibody detects a CD43 epitope involved in lymphocyte activation. European Journal of Immunology 25(4): 1051-1055

Degen, W.G.; van Kempen, L.C.; Gijzen, E.G.; van Groningen, J.J.; van Kooyk, Y.; Bloemers, H.P.; Swart, G.W. 1998: MEMD, a new cell adhesion molecule in metastasizing human melanoma cell lines, is identical to ALCAM (activated leukocyte cell adhesion molecule). American Journal of Pathology 152(3): 805-813

Maggi, C.A.; Astolfi, M.; Giuliani, S.; Goso, C.; Manzini, S.; Meini, S.; Patacchini, R.; Pavone, V.; Pedone, C.; Quartara, L. 1994: MEN 10,627, a novel polycyclic peptide antagonist of tachykinin NK2 receptors. Journal of Pharmacology and Experimental Therapeutics 271(3): 1489-1500

Maggi, C.A.; Quartara, L.; Patacchini, R.; Giuliani, S.; Barbanti, G.; Turini, D.; Giachetti, A. 1993: MEN 10,573 and MEN 10,612, novel cyclic pseudopeptides which are potent tachykinin NK-2 receptor antagonists. Regulatory Peptides 47(2): 151-158

Fontana, R.; Altamura, M.; Arcamone, F.; Mazzariol, A.; Morandotti, G.; Sperning, R.; Cornaglia, G. 1998: MEN 10700, a new penem antibiotic: in-vitro activity and its correlation with beta-lactamase stability, PBP affinity and diffusion through the bacterial cell wall. Journal of Antimicrobial ChemoTherapy 41(5): 513-525

Lecci, A.; Giuliani, S.; Tramontana, M.; Criscuoli, M.; Maggi, C.A. 1997: MEN 11,420, a peptide tachykinin NK2 receptor antagonist, reduces motor responses induced by the intravesical administration of capsaicin in vivo. Naunyn-Schmiedeberg's Archives of Pharmacology 356(2): 182-188

Santicioli, P.; Giuliani, S.; Patacchini, R.; Tramontana, M.; Criscuoli, M.; Maggi, C.A. 1997: MEN 11420, a potent and selective tachykinin NK2 receptor antagonist in the guinea-pig and human colon. Naunyn-Schmiedeberg's Archives of Pharmacology 356(5): 678-688

Takayama, T.; Kameya, T.; Inagaki, K.; Nonaka, M.; Miyazawa, H.; Ogawa, N.; Yano, M.; Morita, T.; Arai, T.; Niino, S. 1993: MEN type 1 associated with mediastinal carcinoid producing parathyroid hormone, calcitonin and chorionic gonadotropin. Pathology Research and Practice 189(9): 1090-1096; Discussion: 1096-1100

Zweigenbaum, P. 1994: MENELAS: An access system for medical records using natural language. Computer Methods and Programs in Biomedicine 45(1-2): 117-120

Mani, S.; Mcdermott, S.; Valtorta, M. 1997: MENTOR: A Bayesian Model for prediction of mental retardation in newborns. Research in Developmental Disabilities 18(5): 303-318

Sanz, F.; Manaut, F.; Rodríguez, J.; Lozoya, E.; López-de-Briñas, E. 1993: MEPSIM: A computational package for analysis and comparison of molecular electrostatic potentials. Journal of Computer-Aided Molecular Design 7(3): 337-347

Kimura, M.; Ohe, K.; Yoshihara, H.; Ando, Y.; Kawamata, F.; Tsuchiya, F.; Furukawa, H.; Horiguchi, S.; Sakusabe, T.; Tani, S.; Akiyama, M. 1998: MERIT-9: A patient information exchange guideline using MML, HL7 and DICOM. International Journal of Medical Informatics 51(1): 59-68

Holdeman, R.; Nehrt, S.; Strome, S. 1998: MES-2, a maternal protein essential for viability of the germline in Caenorhabditis elegans, is homologous to a Drosophila Polycomb group protein. Development 125(13): 2457-2467

Zumbé, J.; Beintker, M.; Denil, J.; Fornara, P.; Miersch, W.D.; Schroeder-Printzen, I.; Schwarzer, U.; Sperling, H.; Weiske, W.H. 1996: MESA and TESE: experiences of the German section of urological microsurgery. Andrologia 28(Suppl): 89-92

Houran, J.; Lange, R.; Black, D., L. 1998: MESA: A portable multi-energy sensor array for low-frequency electromagnetic field fluctuations. Behavior Research Methods Instruments and Computers 30(3): 411-415

Corrao, G.; Bagnardi, V.; Zambon, A.; Torchio, P. 1998: Meta-analysis of alcohol intake in relation to risk of liver cirrhosis. Alcohol and Alcoholism 33(4): 381-392

Rouxel, T.; Danchin, A.; Henaut, A. 1993: METALGEN.DB: metabolism linked to the genome of Escherichia coli, a graphics-oriented database. Computer Applications in the Biosciences: Cabios 9(3): 315-324

Stoffers, H.J.; Sonnhammer, E.L.; Blommestijn, G.J.; Raat, N.J.; Westerhoff, H.V. 1992: METASIM: object-oriented modelling of cell regulation. Computer Applications in the Biosciences: Cabios 8(5): 443-449

Pirbazari, M.; Badriyha, B.N.; Ravindran, V. 1992: MF-PAC for treating waters contaminated with natural and synthetic organics. Journal - American Water Works Association 84(12): 95-103

Granoff, D.M.; McHugh, Y.E.; Raff, H.V.; Mokatrin, A.S.; Van Nest, G.A. 1997: MF59 adjuvant enhances antibody responses of infant baboons immunized with Haemophilus influenzae type b and Neisseria meningitidis group C oligosaccharide-CRM197 conjugate vaccine. Infection and Immunity 65(5): 1710-1715

Traquina, P.; Morandi, M.; Contorni, M.; Van Nest, G. 1996: MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. Journal of Infectious Diseases 174(6): 1168-1175

Higgins, D.A.; Carlson, J.R.; Van Nest, G. 1996: MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. Vaccine 14(6): 478-484

Ahokas, J.T.; Holdway, D.A.; Brennan, S.E.; Goudey, R.W.; Bibrowska, H.B. 1994: MFO activity in carp (Cyprinus carpio) exposed to treated pulp and paper mill effluent in Lake Coleman, Victoria, Australia, in relation to AOX, EOX and muscle PCDD/PCDF. Environmental Toxicology and Chemistry 13(1): 41-50

Hodson, P.V.; Maj, M.K.; Efler, S.; Burinson, B.K.; Van Heiningen, A.R.P.; Girard, R.; Carey, J.H. 1997: MFO induction in fish by spent cooking liquors from kraft pulp mills. Environmental Toxicology and Chemistry 16(5): 908-916

Yin, Zheng-Min 1993: MFP and CAP chemotherapy regimen in the treatment of lung adenocarcinoma: A report of 67 cases. Chinese Journal of Clinical Oncology 20(5): 366-368

Bamidis, P.D.; Hellstrand, E.; Lidholm, H.; Abraham-Fuchs, K.; Ioannides, A.A. 1995: MFT in complex partial epilepsy: spatio-temporal estimates of interictal activity. Neuroreport 7(1): 17-23

Gonatas, J.O.; Mourelatos, Z.; Stieber, A.; Lane, W.S.; Brosius, J.; Gonatas, N.K. 1995: MG-160, a membrane sialoglycoprotein of the medial cisternae of the rat Golgi apparatus, binds basic fibroblast growth factor and exhibits a high level of sequence identity to a chicken fibroblast growth factor receptor. Journal of Cell Science 108: 457-467

Yuan, P.; Si, L.; He, J. 1993: MG-7 antigen expression of gastrointestinal carcinoma and its immunobiology. Journal of Xi'an Medical University 14(1): 1-4

Stieber, A.; Mourelatos, Z.; Chen, Y.J.; Le Douarin, N.; Gonatas, N.K. 1995: MG160, a membrane protein of the Golgi apparatus which is homologous to a fibroblast growth factor receptor and to a ligand for E-selectin, is found only in the Golgi apparatus and appears early in chicken embryo development. Experimental Cell Research 219(2): 562-570

Sahay, N.; Agarwal, R.A. 1997: MGK-264: Pyrethroid synergism against Lymnaea acuminata. Chemosphere 35(5): 1011-1021

Chen, X.J.; Guan, M.X.; Clark-Walker, G.D. 1993: MGM101, a nuclear gene involved in maintenance of the mitochondrial genome in Saccharomyces cerevisiae. Nucleic Acids Research 21(15): 3473-3477

Shattuck, R.L.; Wood, L.D.; Jaffe, G.J.; Richmond, A. 1994: MGSA/GRO transcription is differentially regulated in normal retinal pigment epithelial and melanoma cells. Molecular and Cellular Biology 14(1): 791-802

Huang, L.Q.; Rowan, M.J.; Anwyl, R. 1997: MGluR Ii agonist inhibition of LTP induction, and mGluR Ii antagonist inhibition of LTD induction, in the dentate gyrus in vitro. Neuroreport 8(3): 687-693

Mukhin, A.G.; Ivanova, S.A.; Faden, A.I. 1997: MGluR modulation of post-traumatic neuronal death: role of NMDA receptors. Neuroreport 8(11): 2561-2566

Daniel, H.; Levenes, C.; Conquet, F.; Crépel, F. 1996: MGluR1 mutant mice as a tool to study calcium signalling and multiple innervation in the cerebellum. Journal of Physiology Paris 90(3-4): 171-172

Valerio, A.; Rizzonelli, P.; Paterlini, M.; Moretto, G.; Knöpfel, T.; Kuhn, R.; Memo, M.; Spano, P. 1997: MGluR5 metabotropic glutamate receptor distribution in rat and human spinal cord: A developmental study. Neuroscience Research 28(1): 49-57

Scott, J.E.; Dawson, J.R. 1995: MHC class i expression and transport in a calnexin-deficient cell line. Journal of Immunology 155(1): 143-148

Fehling, H.J.; Swat, W.; Laplace, C.; Kühn, R.; Rajewsky, K.; Müller, U.; von Boehmer, H. 1994: MHC class I expression in mice lacking the proteasome subunit LMP-7. Science 265(5176): 1234-1237

Margulies, D.H.; Corr, M.; Boyd, L.F.; Khilko, S.N. 1993: MHC class I/peptide interactions: binding specificity and kinetics. Journal of Molecular Recognition: Jmr 6(2): 59-69

Yuen, M.H.; Macklin, K.D.; Conti-Fine, B.M. 1996: MHC class II presentation of human acetylcholine receptor in Myasthenia gravis: binding of synthetic gamma subunit sequences to DR molecules. Journal of Autoimmunity 9(1): 67-77

Cannella, B.; Aquino, D.A.; Raine, C.S. 1995: MHC II expression in the CNS after long-term demyelination. Journal of Neuropathology and Experimental Neurology 54(4): 521-530

Riley, E.M.; Olerup, O.; Bennett, S.; Rowe, P.; Allen, S.J.; Blackman, M.J.; Troye-Blomberg, M.; Holder, A.A.; Greenwood, B.M. 1992: MHC and malaria: the relationship between HLA class Ii alleles and immune responses to Plasmodium falciparum. International Immunology 4(9): 1055-1063

Furudate, N.; Sasamoto, Y.; Kotake, S.; Ogasawara, K.; Onoé, K.; Matsuda, H. 1995: MHC and non-MHC gene effects on the development of experimental autoimmune uveoretinitis. Nippon Ganka Gakkai Zasshi 99(5): 537-540

Talmadge, R.J.; Roy, R.R.; Chalmers, G.R.; Edgerton, V.R. 1996: MHC and sarcoplasmic reticulum protein isoforms in functionally overloaded cat plantaris muscle fibers. Journal of Applied Physiology 80(4): 1296-1303

Dworacki, G.; Kruk Zagajewska, A.; Szmeja, Z.; Zeromski, J. 1996: MHC antigen expression and tumor infiltrating lymphocytes assessed quantitatively in situ in laryngeal cancer. Periodicum Biologorum 98(4): 469-472

Kim, T.S.; Cohen, E.P. 1994: MHC antigen expression by melanomas recovered from mice treated with allogeneic mouse fibroblasts genetically modified for interleukin-2 secretion and the expression of melanoma-associated antigens. Cancer Immunology Immunotherapy: Cii 38(3): 185-193

Nguyen, P.; Woodland, D.L.; Blackman, M.A. 1996: MHC bias of Mls-1 recognition is not influenced by thymic positive selection. Cellular Immunology 167(2): 224-229

Eberl, G.; Sabbatini, A.; Servis, C.; Romero, P.; Maryanski, J.L.; Corradin, G. 1993: MHC class I H-2Kd-restricted antigenic peptides: additional constraints for the binding motif. International Immunology 5(11): 1489-1492

Reinhardt, C.; Falk, C.; Steinle, A.; Schendel, D.J. 1994: MHC class I allorecognition: the likes and dislikes of CTL and NK cells. Behring Institute Mitteilungen 1994(94): 61-71

Bjerneroth, G.; Juhlin, C.; Rastad, J.; Akerström, G.; Klareskog, L. 1993: MHC class I and II antigen expression on parathyroid cells and prospects for their allogenic transplantation. Transplantation 56(3): 717-721

Bander, N.H.; Yao, D.; Liu, H.; Chen, Y.T.; Steiner, M.; Zuccaro, W.; Moy, P. 1997: MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma. Prostate 33(4): 233-239

Siedlar, M.; Marcinkiewicz, J.; Zembala, M. 1995: MHC class I and class II determinants and some adhesion molecules are engaged in the regulation of nitric oxide production in vitro by human monocytes stimulated with colon carcinoma cells. Clinical Immunology and Immunopathology 77(3): 380-384

Moskophidis, D.; Lechner, F.; Hengartner, H.; Zinkernagel, R.M. 1994: MHC class I and non-MHC-linked capacity for generating an anti-viral CTL response determines susceptibility to CTL exhaustion and establishment of virus persistence in mice. Journal of Immunology 152(10): 4976-4983

Anal, O.; Akkoç, N.; Sen, A.; Yesil, S.; Yüksel, F.; Büyükgebiz, A. 1997: MHC class i antigen expression in patients with IDDM and their siblings. Journal of Pediatric Endocrinology and Metabolism: Jpem 10(4): 391-394

Solana, R.; Romero, J.; Alonso, C.; Peña, J. 1992: MHC class I antigen expression is inversely related with tumor malignancy and ras oncogene product (p21ras) levels in human breast tumors. Invasion and Metastasis 12(3-4): 210-217

Maffei, A.; Papadopoulos, K.; Harris, P.E. 1997: MHC class I antigen processing pathways. Human Immunology 54(2): 91-103

Dasgupta, J.D.; Granja, C.B.; Yunis, E.J.; Relias, V. 1994: MHC class I antigens regulate CD3-induced tyrosine phosphorylation of proteins in T cells. International Immunology 6(3): 481-489

Savoie, C.J.; Kamikawaji, N.; Sudo, T.; Furuse, M.; Shirasawa, S.; Tana, T.; Sasazuki, T. 1998: MHC class I bound peptides of a colon carcinoma cell line, a Ki-ras gene-targeted progeny cell line and a B cell line. Cancer Letters 123(2): 193-197

Cromme, F.V.; Snijders, P.J.; van den Brule, A.J.; Kenemans, P.; Meijer, C.J.; Walboomers, J.M. 1993: MHC class I expression in HPV 16 positive cervical carcinomas is post-transcriptionally controlled and independent from c-myc overexpression. Oncogene 8(11): 2969-2975

Rückert, R.; Hofmann, U.; van der Veen, C.; Bulfone-Paus, S.; Paus, R. 1998: MHC class i expression in murine skin: developmentally controlled and strikingly restricted intraepithelial expression during hair follicle morphogenesis and cycling, and response to cytokine treatment in vivo. Journal of Investigative Dermatology 111(1): 25-30

Lenz, P.; Elbe, A.; Stingl, G.; Bergstresser, P.R. 1996: MHC class I expression on dendritic cells is sufficient to sensitize for transplantation immunity. Journal of Investigative Dermatology 107(6): 844-848

Kaufman, D.S.; Schoon, R.A.; Leibson, P.J. 1993: MHC class I expression on tumor targets inhibits natural killer cell-mediated cytotoxicity without interfering with target recognition. Journal of Immunology 150(4): 1429-1436

Toomey, J.A.; Shrestha, S.; de la Rue, S.A.; Gays, F.; Robinson, J.H.; Chrzanowska-Lightowlers, Z.M.; Brooks, C.G. 1998: MHC class I expression protects target cells from lysis by Ly49-deficient fetal NK cells. European Journal of Immunology 28(1): 47-56

Suzuki, Y.; Joh, K.; Kwon, O.C.; Yang, Q.; Conley, F.K.; Remington, J.S. 1994: MHC class I gene(s) in the D/L region but not the TNF-alpha gene determines development of toxoplasmic encephalitis in mice. Journal of Immunology 153(10): 4649-4654

Fromm, S.V.; Mey-Tal, S.W.; Coligan, J.E.; Schechter, C.; Ehrlich, R. 1998: MHC class i heavy chain mRNA must exceed a threshold level for the reconstitution of cell surface expression of class i MHC complexes in cells transformed by the highly oncogenic adenovirus 12. Journal of Biological Chemistry 273(24): 15209-15216

Pedersen, A.E.; Jacoby, B.F.; Skov, S.; Claesson, M.H. 1996: MHC class i is functionally associated with antigen receptors in human T and B lymphomas. Cellular Immunology 173(2): 295-302

Anderson, H.A.; Chen, Y.; Norkin, L.C. 1998: MHC class I molecules are enriched in caveolae but do not enter with simian virus 40. Journal of General Virology 79: 1469-1477

Amirayan, N.; Machy, P. 1996: MHC class i molecules are implicated in costimulatory signals during TCR/CD3-induced activation. Cellular Immunology 168(1): 1-12

Suh, W.K.; Mitchell, E.K.; Yang, Y.; Peterson, P.A.; Waneck, G.L.; Williams, D.B. 1996: MHC class I molecules form ternary complexes with calnexin and TAP and undergo peptide-regulated interaction with TAP via their extracellular domains. Journal of Experimental Medicine 184(2): 337-348

Yee, S.T.; Okada, Y.; Ogasawara, K.; Omura, S.; Takatsuki, A.; Kakiuchi, T.; Muno, D.; Kominami, E.; Mizuochi, T. 1997: MHC class I presentation of an exogenous polypeptide antigen encoded by the murine AIDS defective virus. Microbiology and Immunology 41(7): 563-570

Liu, T.; Zhou, X.; Abdel-Motal, U.M.; Ljunggren, H.G.; Jondal, M. 1997: MHC class I presentation of live and heat-inactivated Sendai virus antigen in T2Kb cells depends on an intracellular compartment with endosomal characteristics. Scandinavian Journal of Immunology 45(5): 527-533

Sarin, A.; Haridas, V.; Saxena, R.K. 1993: MHC class I up-regulation protects some but not all targets against LAK-mediated lysis: Possible implications for the existence of LAK cell subpopulations using different recognition strategies. Immunology Letters 38(1): 59-62

Kolesaric, A.; Stingl, G.; Elbe-Bürger, A. 1997: MHC class I+/II- dendritic cells induce hapten-specific immune responses in vitro and in vivo. Journal of Investigative Dermatology 109(4): 580-585

Bartoccioni, E.; Gallucci, S.; Scuderi, F.; Ricci, E.; Servidei, S.; Broccolini, A.; Tonali, P. 1994: MHC class I, MHC class II and intercellular adhesion molecule-1 (ICAM-1) expression in inflammatory myopathies. Clinical and Experimental Immunology 95(1): 166-172

Cremaschi, G.A.; Sterin-Borda, L. 1994: MHC class I-hormone receptor associations: still a physiological enigma?. Acta Physiologica Pharmacologica et Therapeutica Latinoamericana: Organo de la Asociacion Latinoamericana de Ciencias Fisiologicas y de la Asociacion Latinoamericana de Farmacologia 44(3): 55-64

Serreze, D.V.; Gallichan, W.S.; Snider, D.P.; Croitoru, K.; Rosenthal, K.L.; Leiter, E.H.; Christianson, G.J.; Dudley, M.E.; Roopenian, D.C. 1996: MHC class I-mediated antigen presentation and induction of CD8+ cytotoxic T-cell responses in autoimmune diabetes-prone NOD mice. Diabetes 45(7): 902-908

Schneider, C.; Gold, R.; Dalakas, M.C.; Schmied, M.; Lassmann, H.; Toyka, K.V.; Hartung, H.P. 1996: MHC class I-mediated cytotoxicity does not induce apoptosis in muscle fibers nor in inflammatory T cells: studies in patients with polymyositis, dermatomyositis, and inclusion body myositis. Journal of Neuropathology and Experimental Neurology 55(12): 1205-1209

Ortmann, B.; Androlewicz, M.J.; Cresswell, P. 1994: MHC class I/beta-2-microglobulin complexes associate with TAP transporters before peptide binding. Nature (London) 368(6474): 864-867

Just, J.J.; Casabona, J.; Bertrán, J.; Montané, C.; Fortuny, C.; Rodrigo, C.; Mur, A.; Bosque, M.; Jovane, L.; King, M.C. 1996: MHC class II alleles associated with clinical and immunological manifestations of HIV-1 infection among children in Catalonia, Spain. Tissue Antigens 47(4): 313-318

Milne, D.S.; Gascoigne, A.D.; Wilkes, J.; Sviland, L.; Ashcroft, T.; Malcolm, A.J.; Corris, P.A. 1994: MHC class II and ICAM-1 expression and lymphocyte subsets in transbronchial biopsies from lung transplant recipients. Transplantation 57(12): 1762-1766

Ohno, M.; Komiyama, A.; Martin, P.M.; Suzuki, K. 1993: MHC class II antigen expression and T-cell infiltration in the demyelinating CNS and PNS of the twitcher mouse. Brain Research 625(2): 186-196

Baudouin, C.; Fredj-Reygrobellet, D.; Brignole, F.; Lapalus, P.; Gastaud, P. 1993: MHC class II antigen expression by ocular cells in proliferative diabetic retinopathy. Fundamental and Clinical Pharmacology 7(9): 523-530

Haas, N.; Iwen, W.; Grabbe, J.; Uchanska-Ziegler, B.; Czarnetzki, B.M. 1996: MHC class Ii antigen expression is increased in different forms of urticaria. International Archives of Allergy and Immunology 109(2): 177-182

Kleijmeer, M.J.; Ossevoort, M.A.; van Veen, C.J.; van Hellemond, J.J.; Neefjes, J.J.; Kast, W.M.; Melief, C.J.; Geuze, H.J. 1995: MHC class II compartments and the kinetics of antigen presentation in activated mouse spleen dendritic cells. Journal of Immunology 154(11): 5715-5724

Pieters, J. 1997: MHC class II compartments: specialized organelles of the endocytic pathway in antigen presenting cells. Biological Chemistry 378(8): 751-758

Shaw, J.A.; Perry, V.H.; Mellanby, J. 1994: MHC class II expression by microglia in tetanus toxin-induced experimental epilepsy in the rat. Neuropathology and Applied Neurobiology 20(4): 392-398

Höhler, T.; Gerken, G.; Notghi, A.; Knolle, P.; Lubjuhn, R.; Taheri, H.; Schneider, P.M.; Meyer zum Büschenfelde, K.H.; Rittner, C. 1997: MHC class II genes influence the susceptibility to chronic active hepatitis C. Journal of Hepatology 27(2): 259-264

Gyllensten, U.B.; Erlich, H.A. 1993: MHC class II haplotypes and linkage disequilibrium in primates. Human Immunology 36(1): 1-10

Held, W.; Waanders, G.A.; MacDonald, H.R.; Acha-Orbea, H. 1994: MHC class II hierarchy of superantigen presentation predicts efficiency of infection with mouse mammary tumor virus. International Immunology 6(9): 1403-1407

Nielsen, M.; Gerwien, J.; Geisler, C.; Röpke, C.; Svejgaard, A.; Odum, N. 1998: MHC class II ligation induces CD58 (LFA-3)-mediated adhesion in human T cells. Experimental and Clinical Immunogenetics 15(2): 61-68

Lund, F.E.; Randall, T.D.; Woodland, D.L.; Corley, R.B. 1993: MHC class II limits the functional expression of endogenous superantigens in B cells. Journal of Immunology 150(1): 78-86

Sette, A.; Sidney, J.; Gaeta, F.C.; Appella, E.; Colón, S.M.; del Guercio, M.F.; Guéry, J.C.; Adorini, L. 1993: MHC class II molecules bind indiscriminately self and non-self peptide homologs: effect on the immunogenicity of non-self peptides. International Immunology 5(6): 631-638

Odum, N.; Kanner, S.B.; Ledbetter, J.A.; Svejgaard, A. 1993: MHC class II molecules deliver costimulatory signals in human T cells through a functional linkage with IL-2-receptors. Journal of Immunology 150(12): 5289-5298

Nielsen, M.; Odum, N.; Bendtzen, K.; Ryder, L.P.; Jakobsen, B.K.; Svejgaard, A. 1994: MHC class II molecules regulate growth in human T cells. Experimental and Clinical Immunogenetics 11(1): 23-32

Chia, C.P.; Khrebtukova, I.; McCluskey, J.; Wade, W.F. 1994: MHC class II molecules that lack cytoplasmic domains are associated with the cytoskeleton. Journal of Immunology 153(8): 3398-3407

Vázquez-García, M.N.; Aláez, C.; Olivo, A.; Debaz, H.; Pérez-Luque, E.; Burguete, A.; Cano, S.; de la Rosa, G.; Bautista, N.; Hernández, A.; Bandera, J.; Torres, L.F.; Kershenobich, D.; Alvarez, F.; Gorodezky, C. 1998: MHC class II sequences of susceptibility and protection in Mexicans with autoimmune hepatitis. Journal of Hepatology 28(6): 985-990

Malcherek, G.; Wirblich, C.; Willcox, N.; Rammensee, H.G.; Trowsdale, J.; Melms, A. 1998: MHC class II-associated invariant chain peptide replacement by T cell epitopes: engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation. European Journal of Immunology 28(5): 1524-1533

Stang, E.; Bakke, O. 1997: MHC class II-associated invariant chain-induced enlarged endosomal structures: a morphological study. Experimental Cell Research 235(1): 79-92

Mouritsen, S.; Dalum, I.; Engel, A.M.; Svane, I.M.; Svendsen, I.; Werdelin, O.; Elsner, H. 1994: MHC class II-bound self-peptides can be effectively separated by isoelectric focusing and bind optimally to their MHC class Ii restriction elements around pH 5.0. Immunology 82(4): 529-534

Radons, J.; Burkart, V.; Kolb, H. 1997: MHC class II-dependent abnormal reactivity toward bacterial superantigens in immune cells of NOD mice. Diabetes 46(3): 379-385

Shoukry, N.H.; Lavoie, P.M.; Thibodeau, J.; D'souza, S.; Sekaly, R.P. 1997: MHC class II-dependent peptide antigen versus superantigen presentation to T cells. Human Immunology 54(2): 194-201

Waisman, A.; Zisman, E.; Mozes, E. 1996: MHC class II-mediated T cell response to DNA. Cellular Immunology 173(1): 7-14

Brady, M.S.; Eckels, D.D.; Ree, S.Y.; Schultheiss, K.E.; Lee, J.S. 1996: MHC class II-mediated antigen presentation by melanoma cells. Journal of ImmunoTherapy with Emphasis on Tumor Immunology: Official Journal of the Society for Biological Therapy 19(6): 387-397

Perlmutter, L.S.; Scott, S.A.; Barrón, E.; Chui, H.C. 1992: MHC class II-positive microglia in human brain: association with Alzheimer lesions. Journal of Neuroscience Research 33(4): 549-558

Lee, S.P.; Wallace, L.E.; Mackett, M.; Arrand, J.R.; Searle, P.F.; Rowe, M.; Rickinson, A.B. 1993: MHC class II-restricted presentation of endogenously synthesized antigen: Epstein-Barr virus transformed B cell lines can present the viral glycoprotein gp340 by two distinct pathways. International Immunology 5(5): 451-460

Baskar, S.; Azarenko, V.; Garcia Marshall, E.; Hughes, E.; Ostrand-Rosenberg, S. 1994: MHC class II-transfected tumor cells induce long-term tumor-specific immunity in autologous mice. Cellular Immunology 155(1): 123-133

Takahashi, Y.; Ametani, A.; Totsuka, M.; Fujine, K.; Tsuji, N.M.; Kurisaki, J.; Kaminogawa, S. 1998: MHC class II/T-cell receptor interactions potentiate secretion of IgG but not IgM in response to T-dependent antigens. Immunology Letters 61(2-3): 97-101

Dorak, M.T.; Chalmers, E.A.; Sproul, A.M.; Mills, K.I.; Wilson, D.W.; Galbraith, I.; Henderson, N.; Gibson, B.E.; Burnett, A.K. 1993: MHC class III polymorphisms in selection of donors for BMT. Bone Marrow Transplantation 11(1): 37-41

van Vliet, E.; Uhrberg, M.; Stein, C.; Gleichmann, E. 1993: MHC control of IL-4-dependent enhancement of B cell Ia expression and Ig class switching in mice treated with mercuric chloride. International Archives of Allergy and Immunology 101(4): 392-401

Merkenschlager, M.; Benoist, C.; Mathis, D. 1994: MHC control of the naive TCR alpha-chain repertoire. Journal of Immunology 153(7): 3005-3013

Grabowska, A.; Lampson, L.A. 1995: MHC expression in nonlymphoid tissues of the developing embryo: strongest class I or class II expression in separate populations of potential antigen-presenting cells in the skin, lung, gut, and inter-organ connective tissue. Developmental and Comparative Immunology 19(5): 425-450

Lekutis, C.; Letvin, N.L. 1995: MHC expression of African green monkeys of Barbados is limited in heterogeneity. Journal of Medical Primatology 24(2): 81-86

Creech, E.A.; Nakul-Aquaronne, D.; Reap, E.A.; Cheek, R.L.; Wolthusen, P.A.; Cohen, P.L.; Eisenberg, R.A. 1996: MHC genes modify systemic autoimmune disease. The role of the I-E locus. Journal of Immunology 156(2): 812-817

Von Schantz, T.; Wittzell, H.; Göransson, G.; Grahn, M.; Persson, K. 1996: MHC genotype and male ornamentation: genetic evidence for the Hamilton-Zuk model. PROCEEDINGS. Biological Sciences 263(1368): 265-271

Bellgard, M.I.; Tay, G.K.; Hiew, H.L.; Witt, C.S.; Ketheesan, N.; Christiansen, F.T.; Dawkins, R.L. 1998: MHC haplotype analysis by artificial neural networks. Human Immunology 59(1): 56-62

Weissert, R.; Wallström, E.; Storch, M.K.; Stefferl, A.; Lorentzen, J.; Lassmann, H.; Linington, C.; Olsson, T. 1998: MHC haplotype-dependent regulation of MOG-induced EAE in rats. Journal of Clinical Investigation 102(6): 1265-1273

Fouad, F.; Johny, K.; Kaaba, S.; Alkarmi, T.O.; Sharma, P.; Al-Harbi, S. 1994: MHC in systemic lupus erythematosus: A study on a Kuwaiti population. European Journal of Immunogenetics: Official Journal of the British Society for Histocompatibility and Immunogenetics 21(1): 11-14

Rammensee, H.G.; Friede, T.; Stevanoviíc, S. 1995: MHC ligands and peptide motifs: First listing. Immunogenetics 41(4): 178-228

Płytycz, B.; Seljelid, R. 1998: MHC molecules and lymphocytes: evolutionary perspective. Archivum Immunologiae et Therapiae Experimentalis 46(3): 137-142

Fridkis-Hareli, M.; Eren, R.; Sharp, A.; Abel, L.; Kukulansky, T.; Globerson, A. 1993: MHC recognition in colonization of the thymus by bone marrow cells. Cellular Immunology 149(1): 91-98

Harding, F.A.; Flajnik, M.F.; Cohen, N. 1993: MHC restriction of T-cell proliferative responses in Xenopus. Developmental and Comparative Immunology 17(5): 425-437

Goldstein, R.; Moulds, J.M.; Smith, C.D.; Sengar, D.P. 1996: MHC studies of the primary antiphospholipid antibody syndrome and of antiphospholipid antibodies in systemic lupus erythematosus. Journal of Rheumatology 23(7): 1173-1179

Hedrick, P.W.; Parker, K.M. 1998: MHC variation in the endangered gila topminnow. Evolution 52(1): 199,.

Gaur, L.K.; Nepom, G.T.; Snyder, K.E.; Anderson, J.; Pandarpurkar, M.; Yadock, W.; Heise, E.R. 1997: MHC-DRB allelic sequences incorporate distinct intragenic trans-specific segments. Tissue Antigens 49(4): 342-355

Charaf, B.; Sanhadji, K.; Sekkat, S.; Farouqui, B.; Touraine, J.L.; Benslimane, A. 1993: MHC-I non-restricted cytotoxic activity in Macaca sylvana experimentally inoculated with HIV2 and SIV/mac. Thymus 22(1): 1-12

Eggert, F.; Höller, C.; Luszyk, D.; Müller-Ruchholtz, W.; Ferstl, R. 1996: MHC-associated and MHC-independent urinary chemosignals in mice. Physiology and Behavior 59(1): 57-62

Eggert, F.; Uharek, L.; Müller-Ruchholtz, W.; Ferstl, R. 1994: MHC-associated and MHC-independent urinary chemosignals in mice are expressed via the hematopoietic system. Neuropsychobiology 30(1): 42-45

Torchinsky, A.; Fein, A.; Carp, H.J.; Toder, V. 1994: MHC-associated immunopotentiation affects the embryo response to teratogens. Clinical and Experimental Immunology 98(3): 513-519

Moulon, C.; Wild, D.; Dormoy, A.; Weltzien, H.U. 1998: MHC-dependent and -independent activation of human nickel-specific CD8+ cytotoxic T cells from allergic donors. Journal of Investigative Dermatology 111(3): 360-366

Housseau, F.; Zeliszewski, D.; Roy, M.; Paradis, V.; Richon, S.; Ricour, A.; Bougaran, J.; Prapotnich, D.; Vallancien, G.; Benoit, G.; Desportes, L.; Bedossa, P.; Hercend, T.; Bidart, J.M.; Bellet, D. 1997: MHC-dependent cytolysis of autologous tumor cells by lymphocytes infiltrating urothelial carcinomas. International Journal of Cancer 71(4): 585-594

Wedekind, C.; Seebeck, T.; Bettens, F.; Paepke, A.J. 1995: MHC-dependent mate preferences in humans. Proceedings. Biological Sciences 260(1359): 245-249

Penn, D.; Potts, W. 1998: MHC-disassortative mating preferences reversed by cross-fostering. Proceedings. Biological Sciences 265(1403): 1299-1306

Yewdell, J.; Lapham, C.; Bacik, I.; Spies, T.; Bennink, J. 1994: MHC-encoded proteasome subunits LMP2 and LMP7 are not required for efficient antigen presentation. Journal of Immunology 152(3): 1163-1170

Ratanachaiyavong, S.; Lloyd, L.; Darke, C.; McGregor, A.M. 1993: MHC-extended haplotypes in families of patients with Graves' disease. Human Immunology 36(2): 99-111

Rülicke, T.; Chapuisat, M.; Homberger, F.R.; Macas, E.; Wedekind, C. 1998: MHC-genotype of progeny influenced by parental infection. Proceedings. Biological Sciences 265(1397): 711-716

Driscoll, J.; Brown, M.G.; Finley, D.; Monaco, J.J. 1993: MHC-linked LMP gene products specifically after peptidase activities of the proteasome. Nature (London) 365(6443): 262-264

Sharp, A.; Fridkis-Hareli, M.; Eren, R.; Kukulansky, T.; Abel, L.; Globerson, A. 1995: MHC-linked colonization of the thymus and thymocyte development: effects of mature T lymphocytes. International Archives of Allergy and Immunology 106(1): 13-19

Ikegami, H.; Kawaguchi, Y.; Ueda, H.; Fukuda, M.; Takakawa, K.; Fujioka, Y.; Fujisawa, T.; Uchida, K.; Ogihara, T. 1993: MHC-linked diabetogenic gene of the NOD mouse: molecular mapping of the 3' boundary of the diabetogenic region. Biochemical and Biophysical Research Communications 192(2): 677-682

Brown, M.G.; Driscoll, J.; Monaco, J.J. 1993: MHC-linked low-molecular mass polypeptide subunits define distinct subsets of proteasomes. Implications for divergent function among distinct proteasome subsets. Journal of Immunology 151(3): 1193-1204

Di Modugno, F.; Mammi, C.; Rosanò, L.; Rubiu, O.; Nisticò, P.; Chersi, A. 1997: MHC-peptide binding: dimers of cysteine-containing nonapeptides bind with high affinity to HLA-A2.1 class I molecules. Journal of ImmunoTherapy 20(6): 431-436

Zhang, J.; Medaer, R.; Stinissen, P.; Hafler, D.; Raus, J. 1993: MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination. Science 261(5127): 1451-1454

Surman, S.; Deckhut, A.M.; Blackman, M.A.; Woodland, D.L. 1994: MHC-specific recognition of a bacterial superantigen by weakly reactive T cells. Journal of Immunology 152(10): 4893-4902

Pawelec, G. 1994: MHC-unrestricted immune surveillance of leukemia. Cancer BioTherapy 9(3): 265-288

Deres, K.; Beck, W.; Faath, S.; Jung, G.; Rammensee, H.G. 1993: MHC/peptide binding studies indicate hierarchy of anchor residues. Cellular Immunology 151(1): 158-167

Newell, W.R.; Trowsdale, J.; Beck, S. 1994: MHCDB--database of the human MHC. Immunogenetics 40(2): 109-115

Brusic, V.; Rudy, G.; Kyne, A.P.; Harrison, L.C. 1997: MHCPEP, a database of MHC-binding peptides: update 1996. Nucleic Acids Research 25(1): 269-271

Brusic, V.; Rudy, G.; Harrison, L.C. 1998: MHCPEP, a database of MHC-binding peptides: update 1997. Nucleic Acids Research 26(1): 368-371

Brusic, V.; Rudy, G.; Harrison, L.C. 1994: MHCPEP: a database of MHC-binding peptides. Nucleic Acids Research 22(17): 3663-3665

Irminger-Finger, I.; Hurt, E.; Roebuck, A.; Collart, M.A.; Edelstein, S.J. 1996: MHP1, an essential gene in Saccharomyces cerevisiae required for microtubule function. Journal of Cell Biology 135(5): 1323-1339

Falkenberg, H.; Matthes, W.; Schwerin, M. 1993: MHS- and CK assays and their relation to each other and to performances in pig. Archiv fuer Tierzucht 36(2): 175-188

Rossen, J.W.; Voorhout, W.F.; Horzinek, M.C.; van der Ende, A.; Strous, G.J.; Rottier, P.J. 1995: MHV-A59 enters polarized murine epithelial cells through the apical surface but is released basolaterally. Virology 210(1): 54-66

Hingley, S.T.; Gombold, J.L.; Lavi, E.; Weiss, S.R. 1994: MHV-A59 fusion mutants are attenuated and display altered hepatotropism. Virology 200(1): 1-10

De Angelis, G.; De Angelis, R.; Frova, L.; Verdecchia, A. 1994: MIAMOD: A computer package to estimate chronic disease morbidity using mortality and survival data. Computer Methods and Programs in Biomedicine 44(2): 99-107

Garzetti, G.G.; Ciavattini, A.; De Nictolis, M.; Lucarini, G.; Goteri, G.; Romanini, C.; Biagini, G. 1996: MIB 1 immunostaining in cervical intraepithelial neoplasia: prognostic significance in mild and moderate lesions. Gynecologic and Obstetric Investigation 42(4): 261-266

Garzetti, G.G.; Ciavattini, A.; Lucarini, G.; Goteri, G.; de Nictolis, M.; Muzzioli, M.; Fabris, N.; Romanini, C.; Biagini, G. 1995: MIB 1 immunostaining in stage i squamous cervical carcinoma: relationship with natural killer cell activity. Gynecologic Oncology 58(1): 28-33

Dalquen, P.; Baschiera, B.; Chaffard, R.; Dieterich, H.; Feichter, G.E.; Krmer, K.; Torhorst, J. 1997: MIB-1 (Ki-67) immunostaining of breast cancer cells in cytologic smears. Acta Cytologica 41(2): 229-237

Ramsay, J.A.; From, L.; Iscoe, N.A.; Kahn, H.J. 1995: MIB-1 proliferative activity is a significant prognostic factor in primary thick cutaneous melanomas. Journal of Investigative Dermatology 105(1): 22-26

Mochen, C.; Giardini, R.; Costa, A.; Silvestrini, R. 1997: MIB-1 and S-phase cell fraction predict survival in non-Hodgkin's lymphomas. Cell Proliferation 30(1): 37-47

Roland, N.J.; Rowley, H.; Scraggs, M.; Johnson, P.; Jones, A.S. 1996: MIB-1 and involucrin expression in laryngeal squamous carcinoma: The relationship to host and tumour factors and survival. Clinical Otolaryngology and Allied Sciences 21(5): 429-438

Fasano, M.; Yousem, S.; Jagirdar, J. 1998: MIB-1 as a predictor of response in lung allografts with moderate acute cellular rejection. American Journal of Surgical Pathology 22(6): 749-754

Jensen, V.; Høyer, M.; Sørensen, F.B.; Keller, J.; Jensen, O.M. 1996: MIB-1 expression and iododeoxyuridine labelling in soft tissue sarcomas: An immunohistochemical study including correlations with p53, bcl-2 and histological characteristics. Histopathology 28(5): 437-444

Jensen, V.; Jensen, M.L.; Kiaer, H.; Andersen, J.; Melsen, F. 1997: MIB-1 expression in breast carcinomas with medullary features. An immunohistological study including correlations with p53 and bcl-2. Virchows Archiv: An International Journal of Pathology 431(2): 125-130

Albers, P.; Bierhoff, E.; Neu, D.; Fimmers, R.; Wernert, N.; Müller, S.C. 1997: MIB-1 immunohistochemistry in clinical stage I nonseminomatous testicular germ cell tumors predicts patients at low risk for metastasis. Cancer 79(9): 1710-1716

Biesterfeld, S.; Hoffmann, E. 1998: MIB-1 immunohistometry on Tru-cut biopsies in inflammatory and cirrhotic liver disease. Analytical and Quantitative Cytology and Histology 20(4): 268-274

Böni, R.; Doguoglu, A.; Burg, G.; Müller, B.; Dummer, R. 1996: MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma. Journal of the American Academy of Dermatology 35(3 Pt 1): 416-418

Vajtai, I.; Varga, Z.; Aguzzi, A. 1996: MIB-1 immunoreactivity reveals different labelling in low-grade and in malignant epithelial neoplasms of the choroid plexus. Histopathology 29(2): 147-151

Ho, D.M.; Wong, T.T.; Hsu, C.Y.; Ting, L.T.; Chiang, H. 1998: MIB-1 labeling index in nonpilocytic astrocytoma of childhood: A study of 101 cases. Cancer 82(12): 2459-2466

Querzoli, P.; Albonico, G.; Ferretti, S.; Rinaldi, R.; Magri, E.; Indelli, M.; Nenci, I. 1996: MIB-1 proliferative activity in invasive breast cancer measured by image analysis. Journal of Clinical Pathology 49(11): 926-930

Karak, A.K.; Sarkar, C.; Chumber, S.; Tandon, N. 1997: MIB-1 proliferative index in parathyroid adenoma & hyperplasia. Indian Journal of Medical Research 105: 235-238

Ide, M.; Jimbo, M.; Yamamoto, M.; Umebara, Y.; Hagiwara, S.; Kubo, O. 1996: MIB-1 staining index and peritumoral brain edema of meningiomas. Cancer 78(1): 133-143

Pich, A.; Ponti, R.; Valente, G.; Chiusa, L.; Geuna, M.; Novero, D.; Palestro, G. 1994: MIB-1, Ki67, and PCNA scores and DNA flow cytometry in intermediate grade malignant lymphomas. Journal of Clinical Pathology 47(1): 18-22

Kalogeraki, A.; Tzardi, M.; Panagiotides, I.; Koutsoubi, K.; Bolioti, S.; Rontogianni, D.; Stefanaki, K.; Zois, E.; Karidi, E.; Darivianaki, K.; Delides, G.; Kanavaros, P. 1997: MIB1 (Ki-67) expression in non-Hodgkin's lymphomas. Anticancer Research 17(1a): 487-491

Prayson, R.A.; Estes, M.L. 1996: MIB1 and p53 immunoreactivity in protoplasmic astrocytomas. Pathology International 46(11): 862-866

Oka, K.; Arai, T. 1996: MIB1 growth fraction is not related to prognosis in cervical squamous cell carcinoma treated with radiotherapy. International Journal of Gynecological Pathology: Official Journal of the International Society of Gynecological Pathologists 15(1): 23-27

Mizoue, T.; Kawamoto, H.; Arita, K.; Kurisu, K.; Tominaga, A.; Uozumi, T. 1997: MIB1 immunopositivity is associated with rapid regrowth of pituitary adenomas. Acta Neurochirurgica 139(5): 426

Ofner, D.; Grothaus, A.; Riedmann, B.; Larcher, P.; Maier, H.; Bankfalvi, A.; Schmid, K.W. 1996: MIB1 in colorectal carcinomas: its evaluation by three different methods reveals lack of prognostic significance. Analytical Cellular Pathology: the Journal of the European Society for Analytical Cellular Pathology 12(2): 61-70

Ohta, M.; Iwaki, T.; Kitamoto, T.; Takeshita, I.; Tateishi, J.; Fukui, M. 1994: MIB1 staining index and scoring of histologic features in meningioma. Indicators for the prediction of biologic potential and postoperative management. Cancer 74(12): 3176-3189

Bulten, J.; van der Laak, J.A.; Gemmink, J.H.; Pahlplatz, M.M.; de Wilde, P.C.; Hanselaar, A.G. 1996: MIB1, a promising marker for the classification of cervical intraepithelial neoplasia. Journal of Pathology 178(3): 268-273

Cornelissen, J.; Van Kuilenburg, A.B.; Voûte, P.A.; Van Gennip, A.H. 1997: MIBG causes oxidative stress and up-regulation of anti-oxidant enzymes in the human neuroblastoma cell line SK-N-BE(2C). International Journal of Cancer 72(3): 486-490

Boneu, A.; Caselles, O.; Duthil, P.; Marty, M.H.; Lucot, H. 1995: MIBG treatment of six patients with neuroendocrine tumors: Correlation with dosimetric data. Medecine Nucleaire 19(2-3): 129-135

Lemmen, S.; Kropec, A.; Engels, I.; Busse, A.; Daschner, F.D. 1993: MIC and Serum Bactericidal Activity of Clindamycin against Methicillin-resistant and -sensitive Staphylococci. Infection 21(6): 407-409

Spangler, S.K.; Jacobs, M.R.; Appelbaum, P.C. 1997: MIC and time-kill studies of antipneumococcal activity of GV 118819X (sanfetrinem) compared with those of other agents. Antimicrobial Agents and ChemoTherapy 41(1): 148-155

Visalli, M.A.; Jacobs, M.R.; Appelbaum, P.C. 1996: MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci. Antimicrobial Agents and ChemoTherapy 40(2): 362-366

Pankuch, G.A.; Jacobs, M.R.; Appelbaum, P.C. 1996: MIC and time-kill study of antipneumococcal activities of RPR 106972 (a new oral streptogramin), RP 59500 (quinupristin-dalfopristin), pyostacine (RP 7293), penicillin G, cefotaxime, erythromycin, and clarithromycin against 10 penicillin-susceptible and -resistant pneumococci. Antimicrobial Agents and ChemoTherapy 40(9): 2071-2074

Dexin Xiong, Z.X.; Sheng Zhiyong 1996: MIC study of 12 antimicrobial agents to clinical isolates of anaerobes. Zhongguo Kangshengsu Zazhi 21(1): 36-39

Aarestrup, F.M.; Jensen, N.E. 1998: MIC values of eight antibiotics for clonally related Escherichia coli O139 isolates from oedema disease in Denmark. Dansk Veterinaertidsskrift 81(1): 7-8

Bootcov, M.R.; Bauskin, A.R.; Valenzuela, S.M.; Moore, A.G.; Bansal, M.; He, X.Y.; Zhang, H.P.; Donnellan, M.; Mahler, S.; Pryor, K.; Walsh, B.J.; Nicholson, R.C.; Fairlie, W.D.; Por, S.B.; Robbins, J.M.; Breit, S.N. 1997: MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proceedings of the National Academy of Sciences of the United States of America 94(21): 11514-11519

Riopel, M.; Dickman, P.S.; Link, M.P.; Perlman, E.J. 1994: MIC2 analysis in pediatric lymphomas and leukemias. Human Pathology 25(4): 396-399

Lumadue, J.A.; Askin, F.B.; Perlman, E.J. 1994: MIC2 analysis of small cell carcinoma. American Journal of Clinical Pathology 102(5): 692-694

Soslow, R.A.; Bhargava, V.; Warnke, R.A. 1997: MIC2, TdT, bcl-2, and CD34 expression in paraffin-embedded high-grade lymphoma/acute lymphoblastic leukemia distinguishes between distinct clinicopathologic entities. Human Pathology 28(10): 1158-1165

Smith, M.J.; Goodfellow, P.N. 1994: MIC2R: a transcribed MIC2-related sequence associated with a CpG island in the human pseudoautosomal region. Human Molecular Genetics 3(9): 1575-1582

Tsuchiya, N.; Shiota, M.; Moriyama, S.; Ogawa, A.; Komatsu-Wakui, M.; Mitsui, H.; Geraghty, D.E.; Tokunaga, K. 1998: MICA allele typing of HLA-B27 positive Japanese patients with seronegative spondylarthropathies and healthy individuals: differential linkage disequilibrium with HLA-B27 subtypes. Arthritis and Rheumatism 41(1): 68-73

Vitiani, L.R.; Potolicchio, I.; D'Amato, M.; Baricordi, O.R.; Sorrentino, R. 1998: MICA exon 5 microsatellite typing by DNA heteroduplex analysis: A new polymorphism in the transmembrane region. Tissue Antigens 51(3): 309-311

Goto, K.; Ota, M.; Ohno, S.; Mizuki, N.; Ando, H.; Katsuyama, Y.; Maksymowych, W.P.; Kimura, M.; Bahram, S.; Inoko, H. 1997: MICA gene and ankylosing spondylitis: Linkage analysis via a transmembrane-encoded triplet repeat polymorphism. Tissue Antigens 49(5): 503-507

Goto, K.; Ota, M.; Ando, H.; Mizuki, N.; Nakamura, S.; Inoue, K.; Yabuki, K.; Kotake, S.; Katsuyama, Y.; Kimura, M.; Inoko, H.; Ohno, S. 1998: MICA gene polymorphisms and HLA-B27 subtypes in Japanese patients with HLA-B27-associated acute anterior uveitis. IOVS Investigative Ophthalmology and Visual Science 39(3): 634-637

Zwirner, N.W.; Fernández-Viña, M.A.; Stastny, P. 1998: MICA, a new polymorphic HLA-related antigen, is expressed mainly by keratinocytes, endothelial cells, and monocytes. Immunogenetics 47(2): 139-148

Arcangeli, G.; Zaniboni, A.; Milano, S.; Meriggi, F.; Simoncini, E.; Marpicati, P.; Marini, G. 1993: MICE: a new active combination for non-small cell lung cancer. European Journal of Cancer 29A(13): 1848-1850

Mor, N.; Heifets, L. 1993: MICs and MBCs of clarithromycin against Mycobacterium avium within human macrophages. Antimicrobial Agents and ChemoTherapy 37(1): 111-114

Iida, H.; Nakamura, H.; Ono, T.; Okumura, M.S.; Anraku, Y. 1994: MID1, a novel Saccharomyces cerevisiae gene encoding a plasma membrane protein, is required for Ca2+ influx and mating. Molecular and Cellular Biology 14(12): 8259-8271

Shoji, W.; Inoue, T.; Yamamoto, T.; Obinata, M. 1995: MIDA1, a protein associated with Id, regulates cell growth. Journal of Biological Chemistry 270(42): 24818-24825

Zolfaghari, D.; Pfister, A.J. 1998: MIDCABG followed by a gastrointestinal operation in the same anesthetic setting. Annals of Thoracic Surgery 65(5): 1452-1453

Bacher, M.; Meinhardt, A.; Lan, H.Y.; Dhabhar, F.S.; Mu, W.; Metz, C.N.; Chesney, J.A.; Gemsa, D.; Donnelly, T.; Atkins, R.C.; Bucala, R. 1998: MIF expression in the rat brain: implications for neuronal function. Molecular Medicine 4(4): 217-230

Pearson, W.R. 1994: MIF proteins are not glutathione transferase homologs. Protein Science: a Publication of the Protein Society 3(3): 525-527

Blocki, F.A.; Ellis, L.B.; Wackett, L.P. 1993: MIF protein are theta-class glutathione S-transferase homologs. Protein Science: a Publication of the Protein Society 2(12): 2095-2102

Bucala, R. 1996: MIF rediscovered: cytokine, pituitary hormone, and glucocorticoid-induced regulator of the immune response. FASEB Journal 10(14): 1607-1613

Bucala, R. 1994: MIF, a previously unrecognized pituitary hormone and macrophage cytokine, is a pivotal mediator in endotoxic shock. Circulatory Shock 44(1): 35-39

Gong, L.; Kostrzewa, R.M.; Kalbfleisch, J.H. 1993: MIF-1 fails to modify agonist-induced oral activity in neonatal 6-OHDA-treated rats. Peptides 14(6): 1159-1164

Brown, M.T.; Goetsch, L.; Hartwell, L.H. 1993: MIF2 is required for mitotic spindle integrity during anaphase spindle elongation in Saccharomyces cerevisiae. Journal of cell biology 123(2): 387-403

Michel, P.; Pariente, P.; Duru, G.; Dreyfus, J.P.; Chabriat, H.; Henry, P.; Dreyfuss, J.P. 1996: MIG ACCESS: A population-based, nationwide, comparative survey of access to care in migraine in France. Cephalalgia: An International Journal of Headache 16(1): 50-5; Discussion 4

Shankar, C.S.; Ramakrishnan, M.S.; Umesh-Kumar, S. 1996: MIG1 overexpression causes flocculation in Saccharomyces cerevisiae. Microbiology 142: 2663-2667

Hu, Z.; Nehlin, J.O.; Ronne, H.; Michels, C.A. 1995: MIG1-dependent and MIG1-independent glucose regulation of MAL gene expression in Saccharomyces cerevisiae. Current Genetics 28(3): 258-266

Foucher, E. 1996: MIGRATHON: An expert system to estimate the fish migratory flows between different areas. Application to the skipjack tuna (Katsuwonus pelamis) in Eastern tropical Atlantic. Aquatic Living Resources 9(3): 225-234

D'Atri, A. 1994: MILORD: Multi-media Interaction with Large Object-oriented Radiological and clinical Databases. Computer Methods and Programs in Biomedicine 45(1-2): 123-125

Zubillaga, M.; Oliveri, P.; Calcagno, M.L.; Goldman, C.; Caro, R.; Mitta, A.; Degrossi, O.; Boccio, J. 1997: MIN 14C UBT: A combination of gastric basal transit and 14C-urea breath test for the detection of Helicobacter pylori infection in human beings. Nuclear Medicine and Biology 24(6): 565-569

Ray, A.; Deheri, G. 1998: MINDO/III and graph theoretical study of nicotinic acid/amide and their positional isomers. Acta Pharmaceutica 48(1): 9-19

Reid, M.E.; Poole, J.; Green, C.; Neill, G.; Banks, J. 1992: MINY: A novel MNS-related blood group antigen. Vox Sanguinis 63(2): 129-132

Isaya, G.; Miklos, D.; Rollins, R.A. 1994: MIP1, a new yeast gene homologous to the rat mitochondrial intermediate peptidase gene, is required for oxidative metabolism in Saccharomyces cerevisiae. Molecular and Cellular Biology 14(8): 5603-5616

Mewes, H.W.; Hani, J.; Pfeiffer, F.; Frishman, D. 1998: MIPS: a database for protein sequences and complete genomes. Nucleic Acids Research 26(1): 33-37

Mewes, H.W.; Albermann, K.; Heumann, K.; Liebl, S.; Pfeiffer, F. 1997: MIPS: a database for protein sequences, homology data and yeast genome information. Nucleic Acids Research 25(1): 28-30

Ierusalimsky, V., N.; Balaban, P., M. 1997: MIPs-containing cells in terrestrial snails: Comparison of immunostaining and silver intensification. Neuroscience Research Communications 21(3): 213-221

Widimský, J.; Dzúrik, R.; Fetkovská, N.; Balazovjech, I.; Kvasnicka, J.; Lupínek, Z.; Mayer, O.; Pidrman, V. 1992: MIS (Multicentric Isradipine Study of antihypertensive therapy). Cor et Vasa 34(1): 4-14

Ehlde, M.; Zacchi, G. 1995: MIST: a user-friendly metabolic simulator. Computer Applications in the Biosciences: Cabios 11(2): 201-207

Kogelnik, A.M.; Lott, M.T.; Brown, M.D.; Navathe, S.B.; Wallace, D.C. 1996: MITOMAP: a human mitochondrial genome database. Nucleic Acids Research 24(1): 177-179

Kogelnik, A.M.; Lott, M.T.; Brown, M.D.; Navathe, S.B.; Wallace, D.C. 1997: MITOMAP: an update on the status of the human mitochondrial genome database. Nucleic Acids Research 25(1): 196-199

Hedeker, D.; Gibbons, R.D. 1996: MIXOR: A computer program for mixed-effects ordinal regression analysis. Computer Methods and Programs in Biomedicine 49(2): 157-176

Hedeker, D.; Gibbons, R.D. 1996: MIXREG: A computer program for mixed-effects regression analysis with autocorrelated errors. Computer Methods and Programs in Biomedicine 49(3): 229-252

Sasaki, T.; Otani, T.; Matsumoto, H.; Unemi, N.; Hamada, M.; Takeuchi, T.; Hori, M. 1998: MJ347-81F4 A & B, novel antibiotics from Amycolatopsis sp.: taxonomic characteristics, fermentation, and antimicrobial activity. Journal of Antibiotics 51(8): 715-721

Hwang, S.B.; Lam, M.H.; Szalkowski, D.M.; MacIntyre, D.E.; Bach, T.J.; Luell, S.; Meuer, R.; Sahoo, S.P.; Alberts, A.W.; Chabala, J.C. 1993: MK 287: a potent, specific, and orally active receptor antagonist of platelet-activating factor. Journal of Lipid Mediators 7(2): 115-134

Bertorelli, R.; Adami, M.; Di Santo, E.; Ghezzi, P. 1998: MK 801 and dexamethasone reduce both tumor necrosis factor levels and infarct volume after focal cerebral ischemia in the rat brain. Neuroscience Letters 246(1): 41-44

Kaur, S.; Ozer, H.; Starr, M. 1997: MK 801 reverses haloperidol-induced catalepsy from both striatal and extrastriatal sites in the rat brain. European Journal of Pharmacology 332(2): 153-160

Khan, M.A.; Hoffbrand, A.V.; Mehta, A.; Wright, F.; Tahami, F.; Wickremasinghe, R.G. 1993: MK 886, an antagonist of leukotriene generation, inhibits DNA synthesis in a subset of acute myeloid leukaemia cells. Leukemia Research 17(9): 759-762

Jacks, T.; Smith, R.; Judith, F.; Schleim, K.; Frazier, E.; Chen, H.; Krupa, D.; Hora, D.; Nargund, R.; Patchett, A.; Hickey, G. 1996: MK-0677, a potent, novel, orally active growth hormone (GH) secretagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles. Endocrinology 137(12): 5284-5289

Carr, B.A.; Ballou, J.D.; Snell, J.C.; Kulkosky, P.J. 1993: MK-329 blocks the inhibition of alcohol intake by CCK-8. Peptides 14(6): 1193-1197

Evans, B.E. 1993: MK-329: A non-peptide cholecystokinin A antagonist. Drug Development Research 29(4): 255-261

Peerlinck, K.; De Lepeleire, I.; Goldberg, M.; Farrell, D.; Barrett, J.; Hand, E.; Panebianco, D.; Deckmyn, H.; Vermylen, J.; Arnout, J. 1993: MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man. Circulation 88(4 Part 1): 1512-1517

Schwartz, J.I.; Tanaka, W.K.; Wang, D.Z.; Ebel, D.L.; Geissler, L.A.; Dallob, A.; Hafkin, B.; Gertz, B.J. 1997: MK-386, an inhibitor of 5alpha-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen. Journal of Clinical Endocrinology and Metabolism 82(5): 1373-1377

Lin, B.; Dietrich, W.D.; Ginsberg, M., D.; Globus, M., Y.T.; Busto, R. 1993: MK-801 (dizocilpine) protects the brain from repeated normothermic global ischemic insults in the rats. Journal of Cerebral Blood Flow and Metabolism 13(6): 925-932

Wise, R.A.; Mendrek, A.; Carlezon, W.A. 1996: MK-801 (dizocilpine): Synergist and conditioned stimulus in bromocriptine-induced psychomotor sensitization. Synapse 22(4): 362-368

Pavlaković, G.; Rathinavelu, A.; Isom, G.E. 1994: MK-801 Prevents Cyanide-Induced Changes of Fos Levels in Rat Brain. Neurochemical Research 19(10): 1289-1294

Thomas, J.D.; Weinert, S.P.; Sharif, S.; Riley, E.P. 1997: MK-801 administration during ethanol withdrawal in neonatal rat pups attenuates ethanol-induced behavioral deficits. Alcoholism Clinical and Experimental Research 21(7): 1218-1225

Tian, B.; Hartle, D.K. 1994: MK-801 affects cardiovascular responses produced by GABAA agents in area postrema. Brain Research Bulletin 35(1): 63-67

Deutsch, S.I.; Park, C.H.; Lukacs, L.G.; Morn, C.; Koetzner, L.; Mastropaolo, J. 1995: MK-801 alters the GABAA receptor complex and potentiates flurazepam's antiseizure efficacy. Pharmacology Biochemistry and Behavior 51(4): 909-915

Young, D.; Dragunow, M. 1994: MK-801 and NBQX prevent electrically induced status epilepticus. Neuroreport 5(12): 1481-1484

Yokoyama, H.; Onodera, K.; Iinuma, K. 1993: MK-801 and dopaminergic system in electrically-induced convulsions in mice. Yakubutsu Seishin Kodo 13(5): 309-313

Panconi, E.; Roux, J.; Altenbaumer, M.; Hampe, S.; Porsolt, R.D. 1993: MK-801 and enantiomers: Potential antidepressants or false positives in classical screening models?. Pharmacology Biochemistry and Behavior 46(1): 15-20

Monassier, L.; Tibiriça, E.; Roegel, J.C.; Feldman, J.; Bousquet, P. 1996: MK-801 and memantine inhibit a centrally induced increase in myocardial oxygen demand in rabbits. European Journal of Pharmacology 305(1-3): 109-113

Weller, M.; Marini, A.M.; Finiels-Marlier, F.; Martin, B.; Paul, S.M. 1993: MK-801 and memantine protect cultured neurons from glutamate toxicity induced by glutamate carboxypeptidase-mediated cleavage of methotrexate. European Journal of Pharmacology 248(4): 303-312

Sun, X.; Larson, A.A. 1993: MK-801 and phencyclidine act at phencyclidine sites that are not linked to N-methyl-D-aspartate activity to inhibit behavioral sensitization to kainate. Neuroscience 54(3): 773-779

Santucci, A.C.; Spincola, L.J.anne 1994: MK-801 attenuates residual hyperactivity induced by neonatal L-cysteine administration to rats. Developmental Brain Dysfunction 7(4-5): 230-236

Lee, M.G.; Chou, J.Y.; Lee, K.H.; Choi, B.J.; Kim, S.K.; Kim, C.Y. 1997: MK-801 augments pilocarpine-induced electrographic seizure but protects against brain damage in rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry 21(2): 331-344

Freeman, F.M.; Rose, S.P. 1995: MK-801 blockade of fos and jun expression following passive avoidance training in the chick. European Journal of Neuroscience 7(4): 563-569

Nishimura, M.; Sato, K.; Okada, T.; Schloss, P.; Shimada, S.; Tohyama, M. 1998: MK-801 blocks monoamine transporters expressed in HEK cells. Febs Letters 423(3): 376-380

Bell, J.A.; Beglan, C.L. 1995: MK-801 blocks the expression but not the development of tolerance to morphine in the isolated spinal cord of the neonatal rat. European Journal of Pharmacology 294(1): 289-296

Laprade, N.; Soghomonian, J.J. 1995: MK-801 decreases striatal and cortical GAD65 mRNA levels. Neuroreport 6(14): 1885-1889

Asin, K.E.; Bednarz, L.; Nikkel, A.L. 1996: MK-801 differentially affects dopamine D1 and D2 receptor agonist-induced behavioral tolerance and desensitization. Brain Research 725(1): 67-74

Carlezon, W.A.; Mendrek, A.; Wise, R.A. 1995: MK-801 disrupts the expression but not the development of bromocriptine sensitization: a state-dependency interpretation. Synapse 20(1): 1-9

Hughes, P.; Singleton, K.; Dragunow, M. 1994: MK-801 does not attenuate immediate-early gene expression following an amygdala afterdischarge. Experimental Neurology 128(2): 276-283

Schierle, G.S.; Karlsson, J.; Brundin, P. 1998: MK-801 does not enhance dopaminergic cell survival in embryonic nigral grafts. Neuroreport 9(7): 1313-1316

Wolf, M.E.; Xue, C.J.; White, F.J.; Dahlin, S.L. 1994: MK-801 does not prevent acute stimulatory effects of amphetamine or cocaine on locomotor activity or extracellular dopamine levels in rat nucleus accumbens. Brain Research 666(2): 223-231

S.J.cques, P.J.; Kirsch, J.R.; Diringer, M.N.; Traystman, R.J. 1993: MK-801 does not prevent impaired cerebrovascular reactivity to carbon dioxide during hypoglycemia in piglets. American Journal of Physiology 264(6 Part 2): H2124-H2130

Wedzony, K.; Klimek, V.; Gołembiowska, K. 1993: MK-801 elevates the extracellular concentration of dopamine in the rat prefrontal cortex and increases the density of striatal dopamine D1 receptors. Brain Research 622(1-2): 325-329

Pubill, D.; Canudas, A.M.; Gasulla, D.; Pallàs, M.; Escubedo, E.; Camarasa, J. 1996: MK-801 enhances noradrenergic neurotransmission in rat vas deferens. European Journal of Pharmacology 303(3): 171-175

Solberg, Y.; Rosner, M.; Turetz, J.; Belkin, M. 1997: MK-801 has neuroprotective and antiproliferative effects in retinal laser injury. IOVS Investigative Ophthalmology and Visual Science 38(7): 1380-1389

Ogura, H.; Aigner, T.G. 1993: MK-801 impairs recognition memory in rhesus monkeys: comparison with cholinergic drugs. Journal of Pharmacology and Experimental Therapeutics 266(1): 60-64

Hasegawa, M.; Kinoshita, H.; Amano, M.; Hasegawa, T.; Kameyama, T.; Nabeshima, T. 1993: MK-801 increases endogenous acetylcholine release in the rat parietal cortex: A study using brain microdialysis. Neuroscience Letters 150(1): 53-56

Druhan, J.P.; Rajabi, H.; Stewart, J. 1996: MK-801 increases locomotor activity without elevating extracellular dopamine levels in the nucleus accumbens. Synapse 24(2): 135-146

Behrens, S.; Gattaz, W.F. 1992: MK-801 induced stereotypies in rats are decreased by haloperidol and increased by diazepam. Journal of Neural Transmission. General Section 90(3): 219-224

Kim, H.S.; Jang, C.G. 1997: MK-801 inhibits methamphetamine-induced conditioned place preference and behavioral sensitization to apomorphine in mice. Brain Research Bulletin 44(3): 221-227

Nordqvist, A.C.; Holmin, S.; Nilsson, M.; Mathiesen, T.; Schalling, M. 1997: MK-801 inhibits the cortical increase in IGF-1, IGFBP-2 and IGFBP-4 expression following trauma. Neuroreport 8(2): 455-460

Gutstein, H.B.; Trujillo, K.A. 1993: MK-801 inhibits the development of morphine tolerance at spinal sites. Brain Research 626(1-2): 332-334

Sun, X.; Larson, A.A. 1993: MK-801 inhibits the effects of capsaicin in the adult mouse by an action involving phencyclidine (PCP) sites not linked to NMDA activity. Neuroreport 4(10): 1147-1150

Kinouchi, H.; Sharp, F.R.; Chan, P.H.; Mikawa, S.; Kamii, H.; Arai, S.; Yoshimoto, T. 1994: MK-801 inhibits the induction of immediate early genes in cerebral cortex, thalamus, and hippocampus, but not in substantia nigra following middle cerebral artery occlusion. Neuroscience Letters 179(1-2): 111-114

Von Lubitz, D.K.; McKenzie, R.J.; Lin, R.C.; Devlin, T.M.; Skolnick, P. 1993: MK-801 is neuroprotective but does not improve survival in severe forebrain ischemia. European Journal of Pharmacology 233(1): 95-100

Bolton, C.; Paul, C. 1997: MK-801 limits neurovascular dysfunction during experimental allergic encephalomyelitis. Journal of Pharmacology and Experimental Therapeutics 282(1): 397-402

Wozniak, D.F.; Brosnan-Watters, G.; Nardi, A.; Mcewen, M.; Corso, T.D.; Olney, J.W.; Fix, A.S. 1996: MK-801 neurotoxicity in male mice: Histologic effects and chronic impairment in spatial learning. Brain Research 707(2): 165-179

Raboisson, P.; Flood, K.; Lehmann, A.; Berge, O.G. 1997: MK-801 neurotoxicity in the guinea pig cerebral cortex: Susceptibility and regional differences compared with the rat. Journal of Neuroscience Research 49(3): 364-371

Venero, J.L.; Santiago, M.; Machado, A.; Cano, J. 1996: MK-801 partially protects against the acute MPP+ depleting effect on dopamine levels in rat striatal slices. Neurochemistry International 29(4): 411-416

Richter, A.; Löscher, W. 1997: MK-801 potentiates antidystonic effects of clozapine but not of haloperidol in mutant dystonic hamsters. Brain Research 769(2): 296-302

Shen, E.H.; Phillips, T.J. 1998: MK-801 potentiates ethanol's effects on locomotor activity in mice. Pharmacology Biochemistry and Behavior 59(1): 135-143

Cestari, V.; Castellano, C. 1997: MK-801 potentiates morphine-induced impairment of memory consolidation in mice: Involvement of dopaminergic mechanisms. Psychopharmacology 133(1): 1-6

Cerretani, D.; Micheli, L.; Fiaschi, A.I.; Romeo, M.R.; Taddei, I.; Giorgi, G. 1994: MK-801 potentiates the glutathione depletion induced by acetaminophen in rat brain. Current Therapeutic Research 55(6): 707-717

Wolf, M.E.; White, F.J.; Hu, X.T. 1994: MK-801 prevents alterations in the mesoaccumbens dopamine system associated with behavioral sensitization to amphetamine. Journal of Neuroscience: the Official Journal of the Society for Neuroscience 14(3 Pt 2): 1735-1745

Marin, C.; Papa, S.; Engber, T.M.; Bonastre, M.; Tolosa, E.; Chase, T.N. 1996: MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Research 736(1-2): 202-205

Jeziorski, M.; White, F.J.; Wolf, M.E. 1994: MK-801 prevents the development of behavioral sensitization during repeated morphine administration. Synapse 16(2): 137-147

Liu, Y.; Fechter, L.D. 1995: MK-801 protects against carbon monoxide-induced hearing loss. Toxicology and Applied Pharmacology 132(2): 196-202

Agnew, W.F.; McCreery, D.B.; Yuen, T.G.; Bullara, L.A. 1993: MK-801 protects against neuronal injury induced by electrical stimulation. Neuroscience 52(1): 45-53

Kehoe, E.J.; Macrae, M.; Hutchinson, C.L. 1996: MK-801 protects conditioned responses from extinction in the rabbit nictitating membrane preparation. Psychobiology 24(2): 127-135

el-Asrar, A.M.; Morse, P.H.; Maimone, D.; Torczynski, E.; Reder, A.T. 1992: MK-801 protects retinal neurons from hypoxia and the toxicity of glutamate and aspartate. IOVS Investigative Ophthalmology and Visual Science 33(12): 3463-3468

Longuemare, M.C.; Keung, E.C.; Chun, S.; Sharp, F.R.; Chan, P.H.; Swanson, R.A. 1996: MK-801 reduces uptake and stimulates efflux of excitatory amino acids via membrane depolarization. American Journal of Physiology 270(5 Pt 1): C1398-C1404

De Vries, T.J.; Schoffelmeer, A.N.; Binnekade, R.; Mulder, A.H.; Vanderschuren, L.J. 1998: MK-801 reinstates drug-seeking behaviour in cocaine-trained rats. Neuroreport 9(4): 637-640

Boldry, R.C.; Papa, S.M.; Kask, A.M.; Chase, T.N. 1995: MK-801 reverses effects of chronic levodopa on D1 and D2 dopamine agonist-induced rotational behavior. Brain Research 692(1-2): 259-264

Nakazato, E.; Ohno, M.; Watanabe, S. 1998: MK-801 reverses Fos expression induced by the full dopamine D1 receptor agonist SKF-82958 in the rat striatum. European Journal of Pharmacology 342(2-3): 209-212

Hughes, P.; Young, D.; Dragunow, M. 1993: MK-801 sensitizes rats to pilocarpine induced limbic seizures and status epilepticus. Neuroreport 4(3): 314-316

Cory-Slechta, D.A. 1995: MK-801 subsensitivity following postweaning lead exposure. Neurotoxicology 16(1): 83-95

Chan, P.; Langston, J.W.; Di Monte, D.A. 1993: MK-801 temporarily prevents MPTP-induced acute dopamine depletion and MPP+ elimination in the mouse striatum. Journal of Pharmacology and Experimental Therapeutics 267(3): 1515-1520

Mies, G.; Kohno, K.; Hossmann, K.A. 1993: MK-801, a glutamate antagonist, lowers flow threshold for inhibition of protein synthesis after middle cerebral artery occlusion of rat. Neuroscience Letters 155(1): 65-68

Santamaría, A.; Ríos, C. 1993: MK-801, an N-methyl-D-aspartate receptor antagonist, blocks quinolinic acid-induced lipid peroxidation in rat corpus striatum. Neuroscience Letters 159(1-2): 51-54

Layer, R.T.; Bland, L.R.; Skolnick, P. 1993: MK-801, but not drugs acting at strychnine-insensitive glycine receptors, attenuate methamphetamine nigrostriatal toxicity. Brain Research 625(1): 38-44

Wenk, G.L.; Danysz, W.; Mobley, S.L. 1995: MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. European Journal of Pharmacology 293(3): 267-270

French, E.D.; Mura, A.; Wang, T. 1993: MK-801, phencyclidine (PCP), and PCP-like drugs increase burst firing in rat A10 dopamine neurons: comparison to competitive NMDA antagonists. Synapse 13(2): 108-116

Martin, P.; Waters, N.; Waters, S.; Carlsson, A.; Carlsson, M.L. 1997: MK-801-induced hyperlocomotion: differential effects of M100907, SDZ PSD 958 and raclopride. European Journal of Pharmacology 335(2-3): 107-116

Horváth, Z.C.; Czopf, J.; Buzsáki, G. 1997: MK-801-induced neuronal damage in rats. Brain Research 753(2): 181-195

Wedzony, K.; Gołembiowska, K.; Klimek, V. 1993: MK-801-induced symptoms of sensitization. The lack of correlation with the extracellular concentration of dopamine in the rat prefrontal cortex. Brain Research 625(2): 333-336

Dittmann, K.H.; Mayer, C.; Rodemann, H.P.; Petrides, P.E.; Denzlinger, C. 1998: MK-886, a leukotriene biosynthesis inhibitor, induces antiproliferative effects and apoptosis in HL-60 cells. Leukemia Research 22(1): 49-53

Ellsworth, K.; Azzolina, B.; Baginsky, W.; Bull, H.; Chang, B.; Cimis, G.; Mitra, S.; Toney, J.; Bakshi, R.K.; Rasmusson, G.R.; Tolman, R.L.; Harris, G.S. 1996: MK386: a potent, selective inhibitor of the human type 1 5alpha-reductase. Journal of Steroid Biochemistry and Molecular Biology 58(4): 377-384

Cox, J.; Guthrie, R.; Macrae, M.; Kehoe, E.J.mes 1994: MK801 impairs acquisition and expression of conditioned responses in the rabbit nictitating membrane preparation. Psychobiology 22(2): 156-166

Hughes, P.; Dragunow, M.; Beilharz, E.; Lawlor, P.; Gluckman, P. 1993: MK801 induces immediate-early gene proteins and BDNF mRNA in rat cerebrocortical neurones. Neuroreport 4(2): 183-186

Gao, X.M.; Tamminga, C.A. 1995: MK801 induces late regional increases in NMDA and kainate receptor binding in rat brain. Journal of Neural Transmission. General Section 101(1-3): 105-113

Stafstrom, C.E.; Holmes, G.L.; Thompson, J.L. 1993: MK801 pretreatment reduces kainic acid-induced spontaneous seizures in prepubescent rats. Epilepsy Research 14(1): 41-48

Robinson, G.B. 1993: MK801 retards acquisition of a classically conditioned response without affecting conditioning-related alterations in perforant path-granule cell synaptic transmission. Psychobiology 21(4): 253-264

Chaudhary, P.; Ahmed, F.; Sharma, S.C. 1998: MK801-a neuroprotectant in rat hypertensive eyes. Brain Research 792(1): 154-158

Hargreaves, E.L.; Cain, D.P. 1995: MK801-induced hyperactivity: duration of effects in rats. Pharmacology Biochemistry and Behavior 51(1): 13-19

Nurcombe, V.; Fraser, N.; Herlaar, E.; Heath, J.K. 1992: MK: a pluripotential embryonic stem-cell-derived neuroregulatory factor. Development 116(4): 1175-1183

Suzuki, A.; Sugiyama, Y.; Hayashi, Y.; Nyu-i, N.; Yoshida, M.; Nonaka, I.; Ishiura, S.; Arahata, K.; Ohno, S. 1998: MKBP, a novel member of the small heat shock protein family, binds and activates the myotonic dystrophy protein kinase. Journal of Cell Biology 140(5): 1113-1124

Murai, S.; Saito, H.; Abe, E.; Masuda, Y.; Odashima, J.; Itoh, T. 1994: MKC-231, a choline uptake enhancer, ameliorates working memory deficits and decreased hippocampal acetylcholine induced by ethylcholine aziridinium ion in mice. Journal of Neural Transmission. General Section 98(1): 1-13

Irie, K.; Takase, M.; Lee, K.S.; Levin, D.E.; Araki, H.; Matsumoto, K.; Oshima, Y. 1993: MKK1 and MKK2, which encode Saccharomyces cerevisiae mitogen-activated protein kinase-kinase homologs, function in the pathway mediated by protein kinase C. Molecular and Cellular Biology 13(5): 3076-3083

Raingeaud, J.; Whitmarsh, A.J.; Barrett, T.; Dérijard, B.; Davis, R.J. 1996: MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Molecular and Cellular Biology 16(3): 1247-1255

Zechner, D.; Craig, R.; Hanford, D.S.; McDonough, P.M.; Sabbadini, R.A.; Glembotski, C.C. 1998: MKK6 activates myocardial cell NF-kappaB and inhibits apoptosis in a p38 mitogen-activated protein kinase-dependent manner. Journal of Biological Chemistry 273(14): 8232-8239

Holland, P.M.; Suzanne, M.; Campbell, J.S.; Noselli, S.; Cooper, J.A. 1997: MKK7 is a stress-activated mitogen-activated protein kinase kinase functionally related to hemipterous. Journal of Biological Chemistry 272(40): 24994-24998

Sun, H.; Charles, C.H.; Lau, L.F.; Tonks, N.K. 1993: MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo. Cell 75(3): 487-493

Jeon, S.H.; Yoo, B.H.; Kang, U.K.; Ahn, Y.M.; Bae, C.D.; Park, J.B.; Kim, Y.S. 1998: MKP-1 induced in rat brain after electroconvulsive shock is independent of regulation of 42- and 44-kDa MAPK activity. Biochemical and Biophysical Research Communications 249(3): 692-696

Muda, M.; Boschert, U.; Dickinson, R.; Martinou, J.C.; Martinou, I.; Camps, M.; Schlegel, W.; Arkinstall, S. 1996: MKP-3, a novel cytosolic protein-tyrosine phosphatase that exemplifies a new class of mitogen-activated protein kinase phosphatase. Journal of Biological Chemistry 271(8): 4319-4326

Koya, K.; Li, Y.; Wang, H.; Ukai, T.; Tatsuta, N.; Kawakami, M.; Shishido; Chen, L.B. 1996: MKT-077, a novel rhodacyanine dye in clinical trials, exhibits anticarcinoma activity in preclinical studies based on selective mitochondrial accumulation. Cancer Research 56(3): 538-543

Chiba, Y.; Kubota, T.; Watanabe, M.; Matsuzaki, S.W.; Otani, Y.; Teramoto, T.; Matsumoto, Y.; Koya, K.; Kitajima, M. 1998: MKT-077, localized lipophilic cation: antitumor activity against human tumor xenografts serially transplanted into nude mice. Anticancer Research 18(2a): 1047-1052

Koehler, M.; Fitzgerald, T.J.; Goorha, R.M.; Kitchingman, G.; Downing, J.; Mirro, J. 1992: MKW, a novel hematopoietic antigen. Leukemia 6(10): 985-992

Wallace, J.L.; Carter, L.; Mcknight, W.; Tries, S.; Laufer, S. 1994: ML 3000 reduces gastric prostaglandin synthesis without causing mucosal injury. European Journal of Pharmacology 271(2-3): 525-531

Yau, K.K.; McGilchrist, C.A. 1998: ML and REML estimation in survival analysis with time dependent correlated frailty. Statistics in Medicine 17(11): 1201-1213

Ohkubo, S.; Nakahata, N.; Ohizumi, Y. 1996: ML-7 and W-7 facilitate thromboxane A2-mediated Ca2+ mobilization in rabbit platelets. European Journal of Pharmacology 298(2): 175-183

Kabir, N.; Yamamura, H.; Uzzaman, M.; Sarkar, D.; Takagishi, Y.; Inouye, M.; Hidaka, H. 1996: ML-9 and wortmannin, inhibitors of myosin light-chain kinase, inhibit premature compaction induced by an activator of protein kinase C in preimplantation mouse embryos. Environmental Medicine (Nagoya) 40(2): 142-144

Stevens, R.C.; Davis, T.N. 1998: MLC1p is a light is a light chain for the unconventional myosin Myo2p in Saccharomyces cerevisiae. Journal of Cell Biology 142(3): 711-722

Grose, J.H.; Hall, J.W.; Dev, M.B. 1997: MLD in children: effects of signal and masker bandwidths. Journal of Speech Language and Hearing Research: Jslhr 40(4): 955-959

Prolla, T.A.; Pang, Q.; Alani, E.; Kolodner, R.D.; Liskay, R.M. 1994: MLH1, PMS1, and MSH2 interactions during the initiation of DNA mismatch repair in yeast. Science 265(5175): 1091-1093

Tibbles, L.A.; Ing, Y.L.; Kiefer, F.; Chan, J.; Iscove, N.; Woodgett, J.R.; Lassam, N.J. 1996: MLK-3 activates the SAPK/JNK and p38/RK pathways via SEK1 and MKK3/6. EMBO Journal 15(24): 7026-7035

Ing, Y.L.; Leung, I.W.; Heng, H.H.; Tsui, L.C.; Lassam, N.J. 1994: MLK-3: identification of a widely-expressed protein kinase bearing an SH3 domain and a leucine zipper-basic region domain. Oncogene 9(6): 1745-1750

Dreyling, M.H.; Schrader, K.; Fonatsch, C.; Schlegelberger, B.; Haase, D.; Schoch, C.; Ludwig, W.; Löffler, H.; Büchner, T.; Wörmann, B.; Hiddemann, W.; Bohlander, S.K. 1998: MLL and CALM are fused to AF10 in morphologically distinct subsets of acute leukemia with translocation t(10;11): both rearrangements are associated with a poor prognosis. Blood 91(12): 4662-4667

Hilden, J.M.; Smith, F.O.; Frestedt, J.L.; McGlennen, R.; Howells, W.B.; Sorensen, P.H.; Arthur, D.C.; Woods, W.G.; Buckley, J.; Bernstein, I.D.; Kersey, J.H. 1997: MLL gene rearrangement, cytogenetic 11q23 abnormalities, and expression of the NG2 molecule in infant acute myeloid leukemia. Blood 89(10): 3801-3805

Sobulo, O.M.; Borrow, J.; Tomek, R.; Reshmi, S.; Harden, A.; Schlegelberger, B.; Housman, D.; Doggett, N.A.; Rowley, J.D.; Zeleznik-Le, N.J. 1997: MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). Proceedings of the National Academy of Sciences of the United States of America 94(16): 8732-8737

Ross, J.A.; Robison, L.L. 1997: MLL rearrangements in infant leukemia: Is there a higher frequency in females?. Leukemia Research 21(8): 793-795

So, C.W.; Ma, Z.G.; Price, C.M.; Dong, S.; Chen, S.J.; Gu, L.J.; So, C.K.; Wiedemann, L.M.; Chan, L.C. 1997: MLL self fusion mediated by Alu repeat homologous recombination and prognosis of AML-M4/M5 subtypes. Cancer Research 57(1): 117-122

Yu, M.; Honoki, K.; Andersen, J.; Paietta, E.; Nam, D.K.; Yunis, J.J. 1996: MLL tandem duplication and multiple splicing in adult acute myeloid leukemia with normal karyotype. Leukemia 10(5): 774-780

Horstmann, M.; Argyriou-Tirita, A.; Borkhardt, A.; Kabisch, H.; Kapaun, P.; Winkler, K.; Haas, O.A. 1996: MLL/ENL fusion in congenital acute lymphoblastic leukemia with a unique t(11;18;19). Cancer Genetics and Cytogenetics 88(2): 103-109

Iida, S.; Seto, M.; Yamamoto, K.; Komatsu, H.; Tojo, A.; Asano, S.; Kamada, N.; Ariyoshi, Y.; Takahashi, T.; Ueda, R. 1993: MLLT3 gene on 9p22 involved in t(9;11) leukemia encodes a serine/proline rich protein homologous to MLLT1 on 19p13. Oncogene 8(11): 3085-3092

Watari, H.; Arakane, F.; Moog-Lutz, C.; Kallen, C.B.; Tomasetto, C.; Gerton, G.L.; Rio, M.C.; Baker, M.E.; Strauss, J.F. 1997: MLN64 contains a domain with homology to the steroidogenic acute regulatory protein (StAR) that stimulates steroidogenesis. Proceedings of the National Academy of Sciences of the United States of America 94(16): 8462-8467

Moog-Lutz, C.; Tomasetto, C.; Régnier, C.H.; Wendling, C.; Lutz, Y.; Muller, D.; Chenard, M.P.; Basset, P.; Rio, M.C. 1997: MLN64 exhibits homology with the steroidogenic acute regulatory protein (StAR) and is over-expressed in human breast carcinomas. International Journal of Cancer 71(2): 183-191

Arzone, A.; Alma, A.; Bosco, D.; Patetta, A. 1995: MLO-infected weeds in the vineyards of North-western Italy. Journal of Phytopathology (Berlin) 143(5): 257-260

Arber, S.; Hunter, J.J.; Ross, J.; Hongo, M.; Sansig, G.; Borg, J.; Perriard, J.C.; Chien, K.R.; Caroni, P. 1997: MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell 88(3): 393-403

Kazama, Y.; Takakuwa, K.; Tanaka, K. 1995: MLR reactivity against spouse's lymphocytes: Successful cases with unexplained recurrent abortion treated by immunotherapy with spouse's cells. Acta Medica et Biologica 43(4): 211-216

McAlpine, J.B.; Karwowski, J.P.; Jackson, M.; Mullally, M.M.; Hochlowski, J.E.; Premachandran, U.; Burres, N.S. 1994: MLR-52, (4'-demethylamino-4',5'-dihydroxystaurosporine), a new inhibitor of protein kinase C with immunosuppressive activity. Journal of Antibiotics 47(3): 281-288

Beagley, B.; Edge, N.C.; Jaiboon, N.; James, J.J.; Mcauliffe, C.A.; Thorp, M.S.; Watkinson, M.; Whiting, A.; Wright, D.C. 1996: MM2 force field parameterisation, modelling and structure prediction of salen-type monomeric and hydrogen-bonded dimeric manganese complexes. Tetrahedron 52(30): 10193-10204

Carrigan, S.W.; Lii, J.H.; Bowen, J.P. 1997: MM3(96) parameterization for camptothecin analogs: An ab initio and molecular mechanics study. Journal of Computer-Aided Molecular Design 11(1): 61-70

Yuan, Y.; Crane, D.C.; Musser, J.M.; Sreevatsan, S.; Barry, C.E. 1997: MMAS-1, the branch point between cis- and trans-cyclopropane-containing oxygenated mycolates in Mycobacterium tuberculosis. Journal of Biological Chemistry 272(15): 10041-10049

Neuenschwander, H.; Mackie, T.R.; Reckwerdt, P.J. 1995: MMC--a high-performance Monte Carlo code for electron beam treatment planning. Physics in Medicine and Biology 40(4): 543-574

Burgess, S.M.; Delannoy, M.; Jensen, R.E. 1994: MMM1 encodes a mitochondrial outer membrane protein essential for establishing and maintaining the structure of yeast mitochondria. Journal of cell biology 126(6): 1375-1391

Eickelberg, O.; Sommerfeld, C.O.; Wyser, C.; Tamm, M.; Reichenberger, F.; Bardin, P.G.; Solèr, M.; Roth, M.; Perruchoud, A.P. 1997: MMP and TIMP expression pattern in pleural effusions of different origins. American Journal of Respiratory and Critical Care Medicine 156(6): 1987-1992

Xuan, J.W.; Tuck, A.B.; Wilson, S.M.; Chin, J.L.; Chambers, A.F. 1998: MMP-2 expression is associated with, but not sufficient for, malignant conversion of murine LTA cells. Anticancer Research 18(2a): 743-749

Corcoran, M.L.; Hewitt, R.E.; Kleiner, D.E.; Stetler-Stevenson, W.G. 1996: MMP-2: expression, activation and inhibition. Enzyme and Protein 49(1-3): 7-19

Cañete Soler, R.; Gui, Y.H.; Linask, K.K.; Muschel, R.J. 1995: MMP-9 (gelatinase B) mRNA is expressed during mouse neurogenesis and may be associated with vascularization. Brain Research. Developmental Brain Research 88(1): 37-52

Schnider, P.; Maly, J.; Mraz, M.; Brantner-Inthaler, S.; Zeiler, K.; Wessely, P. 1995: MMPI and Critical Flicker Frequency (CFF) analysis in headache patients with and without drug abuse. Headache 35(1): 17-20

Miller, H.B.; Paniak, C.E. 1995: MMPI and MMPI-2 profile and code type congruence in a brain-injured sample. Journal of Clinical and Experimental Neuropsychology 17(1): 58-64

Fals-Stewart, W.; Schafer, J. 1993: MMPI correlates of psychotherapy compliance among obsessive-compulsives. Psychopathology 26(1): 1-5

Weybrew, B.B. 1996: MMPi patterns of physically and psychologically dependent drug abusers. Perceptual and Motor Skills 83(2): 640-642

Strassberg, D.S.; Ross, S.; Todt, E.H. 1995: MMPI performance among women with bulimia: A cluster-analytic study. Addictive Behaviors 20(1): 137-140

Vilming, S.T.; Ellertsen, B.; Troland, K.; Schrader, H.; Monstad, I. 1997: MMPI profiles in post-lumbar puncture headache. Acta Neurologica Scandinavica 95(3): 184-188

Inan, L.; Soykan, C.; Tulunay, F.C. 1994: MMPI profiles of Turkish headache sufferers. Headache 34(3): 152-154

Schmaling, K.B.; Jones, J.F. 1996: MMPI profiles of patients with chronic fatigue syndrome. Journal of Psychosomatic Research 40(1): 67-74

Lucas, B.A.; Newmark, C.S. 1993: MMPi Scale 9 changes in incarcerated felons. Psychological Reports 72(1): 28-30

Ando, H.; Twining, S.S.; Yue, B.Y.; Zhou, X.; Fini, M.E.; Kaiya, T.; Higginbotham, E.J.; Sugar, J. 1993: MMPs and proteinase inhibitors in the human aqueous humor. IOVS Investigative Ophthalmology and Visual Science 34(13): 3541-3548

Forget, H.; Painson, J.C.; Drews, R.T.; Lagacé, G.; Collu, R. 1993: MMQ cells: A model for evaluating the role of G proteins in the modulation of prolactin release. Molecular and Cellular Endocrinology 93(2): 125-133

Ford, R.P.K.; Bell, D.W.; Slade, B.; Mccormack, S.P. 1998: MMR immunisation coverage in Christchurch. New Zealand Medical Journal 111(1071): 301

Johnson, H.; Hillary, I.B.; Mcquoid, G.; Gilmer, B.A. 1995: MMR vaccination, measles epidemiology and sero-surveillance in the Republic of Ireland. Vaccine 13(6): 533-537

Grzesiuk, E.; Janion, C. 1996: MMS-induced mutagenesis and DNA repair in Escherichia coli dnaQ49: Contribution of UmuD' to DNA repair. Mutation Research 362(2): 147-154

Broomfield, S.; Chow, B.L.; Xiao, W. 1998: MMS2, encoding a ubiquitin-conjugating-enzyme-like protein, is a member of the yeast error-free postreplication repair pathway. Proceedings of the National Academy of Sciences of the United States of America 95(10): 5678-5683

Callahan, R. 1996: MMTV-induced mutations in mouse mammary tumors: Their potential relevance to human breast cancer. Breast Cancer Research and Treatment 39(1): 33-44

Zhang, M.; Sheng, S.; Maass, N.; Sager, R. 1997: mMaspin: the mouse homolog of a human tumor suppressor gene inhibits mammary tumor invasion and motility. Molecular Medicine 3(1): 49-59

Turner, J.R.; Odze, R.D.; Crum, C.P.; Resnick, M.B. 1997: MN antigen expression in normal, preneoplastic, and neoplastic esophagus: a clinicopathological study of a new cancer-associated biomarker. Human Pathology 28(6): 740-744

Birley, A.J.; Maclennan, R.; Wahlqvist, M.; Gerns, L.; Pangan, T.; Martin, N.G. 1997: MN blood group affects response of serum LDL cholesterol level to a low fat diet. Clinical Genetics 51(5): 291-295

Delanghe, J.; Duprez, D.; de Buyzere, M.; Robbrecht, D.; Bergez, B.; Leroux-Roels, G.; Clement, D. 1995: MN blood group, a genetic marker for essential arterial hypertension in young adults. European Heart Journal 16(9): 1269-1276

Alda, M.; Grof, P.; Grof, E. 1998: MN blood groups and bipolar disorder: Evidence of genotypic association and Hardy-Weinberg disequilibrium. Biological Psychiatry 44(5): 361-363

Nagae, M.; Aoki, Y.; Nata, M.; Odaira, T.; Sagisaka, K. 1992: MN blood typing of denatured red blood cells. Research and Practice in Forensic Medicine 35: 51-54

Ross, M.E.; Risken, M. 1994: MN20, a D2 cyclin found in brain, is implicated in neural differentiation. Journal of Neuroscience: the Official Journal of the Society for Neuroscience 14(11 Pt 1): 6384-6391

Ross, M.E.; Carter, M.L.; Lee, J.H. 1996: MN20, a D2 cyclin, is transiently expressed in selected neural populations during embryogenesis. Journal of Neuroscience: the Official Journal of the Society for Neuroscience 16(1): 210-219

Xie, J.; Briggs, J.A.; Briggs, R.C. 1997: MNDA dimerizes through a complex motif involving an N-terminal basic region. Febs Letters 408(2): 151-155

Fukunaga, R.; Hunter, T. 1997: MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates. EMBO Journal 16(8): 1921-1933

Wang, X.H.; Nakayama, K.; Shimma, Y.; Tanaka, A.; Jigami, Y. 1997: MNN6, a member of the KRE2/MNT1 family, is the gene for mannosylphosphate transfer in Saccharomyces cerevisiae. Journal of Biological Chemistry 272(29): 18117-18124

Sehlmeyer, U.; Wobus, A.M. 1995: MNNG is less cytotoxic and mutagenic in undifferentiated embryonic cells than in differentiated cells of the mouse in vitro. In Vitro Toxicology 8(2): 121-127

Fox, J.G.; Wishnok, J.S.; Murphy, J.C.; Tannenbaum, S.R.; Correa, P. 1993: MNNG-induced gastric carcinoma in ferrets infected with Helicobacter mustelae. Carcinogenesis 14(9): 1957-1961

Bhalla, A.; Bamezai, R. 1998: MNNG-transformed Bloom syndrome B-lymphoblastoids for the detection of Hodgkin's lymphoma-associated antigen in 2D Westerns. Cancer Letters 126(1): 7-15

Sun-Hoffman, L.; Winicov, I. 1996: MNU affects mouse erythroleukemia cell differentiation at sub-cytotoxic doses. Chemico-Biological Interactions 100(3): 241-254

Rich, P.R.; Madgwick, S.A.; Brown, S.; von Jagow, G.; Brandt, U. 1992: MOA-stilbene: a new tool for investigation of the reactions of the chloroplast cytochrome bf complex. Photosynthesis Research 34(3): 465-477

Saxena, M.; Henderson, G.B. 1996: MOAT4, a novel multispecific organic-anion transporter for glucuronides and mercapturates in mouse L1210 cells and human erythrocytes. Biochemical Journal 320: 273-281

Luca, F.C.; Winey, M. 1998: MOB1, an essential yeast gene required for completion of mitosis and maintenance of ploidy. Molecular Biology of the Cell 9(1): 29-46

Rozinova, E.; Khalil, M.; Bonin, A.M. 1998: MOCA and some proposed substitutes (Cyanacure, Conacure, Polacure 740M and Ethacure 300) as two-stage skin carcinogens in HRA/Skh hairless mice. Mutation Research 398(1-2): 111-121

Frydman, M.; Katz, M.; Cabot, S.G.; Soen, G.; Kauschansky, A.; Sirota, L. 1997: MODED: Microcephaly-oculo-digito-esophageal-duodenal syndrome. American Journal of Medical Genetics 71(3): 251-257

Sladek, F.M.; Dallas-Yang, Q.; Nepomuceno, L. 1998: MODY1 mutation Q268X in hepatocyte nuclear factor 4alpha allows for dimerization in solution but causes abnormal subcellular localization. Diabetes 47(6): 985-990

Wray, N.R.; Goddard, M.E. 1994: MOET breeding schemes for wool sheep: 1. Design alternatives. Animal Production 59(1): 71-86

Wray, N.R.; Goddard, M.E. 1994: MOET breeding schemes for wool sheep: 2. Selection for adult fleece traits. Animal Production 59(1): 87-98

Benecke, C.; Gruener, T.; Kerber, A.; Laue, R.; Wieland, T. 1997: MOLecular structure GENeration with MOLGEN, new features and future developments. Fresenius' Journal Of Analytical Chemistry. 359(1): 23-32

Mayer, A.; Nargang, F.E.; Neupert, W.; Lill, R. 1995: MOM22 is a receptor for mitochondrial targeting sequences and cooperates with MOM19. EMBO Journal 14(17): 4204-4211

Naidu, B., R.; Ngeow, Y.-Fong; Pang, T. 1997: MOMP-based PCR reveals presence of Chlamydia pneumoniae DNA in respiratory and serum samples of patients with acute C. pneumoniae-associated infections. Journal of Microbiological Methods 28(1): 1-9

Evans, M.I.; Chik, L.; O'Brien, J.E.; Chin, B.; Dvorin, E.; Ayoub, M.; Krivchenia, E.L.; Ager, J.W.; Johnson, M.P.; Sokol, R.J. 1995: MOMs (multiples of the median) and DADs (discriminant aneuploidy detection): improved specificity and cost-effectiveness of biochemical screening for aneuploidy with DADs. American Journal of Obstetrics and Gynecology 172(4 Pt 1): 1138-47; Discussion 1147-9

Skolnick, J.; Kolinski, A.; Ortiz, A.R. 1997: MONSSTER: a method for folding globular proteins with a small number of distance restraints. Journal of Molecular Biology 265(2): 217-241

Knegtel, R.M.; Antoon, J.; Rullmann, C.; Boelens, R.; Kaptein, R. 1994: MONTY: A Monte Carlo approach to protein-DNA recognition. Journal of Molecular Biology 235(1): 318-324

Na, S.; Hincapie, M.; McCusker, J.H.; Haber, J.E. 1995: MOP2 (SLA2) affects the abundance of the plasma membrane H(+)-ATPase of Saccharomyces cerevisiae. Journal of Biological Chemistry 270(12): 6815-6823

Uozumi, Y. 1998: MOP: Design, preparation, and use for palladium-catalyzed asymmetric reactions. Yakugaku Zasshi 118(6): 193-205

Hutchinson, R.J.; Fryer, C.J.; Davis, P.C.; Nachman, J.; Krailo, M.D.; O'Brien, R.T.; Collins, R.D.; Whalen, T.; Reardon, D.; Trigg, M.E.; Gilchrist, G.S. 1998: MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group Phase III Trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 16(3): 897-906

Glick, J.H.; Young, M.L.; Harrington, D.; Schilsky, R.L.; Beck, T.; Neiman, R.; Fisher, R.I.; Peterson, B.A.; Oken, M.M. 1998: MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 16(1): 19-26

Gobbi, P.G.; Pieresca, C.; Federico, M.; Di Renzo, N.; Narni, F.; Iannitto, E.; Grignani, G.; Cavanna, L.; Avanzini, P.; Partesotti, G. 1993: MOPP/EBV/CAD hybrid chemotherapy with or without limited radiotherapy in advanced or unfavorably presenting Hodgkin's disease: a report from the Italian Lymphoma Study Group. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 11(4): 712-719

Van Den Berg, P.Y.; Van Bergen Henegowu, C.N.; Buisman, T.C.J. 1994: MOSES, a promising concept for marine research. Ine Pollution Bulletin 29(6-12): 569-572

Cade, R.M.; Errede, B. 1994: MOT2 encodes a negative regulator of gene expression that affects basal expression of pheromone-responsive genes in Saccharomyces cerevisiae. Molecular and Cellular Biology 14(5): 3139-3149

Weill, A.; Scalabrin, C.; Diner, N. 1993: MOVIES-B: An acoustic detection description software: Application to shoal species' classification. Aquatic Living Resources 6(3): 255-267

Przegaliński, E.; Filip, M.; Bijak, M.; Wedzony, K.; Budziszewska, B.; Tokarski, K.; Maćkowiak, M.; Fijał, K. 1996: MP-3022, a new putative antagonist at pre- and postsynaptic 5-HT1A receptors. Polish Journal of Pharmacology 48(1): 13-22

Schmidt, K.; Witt, K.; Ossowski, A.; Miehlke, R.K. 1997: MP-joint arthroplasty with Swanson Silastik-spacer: Longterm and medium term results with and without grommets. Zeitschrift fuer Rheumatologie 56(5): 287-297

Schaeffer, H.J.; Catling, A.D.; Eblen, S.T.; Collier, L.S.; Krauss, A.; Weber, M.J. 1998: MP1: A MEK binding partner that enhances enzymatic activation of the MAP kinase cascade. Science 281(5383): 1668-1671

Osman, A.M.; Boeren, S.; Veeger, C.; Rietjens, I.M. 1997: MP8-dependent oxidative dehalogenation: Evidence for the direct formation of 1,4-benzoquinone from 4-fluorophenol by a peroxidase-type of reaction pathway. Chemico-Biological Interactions 104(2-3): 147-164

Mukhtar, A. 1996: MP84 expression in the urine specimens of acute rejection renal transplant recipients. Renal Failure 18(6): 931-935

Harboe, M.; Wiker, H.G.; Ulvund, G.; Lund-Pedersen, B.; Andersen, A.B.; Hewinson, R.G.; Nagai, S. 1998: MPB70 and MPB83 as indicators of protein localization in mycobacterial cells. Infection and Immunity 66(1): 289-296

Miyoshi, K.; Kanda, A.; Miyake, H.; Ichihara, K.; Kamei, H.; Nagasaka, M. 1993: MPC-1304, another type of dihydropyridine, possessing highly potent vasodilating action. European Journal of Pharmacology 238(2-3): 139-148

Dickerson, R.E.; Goodsell, D.; Kopka, M.L. 1996: MPD and DNA bending in crystals and in solution. Journal of Molecular Biology 256(1): 108-125

Hagting, A.; Karlsson, C.; Clute, P.; Jackman, M.; Pines, J. 1998: MPF localization is controlled by nuclear export. EMBO Journal 17(14): 4127-4138

Gatos, D.; Tzavara, C.; Athanassopoulos, P.; Barlos, K. 1996: MPLC purification of protected peptide fragments. Letters in Peptide Science 3(4): 241-246

Renzi, L.; Gersch, M.S.; Campbell, M.S.; Wu, L.; Osmani, S.A.; Gorbsky, G.J. 1997: MPM-2 antibody-reactive phosphorylations can be created in detergent-extracted cells by kinetochore-bound and soluble kinases. Journal of Cell Science 110: 2013-2025

Che, S.; Weil, M.M.; Nelman-Gonzalez, M.; Ashorn, C.L.; Kuang, J. 1997: MPM-2 epitope sequence is not sufficient for recognition and phosphorylation by ME kinase-H. Febs Letters 413(3): 417-423

Hernandez, J.F.; Pourcher, A.M.; Delattre, J.M.; Oger, C.; Loeuillard, J.L. 1993: MPN miniaturized procedure for the enumeration of faecal enterococci in fresh and marine waters: The must procedure. Water Research 27(4): 597-606

Quarenghi, M.I.; Del Vecchio, L.; Casartelli, D.; Manunta, P.; Rossi, R. 1998: MPO antibody-positive vasculitis in a patient with psoriatic arthritis and gold-induced membranous glomerulonephritis. Nephrology Dialysis Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association 13(8): 2104-2106

Sheehan, J.P.; Palmer, P.E.; Helm, G.A.; Tuttle, J.B. 1997: MPP+ induced apoptotic cell death in SH-SY5Y neuroblastoma cells: An electron microscope study. Journal of Neuroscience Research 48(3): 226-237

Fallon, J.; Matthews, R.T.; Hyman, B.T.; Beal, M.F. 1997: MPP+ produces progressive neuronal degeneration which is mediated by oxidative stress. Experimental Neurology 144(1): 193-198

Chen, T.S.; Koutsilieri, E.; Rausch, W.D. 1995: MPP+ selectively affects calcium homeostasis in mesencephalic cell cultures from embryonal C57/Bl6 mice. Journal of Neural Transmission. General Section 100(2): 153-163

Ambrosio, S.; Espino, A.; Cutillas, B.; Bartrons, R. 1996: MPP+ toxicity in rat striatal slices: Relationship between non-selective effects and free radical production. Neurochemical Research 21(1): 73-78

Desai, V.G.; Feuers, R.J.; Hart, R.W.; Ali, S.F. 1996: MPP(+)-induced neurotoxicity in mouse is age-dependent: evidenced by the selective inhibition of complexes of electron transport. Brain Research 715(1-2): 1-8

Rollema, H.; Skolnik, M.; D'Engelbronner, J.; Igarashi, K.; Usuki, E.; Castagnoli, N. 1994: MPP(+)-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies. Journal of Pharmacology and Experimental Therapeutics 268(1): 380-387

Kikuchi, T.; Munemoto, Y.; Seki, K.; IIda, Y. 1996: MPS of the rectum hard to distinguish from a rectum cancer with amalgamated cyst presacral epidermoid cyst in the adult, report of a case. Journal of the Japan Society of Coloproctology 49(2): 132-138

Song, X.; Ehrich, M. 1997: MPTP affects cholinergic parameters in SH-SY5Y human neuroblastoma cells. In Vitro Toxicology 10(4): 437-453

Takada, M.; Sugimoto, T.; Hattori, T. 1993: MPTP neurotoxicity to cerebellar Purkinje cells in mice. Neuroscience Letters 150(1): 49-52

Hung, H.C.; Lee, E.H. 1998: MPTP produces differential oxidative stress and antioxidative responses in the nigrostriatal and mesolimbic dopaminergic pathways. Free Radical Biology and Medicine 24(1): 76-84

Huguet, F.; Page, G.; Morel, P.; Tallineau, C.; Piriou, A. 1997: MPTP toxicity in rat striatal slices: Dopamine uptake alteration does not appear to be related to lipid peroxidation. Toxicology 122(1-2): 93-99

Freyaldenhoven, T.E.; Ali, S.F.; Hart, R.W. 1995: MPTP- and MPP(+)-induced effects on body temperature exhibit age- and strain-dependence in mice. Brain Research 688(1-2): 161-170

Pérez-Otaño, I.; Mandelzys, A.; Morgan, J.I. 1998: MPTP-Parkinsonism is accompanied by persistent expression of a delta-FosB-like protein in dopaminergic pathways. Brain Research. Molecular Brain Research 53(1-2): 41-52

Tsai, H.W.; Tsai, Y.F. 1993: MPTP-induced brain indoleamine changes are age-related and region-dependent in rats. Neuroscience Research Communications 13(1): 19-26

Emborg-Knott, M.E.; Domino, E.F. 1998: MPTP-Induced hemiparkinsonism in nonhuman primates 6-8 years after a single unilateral intracarotid dose. Experimental Neurology 152(2): 214-220

Ali, S.F.; David, S.N.; Newport, G.D.; Cadet, J.L.; Slikker, W. 1994: MPTP-induced oxidative stress and neurotoxicity are age-dependent: evidence from measures of reactive oxygen species and striatal dopamine levels. Synapse 18(1): 27-34

Pérez-Otaño, I.; Oset, C.; Luquin, M.R.; Herrero, M.T.; Obeso, J.A.; Del Río, J. 1994: MPTP-induced parkinsonism in primates: Pattern of striatal dopamine loss following acute and chronic administration. Neuroscience Letters 175(1-2): 121-125

Charuruks, N.; Voravud, N.; Sriuranpong, V. 1998: MPXI and early neutrophilia: New potential therapeutic biomarkers for recombinant human granulocyte colony-stimulating factor. Journal of Clinical Laboratory Analysis 12(1): 41-46

Alkema, M.J.; Jacobs, J.; Voncken, J.W.; Jenkins, N.A.; Copeland, N.G.; Satijn, D.P.; Otte, A.P.; Berns, A.; van Lohuizen, M. 1997: MPc2, a new murine homolog of the Drosophila polycomb protein is a member of the mouse polycomb transcriptional repressor complex. Journal of Molecular Biology 273(5): 993-1003

Atlas, S.W. 1994: MR angiography in neurologic disease. Radiology 193(1): 1-16

Chicaneria, A.; Spoof, E.; Et, A. 1996: MR appearance of cerebral Drancunculus borealis infection. Ajnr. American Journal of Neuroradiology 17(4): 798-799

Kahan, H.; Sklar, E.M.; Post, M.J.; Bruce, J.H. 1996: MR characteristics of histopathologic subtypes of spinal ependymoma. Ajnr. American Journal of Neuroradiology 17(1): 143-150

Röther, J.; de Crespigny, A.J.; D'Arceuil, H.; Mosley, M.E. 1996: MR detection of cortical spreading depression immediately after focal ischemia in the rat. Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism 16(2): 214-220

Fujimoto, K.; Edamitsu, O.; Meno, S.; Abe, T.; Honda, N.; Ogoh, Y.; Ohzono, H.; Nakaoda, K.; Kojima, K.; Nishimura, H. 1995: MR diagnosis for metastasis or non-metastasis of mediastinal and hilar lymph nodes in cases of primary lung cancer: detectability, signal intensity, and MR-pathologic correlation. Nihon Igaku Hoshasen Gakkai Zasshi. Nippon Acta Radiologica 55(3): 162-171

Tuite, M.J.; De Smet, A.A.; Norris, M.A.; Orwin, J.F. 1995: MR diagnosis of labral tears of the shoulder: value of T2*-weighted gradient-recalled echo images made in external rotation. Ajr. American Journal of Roentgenology 164(4): 941-944

Monu, J.U.; Pope, T.L.; Chabon, S.J.; Vanarthos, W.J. 1994: MR diagnosis of superior labral anterior posterior (SLAP) injuries of the glenoid labrum: value of routine imaging without intraarticular injection of contrast material. Ajr. American Journal of Roentgenology 163(6): 1425-1429

Singson, R.D.; Hoang, T.; Dan, S.; Friedman, M. 1996: MR evaluation of rotator cuff pathology using T2-weighted fast spin-echo technique with and without fat suppression. Ajr. American Journal of Roentgenology 166(5): 1061-1065

Ernst, R.J.; Cornelius, R.S. 1995: MR findings of sclerosing cervicitis. Ajnr. American Journal of Neuroradiology 16(3): 507-508

Chu, K.C.; Rutt, B.K. 1995: MR Gradient coil heat dissipation. Magnetic Resonance in Medicine 34(1): 125-132

Tartaglino, L.M.; Heiman-Patterson, T.; Friedman, D.P.; Flanders, A.E. 1995: MR imaging in a case of postvaccination myelitis. Ajnr. American Journal of Neuroradiology 16(3): 581-582

Potter, H.G.; Montgomery, K.D.; Heise, C.W.; Helfet, D.L. 1994: MR imaging of acetabular fractures: value in detecting femoral head injury, intraarticular fragments, and sciatic nerve injury. Ajr. American Journal of Roentgenology 163(4): 881-886

Ryan, S.P.; Weinberger, E.; White, K.S.; Shaw, D.W.; Patterson, K.; Nazar-Stewart, V.; Miser, J. 1995: MR imaging of bone marrow in children with osteosarcoma: effect of granulocyte colony-stimulating factor. Ajr. American Journal of Roentgenology 165(4): 915-920

Takeuchi, H.; Sakuma, T.; Fukuda, Y.; Harada, J.; Tada, S. 1995: MR imaging of infected spondylodiskitis: interval signal change in vertebral body (including enhanced image of vertebral body). Nihon Igaku Hoshasen Gakkai Zasshi. Nippon Acta Radiologica 55(8): 555-561

Terk, M.R.; Esplin, J.; Lee, K.; Magre, G.; Colletti, P.M. 1995: MR imaging of patients with type 1 Gaucher's disease: relationship between bone and visceral changes. Ajr. American Journal of Roentgenology 165(3): 599-604

Lamb, H.J.; Singleton, R.R.; van der Geest, R.J.; Pohost, G.M.; de Roos, A. 1995: MR Imaging of Regional Cardiac Function: Low-Pass Filtering of Wall Thickness Curves. Magnetic Resonance in Medicine 34(3): 498-502

Reinhart, R.D.; Brown, J.J.; Foglia, R.P.; Aliperti, G. 1994: MR Imaging of annular pancreas. Abdominal Imaging 19(4): 301-303

Kuramochi, A. 1996: MR Imaging of lymphangiomas. Journal of Saitama Medical School 23(1): 47-60

Tada, Y.ichiro 1994: MR Imaging of parotid tumors: Identification of the facial nerve. Jibi Inkoka Tokeibu Geka 66(8): 687-691

Campeau, N.G.; Johnson, C.D.; Felmlee, J.P.; Rydberg, J.N.; Butts, R.K.; Ehman, R.L.; Riederer, S.J. 1995: MR imaging of the abdomen with a phased-array multicoil: prospective clinical evaluation. Radiology 195(3): 769-776

Taylor-Robinson, S.D.; Oatridge, A.; Hajnal, J.V.; Burroughs, A.K.; McIntyre, N.; deSouza, N.M. 1995: MR imaging of the basal ganglia in chronic liver disease: correlation of T1-weighted and magnetisation transfer contrast measurements with liver dysfunction and neuropsychiatric status. Metabolic Brain Disease 10(2): 175-188

Pui, M.H.; Fok, E.C. 1995: MR imaging of the brain: comparison of gradient-echo and spin-echo pulse sequences. Ajr. American Journal of Roentgenology 165(4): 959-962

Ito, K.; Fujita, T.; Uchisako, H.; Tanaka, N.; Matsui, M.; Tsukamoto, K.; Matsumoto, T.; Nakanishi, T. 1994: MR imaging of the uterus: findings from high-resolution multisection dynamic imaging with a surface coil. Ajr. American Journal of Roentgenology 163(4): 873-879

Kitagaki, H. 1995: MR imaging-evaluation of therapeutic effect of radiotherapy for uterine cervix cancer. Nihon Igaku Hoshasen Gakkai Zasshi. Nippon Acta Radiologica 55(4): 215-221

Orel, S.G.; Schnall, M.D.; Newman, R.W.; Powell, C.M.; Torosian, M.H.; Rosato, E.F. 1994: MR imaging-guided localization and biopsy of breast lesions: initial experience. Radiology 193(1): 97-102

Friedman, D.P.; Rosetti, G.F.; Flanders, A.E.; Piccoli, C.W.; Rao, V.M.; Mitchell, D.G.; Tartaglino, L.M.; Gonzalez, C.F.; Schweitzer, M.E.; Mishkin, M.M. 1995: MR imaging: quality assessment method and ratings at 33 centers. Radiology 196(1): 219-226

Harika, L.; Weissleder, R.; Poss, K.; Zimmer, C.; Papisov, M.I.; Brady, T.J. 1995: MR lymphography with a lymphotropic T1-type MR contrast agent: Gd-DTPA-PGM. Magnetic Resonance in Medicine 33(1): 88-92

Burkart, D.J.; Johnson, C.D.; Reading, C.C.; Ehman, R.L. 1995: MR measurements of mesenteric venous flow: prospective evaluation in healthy volunteers and patients with suspected chronic mesenteric ischemia. Radiology 194(3): 801-806

Watters, M.R.; Burton, B.S.; Turner, G.E.; Cannard, K.R. 1996: MR screening for brain stem compression in hypertension. Ajnr. American Journal of Neuroradiology 17(2): 217-221

Lomas, D.J.; Carroll, N.R.; Johnson, G.; Antoun, N.M.; Freer, C.E. 1996: MR sialography. Work in progress. Radiology 200(1): 129-133

Tsai, F.Y.; Wang, A.M.; Matovich, V.B.; Lavin, M.; Berberian, B.; Simonson, T.M.; Yuh, W.T. 1995: MR staging of acute dural sinus thrombosis: correlation with venous pressure measurements and implications for treatment and prognosis. Ajnr. American Journal of Neuroradiology 16(5): 1021-1029

Laakso, M.P.; Partanen, K.; Soininen, H.; Lehtovirta, M.; Hallikainen, M.; Hänninen, T.; Helkala, E.L.; Vainio, P.; Riekkinen, P.J. 1996: MR T2 relaxometry in Alzheimer's disease and age-associated memory impairment. Neurobiology of Aging 17(4): 535-540

Sasaki, M.; Ehara, S.; Tamakawa, Y.; Takahashi, S.; Tohgi, H.; Sakai, A.; Mita, T. 1995: MR anatomy of the substantia innominata and findings in Alzheimer disease: a preliminary report. Ajnr. American Journal of Neuroradiology 16(10): 2001-2007

Roman-Goldstein, S.; Mitchell, P.; Crossen, J.R.; Williams, P.C.; Tindall, A.; Neuwelt, E.A. 1995: MR and cognitive testing of patients undergoing osmotic blood-brain barrier disruption with intraarterial chemotherapy. Ajnr. American Journal of Neuroradiology 16(3): 543-553

Vogl, T.J.; Stemmler, J.; Bergman, C.; Pfluger, T.; Egger, E.; Lissner, J. 1993: MR and MR angiography of Sturge-Weber syndrome. Ajnr. American Journal of Neuroradiology 14(2): 417-425

Steinberg, G.K.; De La Paz, R.; Mitchell, R.S.; Bell, T.E.; Albers, G.W. 1996: MR and cerebrospinal fluid enzymes as sensitive indicators of subclinical cerebral injury after open-heart valve replacement surgery. Ajnr. American Journal of Neuroradiology 17(2): 205

Heinz, R.; Ferris, N.; Lee, E.K.; Radtke, R.; Crain, B.; Hoffman, J.M.; Hanson, M.; Paine, S.; Friedman, A. 1994: MR and positron emission tomography in the diagnosis of surgically correctable temporal lobe epilepsy. Ajnr. American Journal of Neuroradiology 15(7): 1341-1348

Dexter, M.A.; Parker, G.D.; Besser, M.; Ell, J.; Fulham, M.J. 1995: MR and positron emission tomography with fludeoxyglucose F 18 in gliomatosis cerebri. Ajnr. American Journal of Neuroradiology 16(7): 1507-1510

Engelbrecht, V.; Rassek, M.; Huismann, J.; Wendel, U. 1997: MR and proton MR spectroscopy of the brain in hyperhomocysteinemia caused by methylenetetrahydrofolate reductase deficiency. Ajnr. American Journal of Neuroradiology 18(3): 536-539

Brown, M.S.; Simon, J.H.; Stemmer, S.M.; Stears, J.C.; Scherzinger, A.; Cagnoni, P.J.; Jones, R.B. 1995: MR and proton spectroscopy of white matter disease induced by high-dose chemotherapy with bone marrow transplant in advanced breast carcinoma. Ajnr. American Journal of Neuroradiology 16(10): 2013-2020

Huston, J.; Nichols, D.A.; Luetmer, P.H.; Rydberg, C.H.; Lewis, B.D.; Meyer, F.B.; Brown, R.D.; Schleck, C.D. 1998: MR angiographic and sonographic indications for endarterectomy. Ajnr. American Journal of Neuroradiology 19(2): 309-315

Nagasawa, S.; Ohta, T.; Tsuda, E. 1998: MR angiographic source images for depicting surgical topography of anterior communicating artery aneurysm. Surgical Neurology 49(3): 309-315

Ecklund, K.; Hartnell, G.G.; Hughes, L.A.; Stokes, K.R.; Finn, J.P. 1994: MR angiography as the sole method in evaluating abdominal aortic aneurysms: correlation with conventional techniques and surgery. Radiology 192(2): 345-350

Katsushima, S.; Kimura, T.; Matsushita, M.; Oi, H.; Konishi, J. 1998: MR angiography evaluation of the therapeutic response and the prognosis of esophageal varices after endoscopic injection sclerotherapy, report of two cases. Stomach and Intestine 33(2): 221-227

Rose, S.C.; Gomes, A.S.; Yoon, H.C. 1996: MR angiography for mapping potential central venous access sites in patients with advanced venous occlusive disease. Ajr. American Journal of Roentgenology 166(5): 1181-1187

Gillard, J.H.; Oliverio, P.J.; Barker, P.B.; Oppenheimer, S.M.; Bryan, R.N. 1997: MR angiography in acute cerebral ischemia of the anterior circulation: a preliminary report. Ajnr. American Journal of Neuroradiology 18(2): 343-350

Vogl, T.J.; Balzer, J.O.; Stemmler, J.; Bergman, C.; Egger, E.; Lissner, J. 1992: MR angiography in children with cerebral neurovascular diseases: findings in 31 cases. Ajr. American Journal of Roentgenology 159(4): 817-823

Mitani, M. 1995: MR angiography in intrathoracic masses: evaluation of the superior vena cava, its major branches and their relation to the mass. Nihon Igaku Hoshasen Gakkai Zasshi. Nippon Acta Radiologica 55(14): 929-938

Isoda, H.; Ramsey, R.G.; Takehara, Y.; Takahashi, M.; Kaneko, M. 1997: MR angiography of aneurysm models of various shapes and neck sizes. Ajnr. American Journal of Neuroradiology 18(8): 1463-1472

Ito, T.; Sakai, T.; Inagawa, S.; Utsu, M.; Bun, T. 1995: MR angiography of cerebral vasospasm in preeclampsia. Ajnr. American Journal of Neuroradiology 16(6): 1344-1346

Heiserman, J.E.; Drayer, B.P.; Fram, E.K.; Keller, P.J. 1992: MR angiography of cervical fibromuscular dysplasia. Ajnr. American Journal of Neuroradiology 13(5): 1454-1457

Bowen, B.C.; DePrima, S.; Pattany, P.M.; Marcillo, A.; Madsen, P.; Quencer, R.M. 1996: MR angiography of normal intradural vessels of the thoracolumbar spine. Ajnr. American Journal of Neuroradiology 17(3): 483-494

Yucel, E.K.; Silver, M.S.; Carter, A.P. 1994: MR angiography of normal pelvic arteries: comparison of signal intensity and contrast-to-noise ratio for three different inflow techniques. Ajr. American Journal of Roentgenology 163(1): 197-201

Bowen, B.C.; Quencer, R.M.; Margosian, P.; Pattany, P.M. 1994: MR angiography of occlusive disease of the arteries in the head and neck: current concepts. Ajr. American Journal of Roentgenology 162(1): 9-18

Oka, T.; Morimoto, K.; Shimoi, M.; Tsujimura, A.; Yasunaga, Y.; Matsumiya, K.; Takaha, M. 1993: MR angiography of renal cell carcinoma. Urologia Internationalis 50(4): 198-202

Ida, M.; Kurisu, Y.; Yamashita, M. 1997: MR angiography of ruptured aneurysms in acute subarachnoid hemorrhage. Ajnr. American Journal of Neuroradiology 18(6): 1025-1032

Derdeyn, C.P.; Graves, V.B.; Turski, P.A.; Masaryk, A.M.; Strother, C.M. 1997: MR angiography of saccular aneurysms after treatment with Guglielmi detachable coils: preliminary experience. Ajnr. American Journal of Neuroradiology 18(2): 279-286

Mascalchi, M.; Bianchi, M.C.; Quilici, N.; Mangiafico, S.; Ferrito, G.; Padolecchia, R.; Bartolozzi, C. 1995: MR angiography of spinal vascular malformations. Ajnr. American Journal of Neuroradiology 16(2): 289-297

Patel, M.R.; Klufas, R.A.; Kim, D.; Edelman, R.R.; Kent, K.C. 1994: MR angiography of the carotid bifurcation: artifacts and limitations. Ajr. American Journal of Roentgenology 162(6): 1431-1437

Li, W.; Kramer, J.; Kleefield, J.; Edelman, R.R. 1992: MR angiography of the extracranial carotid arteries using a two-slab oblique 3-D acquisition. Ajnr. American Journal of Neuroradiology 13(5): 1423-1428

Togami, I.; Mitani, M.; Kitagawa, T.; Katoh, K.; Joja, I.; Hiraki, Y.; Kimura, T. 1992: MR angiography of the lung using 3-dimensional imaging method. Nihon Igaku Hoshasen Gakkai Zasshi. Nippon Acta Radiologica 52(11): 1602-1604

Swan, J.S.; Grist, T.M.; Weber, D.M.; Sproat, I.A.; Wojtowycz, M.M. 1994: MR angiography of the pelvis with variable velocity encoding and a phased-array coil. Radiology 190(2): 363-369

Goldberg, M.A.; Yucel, E.K.; Saini, S.; Hahn, P.F.; Kaufman, J.A.; Cohen, M.S. 1993: MR angiography of the portal and hepatic venous systems: preliminary experience with echoplanar imaging. Ajr. American Journal of Roentgenology 160(1): 35-40

Tajima, N.; Ito, K.; Okada, S.; Hosaka, J.; Tajima, H.; Kumazaki, T.; Asano, T.; Kato, J. 1995: MR angiography of the venous system of lower extremities with gadolinium-enhanced fast spoiled GRASS. Nihon Igaku Hoshasen Gakkai Zasshi. Nippon Acta Radiologica 55(7): 511-512

Cortell, E.D.; Kaufman, J.A.; Geller, S.C.; Cambria, R.P.; Rivitz, S.M.; Waltman, A.C. 1996: MR angiography of tibial runoff vessels: imaging with the head coil compared with conventional arteriography. Ajr. American Journal of Roentgenology 167(1): 147-151

Korosec, F.R.; Grist, T.M.; Polzin, J.A.; Weber, D.M.; Mistretta, C.A. 1993: MR angiography using velocity-selective preparation pulses and segmented gradient-echo acquisition. Magnetic Resonance in Medicine 30(6): 704-714

Gönner, F.; Heid, O.; Remonda, L.; Nicoli, G.; Baumgartner, R.W.; Godoy, N.; Schroth, G. 1998: MR angiography with ultrashort echo time in cerebral aneurysms treated with Guglielmi detachable coils. Ajnr. American Journal of Neuroradiology 19(7): 1324-1328

Hirabuki, N.; Fujita, N.; Fujii, K.; Hashimoto, T.; Kozuka, T. 1994: MR appearance of Virchow-Robin spaces along lenticulostriate arteries: spin-echo and two-dimensional fast low-angle shot imaging. Ajnr. American Journal of Neuroradiology 15(2): 277-281

Hähnel, S.; Jansen, O.; Geletneky, K. 1998: MR appearance of an intracranial dural arteriovenous fistula leading to cervical myelopathy. Neurology 51(4): 1131-1135

Castillo, M.; Smith, J.K.; Mukherji, S.K. 1995: MR appearance of cerebral cortex in children with and without a history of perinatal anoxia: preliminary observations. Ajr. American Journal of Roentgenology 164(6): 1481-1484

Hatanaka, Y.; Yamashita, Y.; Torashima, M.; Takahashi, M. 1996: MR appearance of fat distribution in ovarian teratoma: pathologic correlation. Nihon Igaku Hoshasen Gakkai Zasshi. Nippon Acta Radiologica 56(7): 477-481

Rahmouni, A.; Divine, M.; Mathieu, D.; Golli, M.; Haioun, C.; Dao, T.; Anglade, M.C.; Reyes, F.; Vasile, N. 1993: MR appearance of multiple myeloma of the spine before and after treatment. Ajr. American Journal of Roentgenology 160(5): 1053-1057

Miller, M.J.; Mark, L.P.; Ho, K.C.; Haughton, V.M. 1996: MR appearance of the internal architecture of Ammon's horn. Ajnr. American Journal of Neuroradiology 17(1): 23-26

Fujita, N.; Shimada, N.; Takimoto, H.; Satou, T. 1995: MR appearance of the persistent hypoglossal artery. Ajnr. American Journal of Neuroradiology 16(4 Suppl): 990-992